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In light of shrinking pharmaceutical drug pipelines and drug resistance, innovative drug 
discovery strategies are of imperative need. Drug repurposing and related strategies such as 
drug rescue and drug remodelling have garnered significant research interest. Various 
clinically approved non-antibiotics including phenothiazines hold promise as novel classes of 
therapeutics in other indications. However, in addition to inherent neuroleptic properties, 
phenothiazines and related antipsychotics elicit adverse side effects at clinically relevant 
doses thus precluding their extensive clinical application. 
 
Herein, it was postulated that the selectivity of phenothiazines and related drugs for non-
neuroleptic indications could be enhanced through rationalized structural remodelling. 
Phenothiazine and related neuroleptics are known to obey a lipophilic chromophore/basic 
side chain paradigm. Deviation from this paradigm is expected to decrease potential for 
neuroleptic effects. Therefore, the remodelling strategies involved introduction of novel 
functionalities that are dissimilar to native phenothiazine structures.   
 
Prior to chemical synthesis, drug metabolism and pharmacokinetic related properties were 
predicted in silico to assess drug-likeness of the new chemical entities derived from 
phenothiazines and related antipsychotics. The in silico profiling also included prediction of 
blood/brain partition coefficients and CNS activity to determine their likelihood of exhibiting 
neuroleptic effects. The new chemical entities were then evaluated against drug-susceptible 
Mycobacterium tuberculosis-H37Rv. Furthermore, a selected series was screened for binding 








Moreover, pharmacokinetic studies were conducted with the selected series to determine in 
vitro microsomal stability, kinetic solubility and in vivo toxicity profiles. Another objective of 
this study was to evaluate the new chemical entities for their potential as anticancer agents.  
 
The key findings herein demonstrated that it is possible to abolish neuroleptic effects through 
rationalized structural manipulation and still retain bio-activities of interest. Several new 
chemical entities including N-alkylsulfonates (DS0031, DS0032, DS0034, DS0035, 
DS00366) and nitrobenzenesulfonamides (DS00325, DS00326, DS00329) of phenothiazines, 
displayed notable antitubercular (GAST/Fe MIC90 range: 9.9-125 µM; 7H9 MIC range 12.5-
25 µg/mL) and anticancer (IC50 range 4.51-12.43 µM) activities in comparison to native 
phenothiazine drugs. Furthermore, in vitro and in vivo preclinical evaluation revealed 
favourable pharmacokinetic profiles. Overall, this study presents novel subclasses of 
phenothiazines that hold promise for further development as non-neuroleptic agents in either 
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Drug repurposing and repositioning as a means to expedite drug discovery 
and development 
Preface 
The containment of the rising tide of resistance to existing drugs is a global priority. In this 
chapter, drug repurposing and related concepts are introduced as alternative strategies for the 
management of communicable and non-communicable diseases. In so doing, the utilization 
of non-antibiotics is reviewed as an unconventional approach for antimicrobial 
chemotherapy. Moreover, a discussion on the biological background of neuroleptic drugs as 
the non-antibiotics of interest is provided. Non-antibiotics are referred to as drugs that are 
originally employed to treat diseases of non-infectious aetiology and also possess 
antimicrobial activity, this definition was adopted herein. Furthermore, they either exhibit 
direct antimicrobial activity or act as adjuvants in combination with conventional antibiotics 
thus showing great potential for curbing drug resistance.   
 
1.1 Drug Resistance 
1.1.1 Drug Resistance: A hurdle in chemotherapeutic interventions   
Drug resistance remains a major setback in the management of communicable diseases and 
also non-communicable diseases. For centuries infectious diseases of bacterial, fungal, 
parasitic and viral origins have been a threat to global public health. Various factors 
contribute to the spread of antimicrobial resistance including genetic, therapeutic and socio-
economic factors. For instance, overuse of existing antibiotics has propagated resistance and 
efforts to eradicate the Tuberculosis (TB) scourge have become futile. An evidential example  
 





of antimicrobial resistance is the evolution of Mycobacterium tuberculosis (M.tb), the 
causative agent of TB, from multidrug-resistant (MDR) to extensively drug-resistant (XDR) 
and more recently totally drug-resistant bacterium.
1,2 
Antimicrobial resistance is also 
attributable to other factors such as the lack of disease prevention/ monitoring programmes 
and shrinking pharmaceutical drug pipelines.
3,4
 Apart from antimicrobial resistance, 
resistance to chemotherapeutics employed in the management of non-communicable diseases 
such as cancer chemotherapeutics is also a grave concern.  
 
Over the years, the World Health Organization (WHO) has continued to introduce policies 
and strategic plans to tackle antimicrobial resistance. Resource inadequacy and lack of 
regulatory authorities are amongst other pressing issues faced by low- to middle-income 
regions such as Africa. Antimicrobial resistance in these regions is further exacerbated by 
counterfeit and / or poor-quality antimicrobial medicines. Effective surveillance programmes 
are essential for tracking and controlling antimicrobial resistance. In 2011 on World Health 
Day, the WHO launched a policy package comprising strategies for the containment of 
antimicrobial resistance. The key strategies contained in the policy package include 
strengthening surveillance and laboratory capacity, regulation and promotion of rational use 
of medicines, accessibility to essential medicines that are of assured quality, fostering 




1.2 Antimicrobial Chemotherapy: Historical background 
Over the past few decades, antibiotics have been the panacea for microbial infections. Early 
in the 20
th
 century, Paul Ehrlich introduced chemotherapy as a medical speciality. His 
research between 1854 and 1915 led to the discovery of methylene blue.
5
 This cationic 
phenothiazinium dye displayed efficacy against Malaria. Alexander Fleming is also one of 





the pioneers of antibiotic drug discovery owing to his serendipitous discovery of penicillin in 
1928.
6,7,8
  Within a short span of time, more antibiotics flooded the drug market, dubbing the 
period between 1950 and 1970‘s the ‗golden age of antibiotics‘.
5,9
 Following the ‗golden age‘ 
era, antibiotic drug pipelines began to dry up partly due to lengthy periods of drug discovery 
and development as well as the emergence of antimicrobial drug resistance. Table 1.1 




Table 1.1: Examples of antibiotic drug classes, their year of discovery and the years in which resistance was 
observed
10,11 
DR: Drug-resistant; MDR: Multidrug-resistant; XDR: Extensively drug-resistant; TB: Tuberculosis 
Class of                    Example 
antibiotics       
Year of 
discovery 
Year of  
introduction 
Antimicrobial resistance identified      
(year and pathogen) 
 








1942      (Streptococcus) 
Beta-lactams              Penicillin 1928 1938 1943      (Staphylococcus aureus) 
1965      (Pneumococcus) 
Quinolines                 Chloroquine 1934 1947 1957     (Plasmodium falciparum) 
Aminoglycosides       Streptomycin 1943 1946 1980s     (DR Tuberculosis) 
Macrolides                 Erythromycin 1948 1951 1968      (Streptococcus) 
Tetracyclines        Chlortetracycline 1944 1952 1959      (Shigella) 
Rifamycins                 Rifampicin 1957 1958 1990s     (MDR Tuberculosis) 
Glycopeptides            Vancomycin 1953 1958 1988     (Enterococcus) 
 







2001    (Staphylococcus aureus) 
2013     (XDR Tuberculosis)
12 
Lipopeptides              Daptomycin 1986 2003 2013     (Staphylococcus aureus)
13
 
Cephalosporins          Ceftaroline   2000 2010 2011    (Staphylococcus aureus) 
Macrolides                 Fidaxomicin 
                                  (Clostridium difficile) 
1948 2011 - 
Diarylquinolines        Bedaquiline 
                                   (MDR-TB) 
1997 2012 - 
 





Curbing antimicrobial resistance is a multi-faceted problem and development of additional 
antibiotics has not provided much relief in treatment and/ or eradication of infectious 
diseases. This necessitates a search for alternative approaches including novel therapeutic 
drug classes that avoid current resistance mechanisms and/or therapeutics that target 
biological systems such as multidrug efflux pumps which confer resistance to antimicrobials.  
 
In efforts to avert resistance, research interest is shifting toward discovery of unconventional 
therapeutics for the treatment of infectious diseases. On-going research reveals utilization of 
non-antibiotics as an alternative approach for antimicrobial chemotherapy.
5,6,14,15
 Drug 
resistance reversal properties of some non-antibiotics such as neuroleptic phenothiazines hold 




1.2 Drug Repurposing: Use of existing drugs for new indications 
1.2.1 Overview of drug repurposing and drug repositioning 
De novo drug discovery and development via traditional approaches is an exhaustive and 
time-consuming process. This multi-stage process from basic research to a marketed drug 
could cost millions of dollars and development stages might take longer than a decade to 
complete (Figure 1.1).
17,18
 Furthermore, the complexity associated with the drug development 





















Figure 1.1: A simplified depiction of the drug discovery and development process from basic research to 
clinical trials and ultimately approval by regulatory authorities e.g. the Food and drug Administration (FDA).  
 
In light of a consistent decline in antibiotics production and the emergence of resistance, 
novel and faster production routes are desperately sought. The use of clinically approved 
drugs for new indications, generically referred to as drug repurposing, has become an 
increasingly attractive strategy in drug discovery and development.
19,20 
Drug repurposing is 
often used interchangeably with the term drug repositioning. Some authors define drug 
repositioning as the derivatization (drug remodelling) of an existing drug as a potential 
therapeutic in another disease, this definition is adopted herein. These strategies are closely 
associated with other concepts such as drug rescue whereby drugs that are abandoned or 
candidates that have failed in development stages are investigated for other indications.
21,22,23 
, 





Clinically approved drugs have validated pharmacokinetic properties and toxicological 
profiles therefore their repurposing could potentially avoid high research costs and lengthy 
timelines. Moreover, technological advances in virtual screening methodologies present an 
opportunity for rapid screening of libraries of clinically approved drugs for therapeutic 
activities against new biomolecular targets in a manner that is both efficient and cost-
effective.
20,24,25 
Numerous clinically approved drugs have been successfully repurposed or are 
being investigated for other indications in efforts to rejuvenate pharmaceutical drug pipelines.  
Examples of clinically developed drugs that have been repurposed or being investigated for 
bio-activity in other diseases are tabulated below (Table 1.2).
22,26,27 
 




New / Investigational Use Reference 
    
Thalidomide                Sedative Multiple myeloma; Leprosy Rajkumar et al., 2000
28
 
Thioridazine   Antipsychotic (MDR-TB & XDR-TB ) Ordway et al., 2003;
29
 Amaral et al., 
2012;
1
 Singh et al., 2014
30
 
Pyramithamine Antimalarial Toxoplasmosis Montoya J G and Liensenfeld O, 2004
31
 





Staphylococcus Pneumonia Rosch et al., 2010
33
 
Doxycycline Antibacterial  Malaria Tan et al., 2011
34
 
Quinine  Antimalarial Arthritis; Lupus Bird  et al., 1995;
35










Febbraro et al., 2014
37
   
Mebendazole  Anti-helminthic Cancer                                                                   Pantziarka et al., 2014
38
 
Linezolid Antibacterial                                      Tuberculosis (MDR & XDR) Lee et al., 2012;
39
 Ambrosio et al., 2015
40
 





Hodgkin  Lymphoma Celegato et al., 2015
42
 




1.2.2 Non-antibiotics as alternative antimicrobial agents 
The rise of antimicrobial resistance has nullified the effects of many conventional antibiotics. 
Over the years, non-antibiotics have been reported to augment the activity of classical 
antibiotics as ‗helper compounds‘ or exhibit direct antimicrobial activity.5 Several drug 
classes of non-antibiotics including neuroleptics, anti-inflammatory agents, antihypertensives 





















































































































































Of note, neuroleptics, phenothiazine derivatives in particular, are appealing to researchers   
due to their wide spectrum of bio-activities including antibacterial, antimalarial, antiemetic, 
anticancer, antihistaminic and many more. More importantly, their multidrug-resistance 





1.3 Multiple biological properties of neuroleptics 
1.3.1 Historical overview 
Clinical observations from the use of methylene blue for treatment of psychosis opened doors 




Figure 1.2: Structural evolution from the precursor structure, methylene blue, to phenothiazine neuroleptic 
thioridazine, and to antimalarial chloroquine.
  
YOFP-Year of first preparation; YOFA-Year of FDA approval. 
 





Chlorpromazine, a phenothiazine derivative, was first synthesized in 1951 by a French 
chemist, Paul Charpentier. Its use for treatment of psychosis revealed a plethora of negative 
side effects such as tardive dyskinesia, memory loss and hypotension.
6
 However, favourable 
effects were also discovered when it was introduced in TB chemotherapy. Patients displayed 
alleviation of TB symptoms and in some cases an almost complete cure.
6,8
 This observation 
was noted during the reign of rifampicin and isoniazid as potent anti-TB drugs, therefore 
novel anti-TB agents were not of imperative research interest. Nevertheless, research interest 
in chlorpromazine was not entirely weakened. Thioridazine, another phenothiazine 
derivative, was later developed and was found to be the least potent phenothiazine 
neuroleptic with much milder side effects including drowsiness. Severe side effects of 
thioridazine are much less frequent and may include QT interval prolongation and episodes 




1.3.2 Neuroleptic action of phenothiazines by blockade of CNS receptors 
The neuroleptic action of phenothiazines and related drugs has been linked to the blockade of 
serotonergic and dopaminergic receptors. They also inhibit other central nervous system 
(CNS) receptors including muscarinic, GABA-ergic, α-adrenergic and histamine receptors. 
Their affinity for CNS receptors is attributable to their structural resemblance to monoamine 





Figure 1.3: Examples of monoamine neurotransmitters. 
 
 






The dopamine receptors are categorized into two primary groups, D1-like receptors (D1 & D5) 
as well as D2-like receptors (D2, D3 & D5). Both receptor families are G-protein-coupled 
receptors that are associated with the activation of adenylate cyclase.  Phenothiazines are 
known to be potent D2 receptor antagonists. Their high affinity for dopamine receptors is 








1.3.3 Repurposing of neuroleptic phenothiazines and related drugs 
The repurposing of phenothiazines and their structural relatives has been investigated 
extensively. As previously mentioned, these drugs have been reported to possess a broad 
spectrum of non-neuroleptic biological activities including antimycobacterial, antiparasitic, 
anticancer, antiviral activities and many more.
6,55,58 
 Of the phenothiazines investigated for 
antimicrobial bio-activities, thioridazine has attracted the most research interest owing to its 
milder side effects. It also shows great potential as an adjuvant in treatment of antibiotic-
resistant TB infections.
1,59











clinical trials against XDR-TB in combination with other drugs such as linezolid and 
moxifloxacin (Figure 1.5).
60,61,62  
Other recent reports include its antitrypanosomal activity 
and reduction of tumor growth in a murine breast cancer model.
63,64
 Imipramine, a 
phenothiazine structural relative, has also been repurposed for various indications including 


























1.3.4 Repositioning of phenothiazines  
The phenothiazine core structure is a privileged scaffold that serves as a pharmacophoric 
subunit for the design of novel structures with a wide range of biological applications. 
Structures of these antipsychotics have been remodelled for a variety of indications including 




1.3.4.1 Antimycobacterial activity of remodelled phenothiazines 
 Phenothiazines and their structural relatives have long been known for their 
antimycobacterial activity. Literature reports have revealed libraries of remodelled 
phenothiazines that display promising antimycobacterial activities.
68,69,70 
In most cases the 
investigation of neuroleptic properties of the remodelled structures is rarely conducted. 
Selected examples of remodelled phenothiazines with antitubercular activity at MICs ranging 
from 0.5-25 µg/mL are given in Table 1.4.  
 
  
Table 1.4: Selected examples of remodelled phenothiazines that show in vitro antitubercular activity 
Phenothiazine Derivative                            Antitubercular 
Activity 

















dopamine and serotonin 
receptor binding activity; 
% inhibition of 
dopamine and serotonin 
receptor subtypes ranged 
from 0% (5-HT2A)  to 
97% (D3) 
 
   Madrid et al., 2007
72
 




Table 1.4 continued…    
Phenothiazine Derivative                            Antitubercular 
Activity 






Displayed no dopamine 
and serotonin activity. 
Only one derivative (X = 














R = Aliphatic or     















MIC- Minimum inhibitory concentration; Structures shown are the most active compounds as per reports. 
 
 
1.3.4.2 Antifungal and antiparasitic properties of remodelled phenothiazines 
Remodelled phenothiazines have also been reported to show antifungal and antiparasitic 
activities (Table 1.5). They have exhibited activity against various types of fungi including 
Candida albicans, Aspergillus flavus, and Exophiala xenobiotica.
70,75
 Their antiparasitic  
acitivities have been demonstrated in various indications including malaria and Chagas 
disease.
76,77 






Table 1.5: Selected examples of remodelled phenothiazines that show in vitro antifungal and antiparasitic 
activities 
Phenothiazine Derivative                            Antifungal/  
Antiparasitic 
Activity 
Investigation of CNS 
Receptor Binding 
  Reference 







































MIC-Minimum inhibitory concentration; EC50-half maximal effective concentration; IC50- half maximal inhibitory 
concentration; Structures shown are the most active compounds as per reports. 
 
 
1.3.4.3 Anticancer activity of remodelled phenothiazines 
Apart from remodelled phenothiazines showing great potential as antimicrobial agents, 
sporadic reports have shown their potential in non-communicable diseases such as cancer.   






Phenothiazine derivatives have shown anticancer activity against a variety of cancer cell 
types including leukaemia, melanoma and CNS cancer (Table 1.6).
78,79,80 
In other reports, 
remodelled structures displayed significant antiproliferative activity as well as activity against 





Table 1. 6: Selected examples of remodelled phenothiazines that show anticancer activity 
Phenothiazine 
Derivative                            
Anticancer 
Activity 
Investigation of CNS 
Receptor Binding 
  Reference 
 
 
ITP IC50  :11.82 µM 
GI50 :  0.030 µM 





    





























>  40 µM 
Binding to dopamine 
receptor subtypes (D1-D5) 
was less than 10% at 0.1 
mM, and greater at 1.0 
mM ligand concentration 





ITP-Inhibition of tubulin polymerization; IC50- half maximal inhibitory concentration; GI50- molar concentration indicating 
50% growth inhibition of cancer cells; Structures shown are the most active compounds as per reports. 





1.4 Documented non-neuroleptic modes of action of phenothiazines  
Phenothiazines interfere with a number of metabolic pathways that are crucial for survival of 
pathogenic microorganisms. Reports reveal that they inhibit type II NADH:menaquinone 
odixoreductase, an essential enzyme involved in the respiratory chain.
82,83 
More recently, 
Warman et al. provided further validation that type II NADH: menaquinone oxidoreductase 
is a molecular target of phenothiazines in M.tb.
84
 Phenothiazines are also reported to have  





Phenothiazines also inhibit calcium (Ca
2+
) transportation consequently preventing its binding 
to Ca
2+
-binding proteins such as calmodulin. This in turn inhibits Ca
2+
-dependent enzyme 
systems such as ATP hydrolysis for cellular energy.
9 
Their drug resistance reversal properties 
are conferred by their ability to inhibit Ca-calmodulin binding in synergistic combination 
with other antibiotics. Moreover, they interfere with bacterial efflux pump mechanisms which 





In various studies, phenothiazine analogs exhibited inhibition against P-glycoprotein efflux 
pumps in Staphylococcus aureus, which confer resistance to fluoroquinolone drugs and also 
activity against efflux pumps present in Escherichia coli.
86 
Other reports reveal that due to 
increased permeability resulting from efflux pump inhibition, phenothiazines interfere with 
DNA-based processes thereby inhibiting replication.
9 
 
Abuhaie and co-workers reported novel phenothiazine-bearing compounds with significant 
activities against cell proliferation and tubulin polymerization.78 Another study by Belei et al. 
demonstrated that phenothiazine derivatives containing a 1,2,3-triazole motif could be  
 






potential inhibitors of farnesyltransferase, an enzyme involved the membrane localization of 
G-protein-Ras.
79 
Thioridazine was found to induce autophagy in glioblastoma and also 
upregulated the activity of Adenosine monophosphate-activated protein kinase (AMPK), an 
enzyme that plays a crucial role in cellular energy homeostasis.
87
  Moreover, thioridazine has 
also been reported to inhibit trypanothione reductase, an enzyme that is essential for the 




1.5 Adverse side effects of phenothiazines preclude their use in other indications 
As discussed earlier, the neuroleptic action of phenothiazines is associated with a blockade of 
CNS dopaminergic receptors. Phenothiazines are also associated with adverse side effects 
including extrapyramidal symptoms such as tardive dyskinesia and bradykinesia.
56,88
 At 
clinically relevant doses, inherent neuroleptic effects along with potential side effects 
preclude their extensive use in other indications. Many studies have reported on structural 
remodelling of phenothiazines for non-neuroleptic bio-activities.
70,74,78,79
 However, 
investigation of their inherent neuroleptic properties is seldom reported and could potentially 
present  hurdles  at late-stage drug development. 
  
 
Novel functionalities that are dissimilar to typical structures of phenothiazine drugs could be 
introduced through drug remodelling. However, it is important to fully probe and understand 
minimal structural requirements for neuroleptic activity. Deviation from these requirements 










(1)  Amaral, L.; Viveiros, M. Why Thioridazine in Combination with Antibiotics Cures Extensively Drug-
Resistant Mycobacterium Tuberculosis Infections. Int. J. Antimicrob. Agents 2012, 39 (5), 376–380. 
(2)  Amaral, L. Totally Drug Resistant Tuberculosis Can Be Treated with Thioridazine in Combination with 
Antibiotics to Which the Patient Was Initially Resistant. Biochem. Pharmacol. Open Access 2012, 01 
(01), 1–2. 
(3)  WHO. http://www.who.int/drugresistance/documents/situationanalysis/en/ (accessed 07/10/2015) 
Worldwide Country Situation Analysis : Response to Antimicrobial Resistance; 2015. 
(4)  WHO. http://www.who.int/tb/publications/global_report/en/ (accessed 30/05/2015), Global 
Tuberculosis Report; 2014. 
(5)  Mazumdar, K.; Asok Kumar, K.; Dutta, N. K. Potential Role of the Cardiovascular Non-Antibiotic 
(Helper Compound) Amlodipine in the Treatment of Microbial Infections: Scope and Hope for the 
Future. Int. J. Antimicrob. Agents 2010, 36 (4), 295–302. 
(6)  Wainwright, M. The Evolution of Antimycobacterial Agents from Non- Antibiotics. Open J. 
Pharmacol. 2012, 2–1. 
(7)  Kristiansen, J. E.; Hendricks, O.; Delvin, T.; Butterworth, T. S.; Aagaard, L.; Christensen, J. B.; Flores, 
V. C.; Keyzer, H. Reversal of Resistance in Microorganisms by Help of Non-Antibiotics. J. Antimicrob. 
Chemother. 2007, 59, 1271–1279. 
(8)  Wainwright, M.; Amaral, L. The Phenothiazinium Chromophore and the Evolution of Antimalarial 
Drugs. Trop. Med. Int. Heal. 2005, 10 (6), 501–511. 
(9)  Martins, M.; Dastidar, S. G.; Fanning, S.; Kristiansen, J. E.; Molnar, J.; Pag, J.; Schelz, Z.; Spengler, G.; 
Viveiros, M.; Amaral, L. Potential Role of Non-Antibiotics ( Helper Compounds ) in the Treatment of 
Multidrug-Resistant Gram-Negative Infections: Mechanisms for Their Direct and Indirect Activities. 
Int. J. Antimicrob. Agents 2008, 31, 198–208. 
(10)  Lewis K. Platforms for Antibiotic Discovery. Nat. Rev. Drug Discov. 2013, 12, 371–387. 
(11)  Ventola, C. L. The Antibiotic Resistance Crisis Part 1: Causes and Threats. P T 2015, 40 (4), 277–283. 
(12)  Jaramillo Ernesto; Weyer Karin; Raviglione Mario. Linezolid for Extensively Drug-Resistant 
Tuberculosis. N Engl J Med 2013, 368 (3), 290–291. 
(13)  Bayer A.S.; Schneider T; Sahl H.G. Mechanisms of Daptomycin Resistance in Staphylococcus Aureus: 
Role of the Cell Membrane and Cell Wall. Ann N Y Acad Sci 2013, 1277, 139–158. 
(14)  Pluta, K.; Morak-Młodawska, B.; Jeleń, M. Recent Progress in Biological Activities of Synthesized 
Phenothiazines. Eur. J. Med. Chem. 2011, 46 (8), 3179–3189. 
(15)  Tan, Y. T.; Tillett, D. J.; McKay, I. A. Molecular Strategies for Overcoming Antibiotic Resistance in 
Bacteria. Mol. Med. Today 2000, 6 (8), 309–314. 
(16)  Kristiansen, J. E.; Thomsen, V. F.; Martins, A.; Viveiros, M.; Amaral, L. Non-Antibiotics Reverse 
Resistance of Bacteria to Antibiotics. In Vivo (Brooklyn). 2010, 24 (5), 751–754. 
(17)  Sarkar, S.; Suresh, M. R. An Overview of Tuberculosis Chemotherapy - A Literature Review. J. Pharm. 
Pharm. Sci. 2011, 14 (2), 148–161. 




(18)  Hughes, J. P.; Rees, S. S.; Kalindjian, S. B.; Philpott, K. L. Principles of Early Drug Discovery. Br. J. 
Pharmacol. 2011, 162 (6), 1239–1249. 
(19)  Kharkar, P. S. Drugs Acting on Central Nervous System (CNS) Targets as Leads for Non-CNS Targets. 
F1000Research 2014, 3 (40), 1–7. 
(20)  Persaud-Sharma V; Zhou S. Drug Repositioning: A Faster Path to Drug Discovery. Adv. 
Pharmacoepidemiol. Drug Saf. 2012, 1 (6), 1–3. 
(21)  Oprea, T. I.; Mestres, J. Drug Repurposing: Far Beyond New Targets for Old Drugs. Am. Assoc. Pharm. 
Sci. 2012, 14 (4), 759–763. 
(22)  Allarakhia, M. Open-Source Approaches for the Repurposing of Existing or Failed Candidate Drugs: 
Learning from and Applying the Lessons across Diseases. Drug Des. , Dev. Ther. 2013, 7, 753–766. 
(23)  Njoroge, M.; Njuguna, N. M.; Mutai, P.; Ongarora, D. S. B.; Smith, P. W.; Chibale, K. Recent 
Approaches to Chemical Discovery and Development Against Malaria and the Neglected Tropical 
Diseases Human African Trypanosomiasis and Schistosomiasis. Chem. Rev. 2014, 114, 11138–11163. 
(24)  Ma D; Chan D; Leung C. Drug Repositioning by Structure-Based Virtual Screening. Chem. Soc. Rev. 
2013, 42, 2130–2141. 
(25)  Shim, J. S.; Liu, J. O. Recent Advances in Drug Repositioning for the Discovery of New Anticancer 
Drugs. Int. J. Biol. Sci. 2014, 10 (7), 654–663. 
(26)  Rangel-Vega, A.; Bernstein, L. R.; Mandujano-tinoco, E. A.; Debabov, D.; Visca, P. Drug Repurposing 
as an Alternative for the Treatment of Recalcitrant Bacterial Infections. Front. Microbiol. 2015, 6 (282), 
1–8. 
(27)  Andrews, K. T.; Fisher, G.; Skinner-adams, T. S. International Journal for Parasitology : Drugs and 
Drug Resistance Drug Repurposing and Human Parasitic Protozoan Diseases. Int. J. Parasitol. Drugs 
Drug Resist. 2014, 4 (2), 95–111. 
(28)  Rajkumar, S. V.; Fonseca, R.; Dispenzieri, A.; Lacy, M. Q.; Lust, J. A.; Kyle, R. A.; Gertz, M. A.; 
Griepp, P. R. Thalidomide in the Treatment of in the Treatment of Relapsed Multiple Myeloma. Mayo 
Clin Proc 2000, 75 (9), 897–901. 
(29)  Ordway, D.; Viveiros, M.; Leandro, C.; Almeida, J.; Martins, M.; Jette, E.; Molnar, J.; Amaral, L.; 
Kristiansen, J. E. Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant 
Mycobacterium Tuberculosis. Antimicrob. Agents Chemother. 2003, 47 (3), 917–922. 
(30)  Singh, A.; Sharma, S. Chemotherapeutic Efficacy of Thioridazine as an Adjunct Drug in a Murine 
Model of Latent Tuberculosis. Tuberculosis 2014, 94 (6), 695–700. 
(31)  Montoya, J. G.; Liesenfeld, O. Toxoplamosis. Lancet 2004, 363 (9425), 1965–1976. 
(32)  Saulnier Sholler, G. L.; Kalkunte, S.; Greenlaw, C.; McCarten, K.; Forman, E. Antitumor Activity of 
Nifurtimox Observed in a Patient with Neuroblastoma. J. Pediatr. Heamtol. Oncol. 2006, 28 (10), 693–
695. 
(33)  Rosch, J. W.; Boyd, A. R.; Hinojosa, E.; Pestina, T.; Hu, Y.; Persons, D. A.; Orihuela C.J.; Toumanen 
E. I. Statins Protect against Fulminant Pneumococcal Infection and Cytolysin Toxicity in a Mouse 
Model of Sickle Cell Disease. J. Clin. Invest. 2010, 120 (2), 627–635. 
(34)  Tan, K. R.; Magill, A. J.; Parise, M. E.; Arguin, P. M. Doxycycline for Malaria Chemoprophylaxis and 
Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis. Am. J. Trop. Med. 
2011, 84 (4), 517–531. 




(35)  Bird, M. R.; O‘Neill, A. I.; Buchanan, R. R.; Ibrahim, K. M.; Des Parkin, J. Lupus Anticoagulant in the 
Elderly May Be Associated with Both Quinine and Quinidine Usage. Pathology 1995, 27 (2), 136–139. 
(36)  Murphy, G., Lisnevskaia, L., Isenberg, D. Systemic Lupus Erythematosus and Other Autoimmune 
Rheumatic Diseases: Challenges to Treatment. Lancet 2013, 382 (9894), 809–818. 
(37)  Febbraro, T.; Lengyel, E.; Romero, I. L. Old Drug, New Trick: Repurposing Metformin for 
Gynecologic Cancers. Gynecol OnCol 2014, 135 (3), 614–621. 
(38)  Pantziarka, P.; Bouche, G.; Meheus, L.; Sukhatme, V.; Sukhatme, V. P. Repurposing Drugs in 
Oncology ( ReDO )— Mebendazole as an Anti-Cancer Agent. ecancer Med. Sci. 2014, 8 (443), 1–16. 
(39)  Lee M; Lee J; Carroll MW; Min S; Song T; Via LE; Goldfeder LC; Kang E; Jin B; Park H; Kwak H; 
Kim H; Jeon HS; Jeong I; Joh JS; Chen RY; Olivier KN; Shaw PA; Follmann D; Song SD; Lee JK; Lee 
D; Kim CT; Dartois V; Park SK; Cho SN; Barry CE 3rd. Linezolid for Treatment of Chronic 
Extensively Drug-Resistant Tuberculosis. N Engl J Med 2012, 367 (16), 1508–1518. 
(40)  Ambrosio, L. D.; Centis, R.; Sotgiu, G.; Pontali, E.; Spanevello, A.; Migliori, G. B. New Anti-
Tuberculosis Drugs and Regimens: 2015 Update. ERJ Open Res. 2015, 1, 1–15. 
(41)  Bhattacharya, A.; Kaur, H.; Kumar Lal, N.; Bharti, N. Repurposing Antimalarial Artemisinin against 
Candidiasis. Int. J. Pharm. Sci. Rev. Res. 2015, 32 (1), 143–147. 
(42)  Celegato, M.; Borghese, C.; Casagrande, N.; Mongiat, M.; Kahle, X. U.; Paulitti, A.; Michele Spina; 
Alfonso Colombatti; Aldinucci, D. Preclinical Activity of Repurposed Drug Auranofin in Classical 
Hodgkin Lymphoma. Blood 2015, 126 (11), 1394–1397. 
(43)  Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The Challenge of New Drug Discovery 
for Tuberculosis. Nature 2011, 469 (7331), 483–490. 
(44)  Kristiansen, J. E.; Amaral, L. The Potential Management of Resistant Infections with Non-Antibiotics. 
J. Antimicrob. Chemother. 1997, 40 (3), 319–327. 
(45)  El-Nakeeb, M. A.; Abou-Shleib, H. M.; Khalil, A. M.; Omar, H. G.; El-Halfawy, O. M. In Vitro 
Antibacterial Activity of Some Antihistamines Belonging to Different Groups against Multi-Drug 
Resistant Clinical Isolates. Brazilian J. Microbiol. 2011, 42, 980–991. 
(46)  Mazur, I.; Wurzer, W. J.; Ehrhardt, C.; Pleschka, S.; Puthavathana, P.; Silverzahn, T.; Wolff, T.; Planz, 
O.; Ludwig, S. Acetylsalicylic Acid (ASA) Blocks Influenza Virus Propagation via Its NF-kB-Inhibiting 
Activity. Cell Microbiol. 2007, 9 (7), 1683–1694. 
(47)  Al-Janabi, A. A. H. S. In Vitro Antibacterial Activity of Ibuprofen and Acetaminophen. J. Glob. Infect. 
Dis. 2010, 2 (2), 105–108. 
(48)  Salem-Milani, A.; Balaei-Gajan, E.; Rahimi, S.; Moosavi, Z.; Abdollahi, A.; Zakeri-Milani, P.; 
Bolourian, M. Antibacterial Effect of Diclofenac Sodium on Enterococcus Faecalis. J Dent 2013, 10 (1), 
16–22. 
(49)  Pelosini L; Treffene S; Hollick EJ. Antibacterial Activity of Preservative-Free Topical Anesthetic Drops 
in Current Use in Ophthalmology Departments. Cornea 2009, 28 (1), 58–61. 
(50)  Hendricks, O.; Butterworth, T. S.; Kristiansen, J. E. The in- v Itro Antimicrobial Effect of Non-
Antibiotics and Putative Inhibitors of Efflux Pumps on Pseudomonas Aeruginosa and Staphylococcus 
Aureus. Int. J. Antimicrob. Agents 2003, 22, 262–264. 




(51)  Basco LK; Le Bras J. In Vitro Activities of Chloroquine in Combination with Chlorpromazine or 
Perchlorperazine against Isolates of Plasmodium Falciparum. Antimicrob. Agents Chemother. Agents 
Chemother 1992, 36, 209–213. 
(52)  Cohn, R. C.; Jacobs, M.; Aronoffl, S. C. In Vitro Activity of Amiloride Combined with Tobramycin 
against Pseudomonas Isolates from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 1988, 
32 (3), 395–396. 
(53)  Andersen, C.; Holland, I.; Jacq, A. Verapamil, A Ca
2+
 Channel Inhibitor Acts as a Local Anaesthetic 
and Induces the Sigma E Dependent Extra-Cytoplasmic Stress Response in E. Coli. Biochim Biophys 
Acta 2006, 1758 (10), 1587–1595. 
(54)  Feinberg, A. P.; Snyder, S. H. Phenothiazine Drugs: Structure-Activity Relationships Explained by a 
Conformation That Mimics Dopamine. Proc. Nat. Acad. Sci. 1975, 72 (5), 1899–1903. 
(55)  Jaszczyszyn, A.; Ga siorowski, K.;  wia tek, P.; Malinka, W.; Cieślik-Boczula, K.; Petrus, J.; Czarnik-
Matusewicz, B. Chemical Structure of Phenothiazines and Their Biological Activity. Pharmacol. 
Reports 2012, 64 (1), 16–23. 
(56)  Jafari, S.; Fernandez-Enright, F.; Huang, X. F. Structural Contributions of Antipsychotic Drugs to Their 
Therapeutic Profiles and Metabolic Side Effects. J. Neurochem. 2012, 120 (3), 371–384. 
(57)  Seeman, P. Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clin. Schizophr. Relat. 
Psychoses 2010, 4 (1), 56–73. 
(58)  Sudeshna, G.; Parimal, K. Multiple Non-Psychiatric Effects of Phenothiazines: A Review. Eur. J. 
Pharmacol. 2010, 648 (1-3), 6–14. 
(59)  Van Soolingen, D.; Hernandez-Pando, R.; Orozco, H.; Aguilar, D.; Magis-Escurra, C.; Amaral, L.; Van 
Ingen, J.; Boeree, M. J. The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a 
Mouse Model of Multidrug-Resistant Tuberculosis. PLoS One 2010, 5 (9), 1–6. 
(60)  Alsaad, N.; Wilffert, B.; van Altena, R.; de Lange, W. C. M.; van der Werf, T. S.; Kosterink, J. G. W.; 
Alffenaar, J.-W. C. Potential Antimicrobial Agents for the Treatment of Multidrug-Resistant 
Tuberculosis. Eur. Respir. J. 2014, 43 (3), 884–897. 
(61)  Amaral, L.; Boeree, M.; Gillespie, S.; Udwadia, Z.; van Soolingen, D. Thioridazine Cures Extensively 
Drug-Resistant Tuberculosis (XDR-TB) and the Need for Global Trials Is Now! Int. J. Antimicrob. 
Agents 2010, 35 (6), 524–526. 
(62)  Udwadia, Z. F.; Sen, T.; Pinto, L. M. Safety and Efficacy of Thioridazine as Salvage Therapy in Indian 
Patients with XDR-TB. Recent Pat Antiinfect Drug Discov 2011, 6, 88–91. 
(63)  Lo Presti, M. S.; Bazán, P. C.; Strauss, M.; Báez, A. L.; Rivarola, H. W.; Paglini-Oliva, P. a. 
Trypanothione Reductase Inhibitors: Overview of the Action of Thioridazine in Different Stages of 
Chagas Disease. Acta Trop. 2015, 145, 79–87. 
(64)  Yin T; He S; Shen G; Ye T; Guo F; Wang Y. Dopamine Receptor Antagonist Thioridazine Inhibits 
Tumor Growth in a Murine Breast Cancer Model. Mol. Med. Rep. 2015, 12 (3), 4103–4108. 
(65)  Dutta P; Pinto J; Rivlin R. Antimalarial Properties of Imipramine and Amitriptyline. J Protozool 1990, 
37 (1), 54–58. 
(66)  Jeon, S.; Kim, S.; Kim, Y.; Kim, Y.; Lim, Y.; Lee, Y.; Shin, S. The Tricyclic Antidepressant 
Imipramine Induces Autophagic Cell Death in U-87MG Glioma Cells. Biochem Biophys Res Commun 
2011, 413 (2), 311–317. 




(67)  Godbole, A. A.; Ahmed, W.; Bhat, R. S.; Bradley, E. K.; Ekins, S.; Nagaraja, V. Targeting 
Mycobacterium Tuberculosis Topoisomerase I by Small-Molecule Inhibitors. Antimicrob. Agents 
Chemother. 2015, 59 (3), 1549–1547. 
(68)  He, C.-X.; Meng, H.; Zhang, X.; Cui, H.-Q.; Yin, D.-L. Synthesis and Bioevaluation of Phenothiazine 
Derivatives as New Antituberculosis Agents. Chinese Chem. Lett. 2015, 26 (08), 951–954. 
(69)  Addla, D.; Jallapally, A.; Gurram, D.; Yogeeswari, P.; Sriram, D.; Kantevari, S. Rational Design, 
Synthesis and Antitubercular Evaluation of Novel 2-(trifluoromethyl)phenothiazine[1,2,3]triazole 
Hybrids. Bioorg. Med. Chem. Lett. 2014, 24 (1), 233–236. 
(70)  Sharma, R.; Samadhiya, P.; Srivastava, S. D.; Srivastava, S. K. Synthesis and Pharmaceutical 
Importance of 2-Azetidinone Derivatives of Phenothiazine. J. Chem. Sci. 2012, 124 (3), 633–637. 
(71)  Bate, A. B.; Kalin, J. H.; Fooksman, E. M.; Amorose, E. L.; Price, C. M.; Williams, H. M.; Rodig, M. J.; 
Mitchell, M. O.; Cho, S. H.; Wang, Y.; Franzblau, S. G. Synthesis and Antitubercular Activity of 
Quaternized Promazine and Promethazine Derivatives. Bioorg. Med. Chem. Lett. 2007, 17 (5), 1346–
1348. 
(72)  Madrid, P. B.; Polgar, W. E.; Tanga, M. J. Synthesis and Antitubercular Activity of Phenothiazines with 
Reduced Binding to Dopamine and Serotonin Receptors. Bioorg. Med. Chem. Lett. 2007, 17, 3014–
3017. 
(73)  Salie, S.; Hsu, N.; Semenya, D.; Jardine, A.; Jacobs, M. Novel Non-Neuroleptic Phenothiazines Inhibit 
Mycobacterium Tuberculosis Replication. J. Antimicrob. Chemother. 2014, 69 (6), 1551–1558. 
(74)  Dunn, E. A.; Roxburgh, M.; Larsen, L.; Smith, R. A. J.; McLellan, A. D.; Heikal, A.; Murphy, M. P.; 
Cook, G. M. Incorporation of Triphenylphosphonium Functionality Improves the Inhibitory Properties 
of Phenothiazine Derivatives in Mycobacterium Tuberculosis. Bioorg. Med. Chem. 2014, 22 (19), 
5320–5328. 
(75)  Sarmiento, G. P.; Vitale, R. G.; Afeltra, J.; Moltrasio, G. Y.; Moglioni, A. G. Synthesis and Antifungal 
Activity of Some Substituted Phenothiazines and Related Compounds. Eur. J. Med. Chem. 2011, 46 (1), 
101–105. 
(76)  Khan, M.; Austin, S.; Chan, C.; Yin, H.; Marks, D.; Vaghjiani, S.; Kendrick, H.; Yardley, V.; Croft, S.; 
Douglas, K. Use of an Additional Hydrophobic Binding Site, the Z Site, in the Rational Drug Design of 
a New Class of Stronger Trypanothione Reductase Inhibitor, Quaternary Alkylammonium 
Phenothiazines. J. Med. Chem. 2000, 43, 3148–3156. 
(77)  Dominquez, J.; Lopez, S.; Charris, J.; Iarruso, L.; Lobo, G.; Semenov, A.; Olson, J.; Rosenthal, P. 
Synthesis and Antimalarial Effects of Phenothiazine Inhibitors of a Plasmodium Falciparum Cysteine 
Protease. J. Med. Chem. 1997, 40, 2726–2732. 
(78)  Abuhaie, C.-M.; Bîcu, E.; Rigo, B.; Gautret, P.; Belei, D.; Farce, A.; Dubois, J.; Ghinet, A. Synthesis 
and Anticancer Activity of Analogues of Phenstatin , with a Phenothiazine A-Ring , as a New Class of 
Microtubule-Targeting Agents. Bioorg. Med. Chem. Lett. 2013, 23 (1), 147–152. 
(79)  Belei, D.; Dumea, C.; Samson, A.; Farce, A.; Dubois, J.; Bîcu, E.; Ghinet, A. New Farnesyltransferase 
Inhibitors in the Phenothiazine Series. Bioorganic Med. Chem. Lett. 2012, 22 (14), 4517–4522. 
(80)  Kastrinsky, D. B.; Sangodkar, J.; Zawarea, N.; Izadmehr, S.; Dhawanb, N. S.; Goutham, N.; Ohlmeyer, 
M. Reengineered Tricyclic Anti-Cancer Agents. Bioorg. Med. Chem. 2015, 23 (19), 6528–6534. 
(81)  Baciu-Atudosie, L.; Ghinet, A.; Farce, A.; Dubois, J.; Belei, D.; Bîcu, E. Synthesis and Biological 
Evaluation of New Phenothiazine Derivatives Bearing a Pyrazole Unit as Protein Farnesyltransferase 
Inhibitors. Bioorg. Med. Chem. Lett. 2012, 22 (22), 6896–6902. 




(82)  Weinstein, E. A.; Yano, T.; Li, L.; Avarbock, D.; Avarbock, A.; Helm, D.; Mccolm, A. A.; Duncan, K.; 
Lonsdale, J. T.; Rubin, H. Inhibitors of Type II NADH : Menaquinone Oxidoreductase Represent a 
Class of Antitubercular Drugs. 2005. 
(83)  Teh, J. S.; Yano, T.; Rubin, H. Type II NADH: Menaquinone Oxidoreductase of Mycobacterium 
Tuberculosis. Infect. Disord. Drug Targets 2007, 7 (2), 169–181. 
(84)  Warman, A. J.; Rito, T. S.; Fisher, N. E.; Moss, D. M.; Berry, N. G.; O‘Neill, P. M.; Ward, S. A.; 
Biagini, G. A. Antitubercular Pharmacodynamics of Phenothiazines. J. Antimicrob. Chemother. 2013, 
68 (4), 869–880. 
(85)  Amaral, L.; Viveiros, M.; Molnar, J. Antimicrobial Activity of Phenothiazines. In Vivo. 2004, 18, 725–
731. 
(86)  Kaatz, G. W.; Moudgal, V. V; Seo, S. M.; Kristiansen, E.; Kristiansen, J. E. Phenothiazines and 
Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus Aureus. Antimicrob. Agents 
Chemother. 2003, 47 (2), 719–726. 
(87)  Cheng, H.; Liang, Y.; Kuo, Y.; Chuu, C.; Lin, C.; Lee, M.; Wu, A. T. H.; Yeh, C.; Chen, E.; Su, C. 
Identification of Thioridazine , an Antipsychotic Drug , as an Antiglioblastoma and Anticancer Stem 
Cell Agent Using Public Gene Expression Data. Cell Death Dis. 2015, 6, 1–13. 
(88)  Field, S. K.; Fisher, D.; Jarand, J. M.; Cowie, R. L. New Treatment Options for Multidrug-Resistant 


















Drug remodelling of neuroleptics and incorporation of in silico techniques 
for drug-likeness assessment 
Preface  
Implementation of innovative drug discovery strategies is a global priority for rejuvenation of 
shrinking pharmaceutical drug pipelines. The evolution of antimicrobials from non-
antibiotics was reviewed in great detail in chapter 1. Drug repurposing is considered an 
appealing strategy in drug discovery thus exploiting clinically approved drugs for their 
validated pharmacokinetic and toxicological profiles. Second best to drug repurposing, drug 
remodelling is useful for creating New Chemical Entities (NCEs) with novel functionalities. 
Moreover, neuroleptic drugs were introduced as the non-antibiotics of interest for structural 
remodelling.  
 
In this chapter, the structural background of neuroleptic drugs including the minimum 
structural requirements for their neuroleptic activity is under review. The understanding of 
pharmacokinetics of drugs including ADMET (A: Absorption; D: Distribution; M: 
Metabolism: E: Excretion and T: Toxicity) is crucial in drug discovery and development, a 
discussion is provided herein. Also, herein, the rationale behind this research study as well as 
specific aims and objectives are outlined. Furthermore, a discussion of the rationally selected 
strategies for remodelling central nervous system (CNS) drugs for non-neuroleptic bio-
activities is provided. Lastly, the integration of in silico prediction tools in the remodelling 
for assessing drug-likeness of the NCEs is described. This includes prediction of CNS 
activity to generate NCEs that are less likely to exhibit neuroleptic effects. 
 





2.1 The chemistry background of neuroleptics 
Structural diversity of neuroleptics brings about their wide spectrum of neuropharmacological 
properties and various therapeutic effects. Neuroleptic drugs exert their neuroleptic action by 
a blockade of CNS receptors including dopaminergic (D1-5), serotonergic (5-HT), muscarinic 
(M1-5), adrenergic (α1-2) and histamine (H1-4) receptors.
1,2  
 
These drugs are generally categorized into two major classes i.e. first generation and second 
generation agents. The former is commonly referred to as ‗typical‘ antipsychotics and the 
latter as ‗atypical‘ antipsychotics. The distinction between the two classes is primarily based 
on their likelihood to produce undesirable extrapyramidal side effects. Atypical 




The two main classes consist of various heterocycles including tricyclic and tetracyclic ring 
systems such as phenothiazines, butyrophenones, thioxanthenes and dibenzodiazepines. 
Binding affinity for CNS receptors varies depending on the nature of these heterocyclic 
drugs.
1,3,4 
Examples of clinically approved typical and atypical antipsychotic drugs, their 
chemical classification along with the types of CNS receptors they inhibit have been 














Table 2.1: Chemical classification of typical and atypical antipsychotics and examples of CNS receptor 
subtypes exhibiting strong binding affinity. (Neurotransmitter: NT; Receptor subtype: RS)
 
Typical antipsychotics Atypical antipsychotics 
Phenothiazines Dibenzodiazepine Thienobenzodiazepine 
         





NT                           RS     
Dopamine               D2, D1, D3 
Serotonin                5-HT2A, 5-HT2C 
Adrenaline              α1 
Histamine               H1 
NT                     RS 
Acetylcholine    M1 
Adrenaline        α1 
Histamine         H1 
Serotonin          5-HT2C 
NT                       RS 
Acetylcholine      M1 
Histamine           H1 
Serotonin            5-HT2A 
                             Butyrophenones             Dibenzothiazepine  Benzisoxazole 
                                                            
                                                                              
                                                                                            









NT                             RS 
Dopamine                 D2 
Adrenaline                α1 
Serotonin                  5-HT2A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
NT                    RS 
Histamine        H1 
Adrenaline       α1 
NT                     RS 
Adrenaline        α1 
Serotonin          5-HT2A 
Dopamine  D2 
                             Thioxanthenes      
          
                                                                                  
Thiothixene                          Chlorprothixene                           
                         Indole 
 
 
                              
                           Ziprasidone 
NT                           RS 
Dopamine               D2 
Histamine               H1 
Adrenaline              α1 
NT                           RS 
Serotonin                 5-HT2A, 5-HT2C  
Dopamine                D2 
Adrenaline               α1 
 
 





2.1.1 Historical background  
Psychiatric application of neuroleptic drugs in management of psychotic disorders spans over 
many decades. Neuroleptic drugs, phenothiazines in particular, structurally evolved from 
methylene blue. Chlorpromazine was first prepared by a French chemist, Paul Charpentier, in 
1951 and became available as a prescription drug around 1952 in France.
1,5
 The 
psychotherapeutic use of chlorpromazine was deemed a significant breakthrough in 
neuropsycopharmacology. Shortly thereafter, other structurally related antipsychotics were 





In 1971, clozapine, the first atypical antipsychotic was marketed in Europe. The discovery of 
structurally similar atypical drugs such as olanzapine followed a few years later.
1,7
 By the 
early 2000s, drugs such as ziprasidone and risperidone were introduced as psychotropics. The 
low risk of extrapyramidal effects development associated with these tetracyclic atypical 
antipsychotics is reportedly due to their unique chemical structures.
5,8,9,10 
A simplified 
timeline of clinically approved antipsychotic therapeutics is shown in Figure 2.1.
  
 
As discussed in chapter 1, phenothiazines have attracted notable research interest not only in 
neuropsychology but also for other indications.
1,2,11,12
 Therefore, the privileged phenothiazine 
scaffold and scaffolds of related neuroleptics are of interest to this research study partly  for 









Figure 2.1: A timeline of antipsychotic therapeutics since the early 1950s. 
 
2.1.2 General structures of phenothiazines and related drugs 
Various classes of antipsychotic drugs obey a lipophilic chromophore/basic side chain 
paradigm including phenothiazines as exemplified in Figure 2.2. The first preparation of a 
phenothiazine chromophore was achieved by August Bernthsen in 1883 via fusion of 




Figure 2.2: The phenothiazine chromophore showing the adopted nomenclature (left) and the general structure 
of phenothiazine drugs illustrating the lipophilic chromophore/basic side chain paradigm (right).  





The tricyclic phenothiazine chromophore is related to the thiazine class of heterocycles. 
Derivatization of the phenothiazine scaffold mostly occurs by substitution at the thiazine 
nitrogen and /or 2
nd
 position of the tricyclic ring system. Derivatives formed by substitution 
at the thiazine nitrogen are referred to as 10-H derivatives.
2,11 
Phenothiazine drugs currently 
in clinical use for treatment of psychosis are classified according to the type of terminal 
nitrogen moiety. The subgroups of these drugs include (i) aliphatics (bearing acyclic 
moieties); (ii) piperidines (bearing piperidine-derived moieties) and (iii) piperazines (bearing 




Figure 2.3:  Alkylaminoalkyl structure moieties for determining classes of phenothiazine drugs. 
 
Literature reports rank the intensity of their neuroleptic action based on the nature of the 
terminal amine moiety. The ranking (in decreasing order) is as follows: piperazine > 
piperidine > aliphatic. Other structural features essential for their neuroleptic action is nature 
of substitution at C-2 and length of alkyl chain linking thiazine and distal nitrogens. Electron-
withdrawing substituents at C-2 are known to intensify neuroleptic action as follows: - 
SO2NR2 > -CF3 > -COCH3 > -Cl.
2,14
 A full account of structural traits associated with their 
neuroleptic activity is  provided below. 
 
 





2.2 Structural traits and physicochemical properties for neuroleptic action 
2.2.1 Conformational resemblance to dopamine 
The three-dimensional configuration of phenothiazines and other structurally related drugs 




Figure 2.4: An illustration of the resemblance between chlorpromazine (A) and dopamine (B); Superimposition 
of B on part of A, 3-D structure obtained using ChemBio3D Ultra version 11.0. 
 
In 1975, Feinberg et al. conducted computational modelling studies to investigate the role of 
phenothiazine chemical structures in their interaction with dopaminergic receptors. In their 
findings, the nature of substituents at position-2 of the chromophore and the type of 
alkylamino side chain were determinants of binding affinity for dopaminergic receptors. This 
was attributed to the favourable Van der Waals interactions between the side chain (Ring A) 
















Figure 2.5: An energy-minimized conformation of trifluoperazine to illustrate the adopted dopamine-like 
configuration owing to Van der Waals forces (ChemBio3D Ultra version 11.0.). Alkylamino side chain tilts 
towards C-2 substituent promoting a dopamine-like configuration.
 
 
2.2.2 Higher degree of lipophilicity: Facilitates BBB penetration 
Permeation of the blood-brain barrier (BBB) is a prerequisite for CNS-active agents. A 
restrictive layer of endothelial cells with tight junctions constitutes the BBB. The protective 
barrier prevents passive diffusion of molecules from the blood stream into the CNS, 
particularly those greater than 20 Å in diameter.
16,17,18
 CNS drugs possess characteristic 
physicochemical parameters owing to the selectivity of the  BBB membrane. Lipid solubility 
is amongst others a crucial property of CNS drugs and is known to facilitate diffusion across 
the BBB. In contrast, highly polar molecules with a topological surface area (TPSA) greater 
than 90 Å
2




2.2.3 Ionizability: Protonation of the distal amine moiety 
Phenothiazines  are known to be amphiphilic in nature.
2
 In conjunction with a lipophilic 
chromophore, the majority of these drugs possess a basic alkylamino side chain.
1,2,11
 Apart 
from their lipophilic nature, the presence of a proton accepting amine species is known to  
 





favor penetration of the BBB. It is also known that at physiological pH, the distal amine 
moiety of these drugs acquires a positive charge.
2,11,22
 The strength of acidity and basicity is a 
crucial pKa determinant of diffusion across the BBB. Strongly acidic species (pKa < 4) and 




2.3 Overview of remodelling strategies reported in literature 
Seemingly trivial structural transformations such as substitution at position-2 of the ring have 
shown strong correlations to potency of these drugs. Numerous libraries of phenothiazine 
derivatives and related structures are documented in literature for biological activity or non-
biological applications.
2,11,19 
The tricyclic chromophore has several sites of possible 
modifications, hence the large number of structural diversifications reported.
2,11,22,24 
 
Structural modifications reported in literature include substitution around the tricyclic ring 
system, introduction of cyclic and non-cyclic alkyl side chains, increase in steric volume via 
dimerization or linkage to other heterocycles, introduction of heteroatoms into the ring 
system, oxidation of the thiazine sulfur, ring expansions and many more.
11
  In most cases 




Apart from understanding the minimum structural requirements for neuroleptic action of 
phenothiazines and related drugs, it is also important to understand drug metabolism and 
pharmacokinetics (DMPK) properties including ADMET properties that are associated with 









2.4 Significance of early ADMET evaluation 
Prior to the early 2000s, poor DMPK profiles were primary contributors to attrition in late-
stage drug development. Apart from poor pharmacokinetics, other factors such as toxicity, 
adverse effects and lack of efficacy largely contributed to failures of many drug 
candidates.
30,31 
It has therefore become routine for the aforementioned properties to be 




2.4.1 Overview of DMPK including ADMET 
In simple terms, pharmacokinetics is usually referred to as ‗what the body does to the drug‘ 
as opposed to pharmacodynamics which is ‗what the drug does to the body‘. 
Pharmacokinetics is the investigation of the time course of a drug within the body post-
administration and thus incorporates ADME processes.  Pharmacodynamics involves the 
relationship between concentration of a drug and the effects elicited at the site of action 
including mechanisms of its action.
30,34 
ADME encapsulates the processes involved in the 
fate of a drug within the body thus affects various parameters including the percentage of 




An orally-administered drug (non-intravenous administration) could either get excreted from 
the body without any biotransformation or could get absorbed through the gut wall followed 
by transportation to the liver. Many drug molecules transverse biological membranes by 
passive diffusion or as substrates of transporter proteins.
35
 Transporters could either promote 
or hinder permeability of molecules across membranes. Proteins such as P-glycoprotein and 
cytochrome P450 3A4 are known to serve as a barrier to absorption of drugs from the 
 







 The drug that is absorbed through the gut wall is transported to the 
liver via the hepatic portal vein. From the liver, the drug reaches the systemic circulation 




Elimination of foreign molecules (xenobiotics) including drug molecules primarily occurs via 
metabolism. Biotransformation of drugs to respective metabolites could occur before the drug 
reaches the systemic circulation. This happens primarily in the liver and/or sometimes in the 
gut wall and is referred to as first-pass metabolism.
30
  Metabolism is traditionally categorized 
into two phases i.e. phase I metabolism and phase II metabolism. The former involves 
functionalization of a drug molecule via redox reactions or hydrolysis whereby enzyme 
classes such as cytochrome P450s (CYP450s) play a crucial role.
37
 The latter involves further 
transformation of the functionalized molecule, although not necessarily sequential, via 




2.4.2 Evaluation of properties associated with ADMET 
As alluded to earlier, determination of ADMET via in silico predictions and subsequently in 
vitro or in vivo approaches is crucial at very early stages of drug development. In silico 
approaches are advantageous in that a virtual library of compounds is required hence less 
time-consuming and more cost-effective. Reliable ADMET predictive models may provide 
useful information prior to synthesis and subsequent in vitro and in vivo evaluation.   
 
2.4.3 In vitro and in vivo ADMET 
Various in vitro and in vivo models are utilized as standardised procedures for early hit-to-
lead optimization.
30,32  
Liver microsomal stability and whole hepatocyte models are the most 





common studies carried out for in vitro metabolism.
39
 The models involve major metabolic 
enzymes including CYP450 (Phase I metabolism) as well as UDP-glucuronosyltransferase 
(phase II metabolism).
32,38
 For evaluation of cell permeability, key in vitro assays include 
Caco-2 or MDCK cell-based models.
30,38,40
 Studying the aforementioned factors including 
others such  solubility helps in decision-making and selection of compounds with desirable 
pharmacokinetic properties for further in vivo studies.  
 
In vivo pharmacokinetics studies (either using mice or other non-human primates) provide 
information on factors such as drug clearance, volume of distribution, bioavailability and 
half-life.
30,40
 Most DMPK/ADMET-related assays are conducted using automated technology 




Another aspect of early evaluation of DMPK/ADMET properties includes drug metabolite 
identification and profiling.
32,41
 This provides a better understanding as to whether the 
toxicity of a drug candidate is a result of exposure to the parent drug or toxic metabolites.
38 
Additionally, other safety-related studies include human Ether-á-go-go-Related Gene (hERG) 




2.4.4 In silico prediction of ADMET and associated physicochemical properties 
In silico prediction tools use molecular descriptors derived from 3D molecular interaction 
fields as inputs to build mathematical/ statistical models.
17
 The predictive capacity and 
reliability of such models vary based on various factors such as molecular descriptor inputs  
 





used in building the models, the chemical space/ diversity covered by set of compounds used 
to train models as well as data quality of the training set of  compounds.
20,21  
 
In general, in silico predictions are associated with a number of limitations. In silico ADMET 
prediction is limited by complexities arising from participating organs and multiple biological 
processes that occur in vivo. Therefore, in silico predicted results are merely guidelines and 
are not over-interpreted. Furthermore, where possible the results are usually corroborated by 
in vitro and in vivo ADMET evaluations.  
 
2.4.5 Physicochemical parameters associated with ADMET 
Various physicochemical properties affect ADMET processes and their determination either 
experimentally or in silico is of utmost importance (Table 2.2).  Drug-likeness can be 
predicted in silico on the basis of rules such as Lipinski‘s rule of five (RO5) and this aids in 
filtering out compounds with poor physical properties (Table 2.2).
21 
Over the years, RO5 has 
been amended to include other properties such as polar surface area and rotatable bonds. 
Similar to RO5, the rule of three has also been introduced to describe compounds with lead-
like properties.
43
 RO5 remains popular even though it has limitations. Its simplicity allows 



























Association with ADME 
and related processes 
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Mass per one mole of a substance. Linked to ability of a 
drug to cross membranes 
e.g.  blood-brain barrier. 




Takes into account the number of 
hydrogen bond donors (HBD) and 
acceptors (HBA). Involves the 
interaction of a drug molecule with 
its aqueous environment. 
 
Strong HB linked to low 
permeability and 
absorption. 
HBD ≤ 5 
HBA ≤ 10 
Solubility 
 
A drug has to dissolve in an aqueous 
environment e.g. gastrointestinal 
tract contents or blood plasma prior 
to absorption. In case of ionizable 
molecules, solubility is affected by 
the pH of the aqueous environment. 
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2.5. Research Aims and Objectives 
Apart from clinical application of phenothiazines in psychiatry, their diverse range of 
antimicrobial and other non-neuroleptic properties has been extensively investigated (Chapter 
1). However at clinically effective doses, they elicit adverse side effects including 
extrapyramidal symptoms, in addition to their neuroleptic effects. Therefore, their extensive 
application in other indications is limited.  In full knowledge of the minimum structural 
requirements for their neuroleptic action, it was postulated that the selectivity of 
phenothiazines and related neuroleptics for other indications could be improved through 
rationalized structural remodelling. 
 
2.5.1 Overall objective 
The overall objective of this study is to structurally remodel neuroleptic phenothiazines and 
related drugs such that their inherent neuroleptic effects are abrogated whilst their 
antitubercular or anticancer properties are retained. 
 
2.5.2 Specific aims and objectives 
(i) To remodel phenothiazines and related neuroleptics to generate a focused library of new 
chemical entities (NCEs) with reduced likelihood to exhibit neuroleptic effects. 
 In consideration of the minimum structural requirements of phenothiazines for neuroleptic 
action, remodelling strategies were rationally considered in order to generate NCEs that are 
less likely to exhibit neuroleptic effects. In silico tools will be employed to assess drug-
likeness of the NCEs as well as their likelihood of exhibiting neuroleptic effects. The in silico 
predictions can be obtained using QikProp, a Schrödinger program that computes  
 





pharmaceutically relevant properties of potential drug candidates. NCEs with promising 
drug-like properties would be prioritized for chemical synthesis. 
 
(ii) To evaluate the remodelled phenothiazines as potential antitubercular agents. 
Chemically synthesized remodelled phenothiazines will be evaluated against virulent 
Mycobacterium tuberculosis (M.tbH37Rv) by screening the library of NCEs for in vitro 
extracellular growth inhibition against M.tbH37Rv. Further assessment will include screening 
selected NCEs for their ability to inhibit intracellular M.tbH37Rv in bone marrow-derived 
macrophages, which will also be indicative of cytotoxicity. 
 
(iii) To investigate the neuroleptic potential of the remodelled phenothiazines using 
experimental approaches.  
To corroborate the in silico CNS activity predictions, selected NCEs will be screened in 
dopamine and serotonin receptor radioligand binding assays offered as a commercial service 
by Perkin Elmer (formerly Caliper Life Sciences) Maryland USA.  
 
(iv) To elucidate the pharmacokinetic profiles of NCEs with promising antimycobacterial 
properties and more importantly, reduced likelihood of neuroleptic effects. 
In vitro microsomal metabolic stability, kinetic solubility and in vivo toxicity of selected 
NCEs will be evaluated to corroborate in silico predictions. 
 
(iv) To evaluate the remodelled phenothiazines as potential anticancer agents.  
To investigate the anticancer properties of selected NCEs, they will be subjected to an MTT 
cell viability screen.  





2.6 Strategies employed in the remodelling of phenothiazines and related drugs 
Phenothiazines are among the most widely prescribed neuroleptic drugs worldwide.
44 
As 
mentioned earlier, they exert their neuroleptic effects by blockade of various CNS receptors 
including dopaminergic and serotonergic receptors.
1,2
 The structural traits and properties of 
neuroleptic drugs delineated in section 2.2 were thoroughly examined pre-remodelling.  
These include conformational resemblance to dopamine, high degree of lipophilicity for 
blood-brain barrier penetration and presence of a proton accepting distal amine moiety.  
The overall rational approach taken herein was to design NCEs with novel functionalities that 
deviate from the minimum structural requirements for neuroleptic activity. In consideration 
of the significance of early ADMET evaluation discussed in section 2.4, in silico tools were 
incorporated into the remodelling process to generate NCEs with desirable drug-like 
properties that are less likely to exhibit neuroleptic effects.  
 
2.6.1 Strategy 1:  Replacement of the distal amine with a sulfonate functionality 
2.6.1.1 Rationale behind the selected remodelling strategy 
A high degree of hydrophobicity is known to facilitate diffusion across the BBB.
2
 To 
decrease the propensity of BBB penetration, the distal amine moiety was replaced with a 
polar sulfonate functionality (Figure 2.6).  Furthermore, the presence of a proton accepting 
alkylamine species is also known to favor BBB penetration as discussed earlier. Therefore, 
replacement with a sulfonate moiety not only results in an increase in aqueous solubility but 
also a change in charge from a protonated positively charged alkylamine species to a 











Figure 2.6: Remodelling of typical antipsychotics to form NCEs with increased aqueous solubility. It is 
accepted that sulfonates are negatively charged at physiological pH. Therefore, the lack of a proton accepting 
alkylamine species further reduces the potential of the remodelled phenothiazines (DS0031-35) to cross the 
BBB. 
 
2.6.1.2 N-butylsulfonates of phenothiazines: Rationale behind alkyl linker extension 
Reportedly, variation of alkyl linker length of phenothiazines affects their affinity for CNS 
receptors.
2,14
 From a structure-activity relationship (SAR) perspective, extension of the alkyl 
linker of NCEs described in section 2.6.1.1  would shed some light on the effect of chain 
length variation  on the bio-activities of interest. The phenothiazines were remodelled 
accordingly as shown in Figure 2.7. 






Figure 2.7: Alkyl chain extension and application of the strategy 1 delineated in section 2.6.1 to form N-
butylsulfonates NCEs (DS00366, DS00369 and DS00370). 
 
2.6.1.3 N-propylsulfonates of ring-expanded phenothiazine-like scaffolds 
2.6.1.3.1 Rationale behind ring expansion 
Atypical antipsychotics such as clozapine and imipramine have seven-membered rings as part 
of their tricyclic heteroaromatic ring system. The non-neuroleptic biological properties of the 
majority of these drugs have not been extensively investigated. As alluded to earlier, these 
atypical drugs bear structural resemblance to the phenothiazine class of antipsychotics.
1
 To  
 
 





broaden the scope of investigation into remodelled CNS drugs, it was decided to design 
NCEs that closely resemble the structures of atypical antipsychotics as depicted in Figure 2.8.  
 
 
Figure 2.8: Water-soluble ring-expanded phenothiazine-like NCEs mimicking atypical antipsychotic structures. 
Sulfonates are expected to exist as negatively charged species at physiological pH.  
 
2.6.1.4 Propylsulfonates of non-thiazine tricyclic scaffolds 
2.6.1.4.1 Rationale behind replacement of phenothiazine central thiazine ring  
In efforts to widen the scope of investigation into remodelling of phenothiazines and to 
determine the importance of the central thiazine ring of phenothiazines in bio-activities of 
interest, the central ring was replaced as depicted in Figure 2.9.   
 






Figure 2.9: Non-thiazine scaffolds and application of remodelling strategy 1 delineated in section 2.6.1.   
 
2.6.1.5 Prediction of physicochemical properties associated with Lipinski’s rule of five 
Physicochemical properties associated with Lipinski‘s rule of five (RO5) were predicted in 
silico to assess drug-likeness of the generated NCEs. These properties including molecular 
weight, lipophilicity (log P), hydrogen bond donors and acceptors affect lipid solubility and 
hence BBB penetration. The in silico predictions revealed distinctions among properties of 
derived NCEs and those of parent drugs. As discussed earlier, the replacement of the distal 
alkylamine moiety with a sulfonate functionality is expected to result in a decrease in 
hydrophobicity. In general, the decrease in lipophilicity was evident in the clogP values of the 
NCEs in comparison to parent drugs (Table 2.3). Furthermore, all the NCEs were compliant 








Table 2.3: Prediction of molecular descriptors associated with solubility and permeation on the basis of 
Lipinski‘s rule of five (Propylsulfonates of phenothiazines and phenothiazine-like scaffolds) 
NCE or parent CNS drug     MW clogP HBD HBA 
N-propylsulfonates of phenothiazines     
DS0031     389.4   4.213  1  4 
Trifluoperazine    407.5   4.759  0  3 
DS0032     367.5    3.772  1    4 
Thioridazine     370.6           5.90  0                   2 
DS0033     363.5   2.592  1   5 
Acepromazine     326.4   4.479   0  3 
DS0034     355.9   3.556  1  4 
Chlorpromazine     318.9   5.291               0  2 
DS0035     321.4   2.906       1  4 
Promazine     284.4   4.550  0  2 
N-butylsulfonates of phenothiazines        
DS00369     381.1    4.438  1  4 
DS00370     369.9   4.274  1  4 
DS00366     335.4   3.754  1  4 
N-propylsulfonates of ring-expanded scaffolds        
DS00381     317.4  2.573  1 4 
Imipramine    280.4  4.4.21  0 2 
DS003123     331.4  3.122  2 6 
Clozapine    326.8    3.379  1 4 
DS003125      319.4  2.193  1 5 
Loxapine    293.4  3.307  0 4 
DS00380        335.4  2.660  1 4 
Quetiapine    383.5  3.524  1 5 
Propylsulfonates of non-thiazine scaffolds        
DS00386 320.4     3.749  1  4 
DS00387 317.4     2.163  1  6 
Predictions obtained using StarDrop 5.5; MW: Molecular weight; clogP: log of octanol-water partition 
coefficient; HBD: Hydrogen-bond donor count (NH, NH2 & OH groups) HBA: Hydrogen Bond Acceptors 
count (O & N atoms). 





2.6.2 In silico prediction of blood-brain barrier penetration and ADMET properties 
In addition to assessment of drug-likeness on the basis of RO5, in silico tools were also 
employed to predict properties associated with ADMET. Neuroleptic drugs have the 
propensity to cross the blood-brain barrier (BBB).
2
 Therefore, it was important to predict 
BBB penetration and CNS activity so as to evaluate the likelihood of the NCEs to exhibit 
neuroleptic effects. Other predicted parameters include solubility, permeability (Caco-2 and 
MDCK cell permeability), number of metabolic reactions and hERG inhibition.  
 
The abovementioned ADMET properties were evaluated using QikProp. QikProp is a 
Schödinger program that computes pharmaceutically relevant properties of potential drug 
candidates.
31
 Contrary to properties that can be calculated directly from molecular structure 
(e.g. molecular weight and rotatable bonds), the prediction of more complex properties (e.g. 
solubility, BBB penetration, intestinal permeability and hERG inhibition) largely relies on 
data used in training the models. This poses a great challenge in accurately modelling such 
properties. Therefore, the results obtained from these models are only viewed as rough 
estimations to guide the remodelling. Radar plots were used for comparison of predicted 
properties of the generated NCEs with that of native neuroleptic drugs. Shortened NCE codes 
were used on all the plots for aesthetic purposes e.g. DS0035 is the same as DS35. 
 
2.6.2.1 In silico prediction of BBB penetration and CNS activity 
CNS activity of the remodelled phenothiazines and parent neuroleptic drugs was predicted on 
a scale ranging from -2 (considered inactive) to +2 (considered active) using Qikprop.
31
 All 
the remodelled phenothiazines were predicted to be inactive (values ≤ -1) in comparison to  
 
 





parent drugs (values = +2). The radar plot of predicted blood/brain partition coefficients 









Figure 2.10:  QikProp predicted CNS activity and Blood/Brain partition coefficient (QPlogBB). QP- QikProp; 
CNS activity scale -2 (inactive) to +2 (active);  CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), 
Imipramine (IP), Loxapine (LX), Promazine (PRM), Clozapine (CZ), Acepromazine (ACP), Trifluoperazine 
(TFP);  antitubercular Isoniazid (INH);  anticancer Temozolomide (TMZ); QikProp scale for CNS activity: -
2 (inactive) to +2 (active); All neuroleptic drugs were predicted to be CNS active (+2). All alkylsulfonates 
described in section 2.5.1.1 -2.5.1.4 were predicted to be CNS inactive (-1); Note: Shortened NCE codes were 
used on all the radar plots e.g. DS0035 is the same as DS35. 
 
2.6.2.2 In silico prediction of properties associated with ADMET 
In addition to prediction of CNS activity of the remodelled phenothiazines, other properties 



























































QikProp predicted CNS activity

















Figure 2.11:  QikProp predicted aqueous solubility (QPlogS), predicted Caco-2 cell permeability, predicted 
MDCK cell permeability, predicted number of metabolic reactions and predicted hERG inhibition;  QP- 
QikProp; CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), Imipramine (IP), Loxapine (LX), Promazine 
(PRM), Clozapine (CZ); antitubercular Isoniazid (INH);  anticancer Temozolomide (TMZ).    QikProp ranges 
for 95% of known drugs: QPlogS (-6 to 0.5), Caco-2 (< 25 poor, > 100 high) MDCK (<25 poor, >500 great), # 
metabolic reactions (1-8); loghERG < -5 raises concern.  
 
As discussed earlier, aqueous solubility and permeability are one of the key determinants of 
drug absorption. All the predicted aqueous solubility values fell within the QikProp solubility 
range for 95% of known drugs i.e. -6 to 0.5 (Figure 2.11).
31

















































































































QPlog IC50 for HERG K+ channel blockage





remodelled phenothiazines is expected to be greater than that of parent drugs due to the 
presence of a polar alkylsulfonate moiety. The plot reveals slight differences in the predicted 
solubility values (Figure 2.11). 
 
For prediction of metabolic stability, the predicted number of likely metabolic reactions (≤ 5) 





 The QikProp predicted permeability values in nm/sec are interpreted as (< 25 poor, > 100 
high) for Caco-2 and (< 25 poor, > 500 great) for MDCK.
31
 The NCEs showed good 
predicted Caco-2 and MDCK cell permeability. All parent CNS drugs showed greater 
permeability which could be attributable to their relatively high lipophilicity (Figure 2.11).   
 
 As mentioned earlier, evaluation of hERG inhibition is important for determination of 
possible cardiac toxicity.
38
 QikProp predicted hERG inhibition values (logIC50 for hERG K
+
-
channel inhibition) less than -5 suggest possible toxicity.
31
 For all the remodelled 
phenothiazines, values were greater than -5.Chlorpromazine and other neuroleptic drugs were 
predicted to be cardio-toxic with loghERG values over -6 (Figure 2.11).  
 
2.6.3 Strategy 2: Replacement of the tricyclic phenothiazine core with bicyclic quinoline 
2.6.3.1 Rationale behind N-propylsulfonates of quinolines  
Phenothiazines share ancestral roots with quinoline and acridine based antimalarial drug 
classes, hence the striking structural resemblance.
28
 Various well-known antimalarial drugs 
structurally evolved from the phenothiazinium dye, methylene blue. Substitution of the 
 
 





phenothiazine ring system with that of acridine or quinoline furnished highly potent 
antimalarial drugs such as quinacrine and chloroquine, respectively.
28,45
 These antimalarial 
drug classes display the same lipophilic chromophore/ basic side chain paradigm observed in 
tricyclic phenothiazines.
46,47 
For this reason, the bicyclic quinoline scaffolds became 
appealing to this research study and were remodelled as illustrated in Figure 2.12.  
 
 
Figure 2.12: Application of remodelling strategy delineated in section 2.6.1 and replacement of the lipophilic 
tricyclic ring system of phenothiazines. Sulfonates are expected to exist as negatively charged species at 
physiological pH. 
 
Similar to propylsulfonates NCEs described in section 2.6.1, the bicyclic quinoline NCEs 
also complied with the RO5 (Table 2.4). Furthermore, in comparison to the propylsulfonates 
of phenothiazines, these quinoline NCEs are the least lipophilic. 





Table 2.4: Prediction of molecular descriptors associated with solubility and permeation on the basis of 
Lipinski‘s rule of five (N-propylsulfonates of quinolines) 
NCE or parent CNS drug  MW clogP HBD HBA 
DSQ1 266.3 1.669 2 5 
DSQ2 266.3 1.799 2 5 
DSQ3 266.3 1.407 2 5 
DSQ4 300.8 2.037 2 5 
DSQ5 266.3 1.609 2 5 
DSQ6 266.3 1.567 2 5 
Chloroquine 319.9 4.327 1 4 
Primaquine 315.4 3.992 1 5 
 
Predictions obtained using StarDrop 5.5; MW: Molecular weight; clogP: log of octanol-water partition 
coefficient; HBD: Hydrogen-bond donor count (NH, NH2 & OH groups) HBA: Hydrogen Bond Acceptors 
count (O & N atoms). 
 
2.6.3.2 In silico prediction of BBB penetration and CNS activity 
The predicted blood/brain partition coefficients and CNS activity were in accordance with the 
decrease in hydrophobicity observed earlier for the quinoline NCEs. The NCEs were all 
predicted to be CNS inactive (values = -2) as illustrated in Figure 2.13. Interestingly, 
antimalarial chloroquine and primaquine were predicted to be moderately CNS active (values 




















Figure 2.13:  QikProp predicted CNS activity and Blood/Brain partition coefficient (QPlogBB). QP- QikProp; 
CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), Imipramine (IP), Loxapine (LX), Promazine (PRM), 
Clozapine (CZ);  antitubercular Isoniazid (INH);  anticancer Temozolomide (TMZ); antimalarial Chloroquine 
(CR), antimalarial Primaqine (PR); QP CNS activity scale: -2 (inactive) to +2 (active); All neuroleptic drugs 
were predicted to be CNS active (+2). All N-propylsulfonates of quinolines (DSQ1-Q6) were predicted to be 
CNS inactive (-2).  
 
2.6.3.3 In silico prediction of properties associated with ADMET 
The predicted ADMET properties of the quinoline NCEs displayed the same radar plot 
patterns as with N-propylsulfonates of phenothiazines described earlier in section 2.6.1 
(Figure 2.14). In contrast, chloroquine was predicted to be a hERG inhibitor (loghERG <-5) 
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Figure 2.14:  QikProp predicted aqueous solubility (QPlogS), predicted Caco-2 cell permeability, predicted 
MDCK cell permeability, predicted number of likely metabolic reactions and predicted hERG inhibition;  QP- 
QikProp; CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), Imipramine (IP), Loxapine (LX), Promazine 
(PRM), Clozapine (CZ); antitubercular Isoniazid (INH);  anticancer Temozolomide (TM); Chloroquine (CR); 
Primaquine (PM).QikProp ranges for 95% of known drugs: QPlogS (-6 to 0.5), Caco-2 (< 25 poor, > 100 
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2.6.4 Strategy 3: Molecular hybridization 
2.6.4.1 Rationale behind molecular hybrids of phenothiazines 
Molecular hybridization is a rational design strategy that involves combination of two or 
more pharmacophoric subunits to form hybrids. This strategy aims to produce bioactive 
agents with better efficacy than parent drugs.
48,49,50 
Furthermore, hybrids generated may show 
different selectivity profiles, fewer side effects, different and/or dual mechanisms of action 
compared to parent drugs.
48
 This concept also paves the way for targeting multifactorial 
diseases such as neurodegenerative disorders and cancer.
50,51
 Hybrids of repurposed 





Using this pharmacophoric hybridization strategy, a series of isoniazid hybrids were 
generated by combination with phenothiazine core structures. Additionally, another series of 
phenothiazine hybrids was generated from hybridization with ortho-/para-
nitrobenzenesulfonyl chlorides to form sulfonamides found in a class of antibiotics called 
sulfanilamides (Figure 2.15).  
 
Non-N-alkylated phenothiazine derivatives linked to various heterocyclic rings have been 
reported to exhibit a range of biological properties including antibacterial, antifungal and 
anticancer activities. This includes monocyclics such as pyrazoles, tetrazoles and thiazoles.
11 
Substitution at C-2 of phenothiazines is known to greatly influence the intensity of their 
neuroleptic action due to favourable van der Waals interactions.
2,15
 Herein, phenothiazine 
was linked to pyrazole and isoxazole heterocyclic moieties at C-2 (Figure 2.15).  
 





Figure 2.15: Molecular hybridization of phenothiazines with antibacterial pharmacophores including isoniazid 
and sulfanilamide precursors. Phenothiazines were also linked to monocyclic heterocycles (pyrazole and 
isoxazole) which are common in biologically active molecules. 
 
All the NCEs were compliant to the RO5 except dimers of isoniazid hybrids which have 
molecular weights greater than 500 and clogPs greater than 5 (Table 2.5). As discussed 
earlier, a higher degree of lipophilicity is known to facilitate BBB penetration.  As with 
propylsulfonates of phenothiazines, a decrease in hydrophobicity was also evident herein. 




Table 2.5: Prediction of molecular descriptors associated with solubility and permeation on the basis of 
Lipinski‘s rule of five (Hybrids of phenothiazines). Values violating RO5 are shown in red 
NCE or parent CNS drug MW clogP HBD HBA 
Isoniazid  hybrids     
DS00362b 418.5 3.821 2 8 
Acepromazine 326.4  4.479 0 3 
DS00362 (dimer) 699.9 7.567 1 6 
DS00364a 410.9 4.755 2 6 
Chlorpromazine 318.9 5.291              0 2 
DS00364  (dimer) 684.7 9.514 1 5 
DS00365a 376.5 4.267 2 6 
Promazine 284.4 4.550 0 2 
DS00365 (dimer) 615.8 9.030 1 5 
Nitrobenzenesulfonamides     
DS00325 384.4 3.084 0 6 
DS00342 384.4 2.939 0 6 
DS00326 452.4 4.123 0 6 
Trifluoperazine 407.5 4.759 0 3 
DS00338 452.4 3.806 0 6 











Pyrazole and isoxazole  linked phenothiazines     
DS00397 266.3 3.729 1 2 
DS00398 265.3 3.482 2 2 
Predictions obtained using StarDrop 5.5; MW: Molecular weight; clogP: log of octanol-water partition 
coefficient; HBD: Hydrogen-bond donor count (NH, NH2 & OH groups) HBA: Hydrogen Bond Acceptors 
count (O & N atoms). 
 
2.6.4.2 In silico prediction of BBB penetration and CNS activity. 
The predicted blood/brain partition coefficients as well as predicted CNS activity exhibited 
the same radar plot patterns as observed before. The predicted CNS activity values for the  




hybrids ranged from -2 (inactive) to +1 (moderately active). Notably, the presence of an 
acetyl group at the 2-position of the phenothiazine chromophore appeared to influence 
predicted CNS activity. All NCEs with an acetyl group at C-2 (DS00341, DS00362 and 
DS00362b) were predicted to be CNS inactive (values = -2). Phenothiazines linked to 
pyrazole (DS00398) and isoxazole (DS00397) were predicted to be moderately CNS active 









Figure 2.16:  QikProp predicted CNS activity and Blood/Brain partition coefficient (QPlogBB). QP- QikProp; 
Activity scale -2 (inactive) to +2 (active);  CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), Imipramine 
(IP), Loxapine (LX), Promazine (PRM), Clozapine (CZ);  antitubercular Isoniazid (INH);  anticancer 
Temozolomide (TMZ);  QP CNS activity scale: -2 (inactive) to +2 (active); All neuroleptic drugs were 
predicted to be CNS active (values = +2). Predicted CNS activity values ranged from -2 to 1 with NCEs 
DS00397 and DS00398 showing moderate CNS activity. DS00341, DS00362 and DS00362b were predicted to 
be the most CNS inactive (-2) of this series; Note: Shortened NCE codes were used on all the radar plots e.g. 
DS0035 is the same as DS35. 
 
2.6.4.3 In silico prediction of properties associated with ADMET 
As before, four properties were predicted using QikProp including aqueous solubility, 













































































Figure 2.17:  QikProp predicted aqueous solubility (QPlogS), predicted Caco-2 cell permeability, predicted 
MDCK cell permeability, predicted number of metabolic reactions and predicted hERG inhibition;  QP- 
QikProp; CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), Imipramine (IP), Loxapine (LX), Promazine 
(PRM), Clozapine (CZ); antitubercular Isoniazid (INH);  anticancer Temozolomide (TMZ).    QikProp ranges 
for 95% of known drugs: QPlogS (-6 to 0.5), Caco-2 (< 25 poor, > 100 high) MDCK (<25 poor, >500 great), # 
metabolic reactions (1-8); loghERG < -5 raises concern. Predicted values for isoniazid dimers (DS00362, 
DS00364 and DS00365) suggested they possess poor pharmacokinetic properties.    
 
The predicted logS values fell within the QikProp solubility range for 95% of known drugs 
(i.e. -6 to 0.5) except for isoniazid hybrids dimers (values greater than -9.).
31
 The isoniazid 




























































































































hERG channel blockers (Figure 2.17). This suggested that these hybrid dimers did not 
possess desirable ADMET properties and were thus of least priority for chemical synthesis. 
 
2.6.5 Strategy 4: Replacement of amine moiety with other non-basic functionalities 
2.6.5.1 Rationale behind the design 
Apart from conversion of the amine moiety to a sulfonate group, neutral species such as 
nitriles and esters were also considered to further probe replacement of the basic distal amine 
of phenothiazines (Figure 2.18). Since the presence of proton accepting nitrogen moieties 




Figure 2.18: Replacement of tertiary amine moiety of phenothiazine with non-basic functionalities. * Mono-
bromination would allow evaluation of the effect of a halogen substituent at an unusual position 3 or 6 on bio -
activity. Interestingly, a dibrominated NCE DS00396 would bear some structural similarity to DNA 
intercalators such as ethidium bromide.
53
 





This series of NCEs also showed compliance to the RO5. Furthermore, replacement of the 
distal amine moiety with a nitrile functionality resulted in lower clogP values (Table 2.6). 
Ester DS00390, amide DS00385 as well as dibromo-substitued NCE DS00396 showed 
slightly higher clogP values in comparison to promazine. This raised concern as an increase 
in hydrophobicity could favour BBB penetration. 
 
Table 2.6: Prediction of molecular descriptors associated with solubility and permeation on the basis of 
Lipinski‘s rule of five (Phenothiazines with other non-basic side chains) 
NCE or CNS drug     MW clogP HBD HBA 
DS00385 326.4 4.572 1 3 
Promazine 284.4 4.550 0  2 
DS00392 320.3 4.835 0 2 
Trifluoperazine 407.5 4.759 0 3 
DS00393 286.8 4.395 0 2 
Chlorpromazine  318.9 5.291              0 2 
DS00394 252.3 3.955 0 2 
DS00395 295.4 3.103 1 4 
DS00396 410.1 4.834 0 2 
DS00390 377.4 4.569 0 6 
 
Predictions obtained using StarDrop 5.5; MW: Molecular weight; clogP: log of octanol-water partition 
coefficient; HBD: Hydrogen-bond donor count (NH, NH2 & OH groups) HBA: Hydrogen Bond Acceptors 










2.6.5.2 In silico prediction of BBB penetration and CNS activity                 
The radar plot of predicted blood/brain barrier partition coefficients displayed the same 
pattern as that of predicted CNS activity. This series of NCEs were predicted to be 









Figure 2.19:  QikProp predicted CNS activity and Blood/Brain partition coefficient (QPlogBB). QP- QikProp; 
QP CNS activity scale -2 (inactive) to +2 (active);  CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), 
Imipramine (IP), Loxapine (LX), Promazine (PRM), Clozapine (CZ);  antitubercular Isoniazid (INH); 
anticancer Temozolomide (TMZ); all neuroleptic drugs were predicted to be CNS active (+2). Predicted CNS 
acivity values ranged from -1 to 1; Note: Shortened NCE codes were used on all the radar plots e.g. DS0035 is 
the same as DS35. 
 
2.6.5.3 In silico prediction of properties associated with ADMET 
 Predicted properties fell within the QikProp ranges for 95% of known drugs.
31
 The NCEs 
were predicted to have good Caco-2 and MDCK cell permeability. NCE DS00396 displayed 
the highest MDCK cell permeability (greater than 7300, not shown on the plot). Furthermore, 
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Figure 2.20:  QikProp predicted aqueous solubility (QPlogS), predicted Caco-2 cell permeability, predicted 
MDCK cell permeability, predicted number of metabolic reactions and predicted hERG inhibition;  QP- 
QikProp; CNS drugs: Chlorpromazine (CPZ), Thioridazine (TZ), Imipramine (IP), Loxapine (LX), Promazine 
(PRM), Clozapine (CZ); antitubercular Isoniazid (INH);  anticancer Temozolomide (TMZ).    QikProp ranges 
for 95% of known drugs: QPlogS (-6 to 0.5), Caco-2 (< 25 poor, > 100 high) MDCK (<25 poor, >500 great), # 





































































































2.7 Concluding Remarks 
An in depth evaluation of minimum structural requirements for neuroleptic activity guided 
the remodelling of existing CNS drugs to create a diverse focused library of non-neuroleptic 
NCEs for bio-activities of interest i.e. antitubercular and anticancer activities. The library 
comprises novel functionalities such as alkylsulfonates which resulted in increased aqueous 
solubility, a property that deviates from a considerably high degree of hydrophobicity 
exhibited by CNS drugs. The other remodelling strategies included molecular hybridization 
with antibacterial pharmacophores and introduction of other non-basic moieties such as 
nitriles and esters. The overall remodelling approach applied herein was to deviate from the 
lipophilic chromophore/basic side chain paradigm obeyed by phenothiazines and structurally 
related drugs.  
In silico predictions tools were integrated into the structural remodelling to assess drug-
likeness of the resulting NCEs on the basis of Lipinski‘s rule of five. Most NCEs were 
compliant to the rule. ADMET properties including aqueous solubility, Caco-2 & MDCK cell 
permeability, number of likely metabolic reactions and hERG inhibition were also predicted 
in silico. In silico evaluation of these ADMET properties suggested that most of the 
remodelled phenothiazines had favourable drug-like properties. Furthermore in silico 
prediction of CNS activity suggested the NCEs had reduced likelihood of exhibiting 
neuroleptic effects. 
 
In the next chapter, an extensive discussion of synthetic methods employed for chemical 
synthesis of these remodelled phenothiazines (for in vitro evaluation as antitubercular or 
anticancer agents) is provided.  
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Chemical synthesis of remodelled phenothiazines as potential 
antitubercular or anticancer agents 
Preface 
In the previous chapter, strategies selected for remodelling phenothiazines and related drugs 
for non-neuroleptic bioactivities were discussed. Furthermore, in silico prediction tools were 
incorporated to assess drug-likeness on the basis of Lipinski‘s rule of five (RO5). Properties 
associated with ADMET (A: Absorption; D: Distribution; M: Metabolism; E: Excretion; T: 
Toxicity) such as aqueous solubility, Caco-2 and MDCK cell permeability, a number of 
likely metabolic reactions as well as hERG inhibition were also predicted in silico. In silico 
prediction of CNS activity also guided the selection of NCEs that are less likely to exhibit 
neuroleptic effects. The resulting new chemical entities (NCEs) with promising drug-like 
properties were prioritized for chemical synthesis. 
 
In this chapter, an extensive discussion of employed synthetic methods and spectroscopic 
characterization of the NCEs is provided.  The synthesis afforded a focused library 
comprising pairs of remodelled phenothiazine NCEs and parent neuroleptic drugs for 
biological evaluation as potential antitubercular or anticancer agents. 
 
3.1 Remodelled phenothiazines and related neuroleptic drugs 
The remodelling strategies described in chapter 2 include replacement of the basic terminal 
amine moiety of phenothiazines with a polar sulfonate functionality and other non-basic 
funtionalities, introduction of bicyclic quinoline scaffolds and molecular hybridization with  
 




antibacterial pharmacophores. Using these strategies, a diverse library of remodelled 
phenothiazines including N-alkylsulfonates, isoniazid molecular hybrids, nitrobenzene 
sulfonamides and N-alkylnitriles was generated. The chemical synthesis of these remodelled 
phenothiazines is discussed herein.  
 
3.2 N-propylsulfonates of phenothiazines 
N-propylsulfonates of phenothiazines (3.1a-e) were obtained by replacement of the amine 




Figure 3.1: Remodelled phenothiazine drugs illustrating deviation from the lipophilic chromophore/basic side 
chain paradigm. 
 
3.2.1 Retrosynthetic analysis, synthesis and analytical characterization 
The classic preparation of alkylsulfonates (RSO3
-
) was first introduced by a German chemist, 
Aldoph Strecker, in 1868. The Strecker sulfite alkylation reaction involves nucleophilic  




substitution of alkyl halides by sulfite salts in the presence of an iodide as a catalyst.
1
 Other 
synthetic procedures for preparation of alkylsulfonic acid (RSO3H) or their conjugate bases 
(RSO3
-
) include oxidation of free thiols (RSH) via formation of sulfenic acids (RSOH) and 
sulfinic acids (RSO2H) using oxidants such as hydrogen peroxide,
 
 and alkaline hydrolysis of 
sulfonate esters.
2,3
 Herein, the oxidation route (A) was ruled out to protect the structural 
integrity of the phenothiazine chromophore. A nucleophilic, N-alkylating, ring-opening 
methodology B was adopted (Scheme 3.1). 
 
 
Scheme 3.1: Possible routes to synthesis of N-propylsulfonates 3.1a-e; One-step route B was a better choice 
over A and C as it involved the use of readily accessible starting materials. 
 
The synthesis of phenothiazine-based N-propylsulfonates 3.1a-e was envisaged as achievable 
via a non-concerted N-alkylation reaction involving deprotonation of phenothiazine under  




strong basic conditions subsequently followed by nucleophilic ring-opening of cyclic 
sulfonate ester 3.3 (Figure 3.2). Resonance and electron-withdrawing inductive effects of the 
sulfonate group in 3.3 render the neighbouring carbon (RC-OSO2R1) electron-deficient hence 
susceptible to nucleophiles. 
 
 
Figure 3.2: Proposed reaction mechanism for nucleophilic ring-opening of sultone 3.3 to afford NCEs 3.1a-e. 
 
The detailed reaction conditions for the N-alkylation are outlined in Scheme 3.2. It was 
mandatory to work under anhydrous and inert atmospheric conditions owing to the 
pyrophoric nature of sodium hydride and possible sultone hydrolysis under the slightest wet 
basic conditions. Furthermore, working under an inert atmosphere of nitrogen was necessary 
to avoid possible air oxidation of the phenothiazine core.  Moreover, solutions of 
phenothiazines are prone to free radical reactions under exposure to light thus the reactions 












Scheme 3.2: Reagents and conditions: (i) NaH (60% dispersion in mineral oil, 1.1 eq), dry DMF, rt → 50 °C, 
N2, 1.5 h; (ii) 3.3 (1.1 eq) in dry DMF, rt, N2, 16 h. 3.1a (27%), 3.1b (17%), 3.1c (23%), 3.1d (40%), 3.1e 
(38%). 
 
Isolation and purification of these N-propylsulfonates 3.1a-e was carried out using reversed-
phase chromatography due to the presence of a polar sulfonate side chain imparting aqueous 
solubility. In general, the reversed-phase mobile phase for elution is primarily aqueous and 
may include organic modifiers such as methanol and acetonitrile. Gradient elution was 
preferred over isocratic elution for better separation.  Water was used as the eluent and 
methanol was gradually (0-10%) introduced. Unreacted hydrophobic starting materials were 
retained on the column using the above-mentioned solvent system. Notably, the amphiphilic 
salts 3.1a-e displayed considerable retention on the column compared to the sultone 
hydrolysis product 3.3a. This purification process avoids the use of large quantities of 
organic solvents, which is advantageous from a commercial and ―green‖ perspective. 
 
The desired compounds (3.1a-e) were obtained as coloured solids in relatively low yields of 
less than 40%. The plausible explanation for the low yields is the occurrence of a competing 
reaction i.e. hydrolysis of sultone 3.3 as alluded to earlier. Although significant efforts were 
put into place maintaining dry reaction conditions when using DMF as a solvent, the presence  
 




of any trace of moisture would promote the formation of ‗naked‘ hydroxide ions from 
hydride ions. These hydroxide ions in DMF are much more nucleophilic hence the significant 
sultone hydrolysis.  Initially, no significant attempts were made in yield optimization as the 
amounts isolated were sufficient for in vitro bio-activity screening. Large-scale synthesis of 
NCEs 3.1a-e was carried out at a later stage for preclinical in vivo toxicity and in vivo 
efficacy evaluation. In consideration of the high-boiling point and environmental unfriendly 
nature of DMF, THF was the solvent of choice for the large-scale reactions. Furthermore, 
anhydrous THF is commercially available on large scale and its use contributed to greater 
than 90% product yield. Moreover, purification was carried out by trituration with ethyl 
acetate to extract the minimal amount of sultone by-product and recover unreacted starting 
material. 
 
In general, the following analytical techniques were employed for structure elucidation, 





C); LCMS and/or HRMS; IR. Full characterization details are 
outlined in chapter 7. 
 
Inductive effects and anisotropic effects produced by the π-system of aromatic rings along 
with the presence of electron-donating/withdrawing groups were evident in resonance 




C NMR spectra of NCEs 3.1a-e. Their 
1
H NMR spectra 
revealed sets of peaks in the aromatic region downfield and three sets of methylene peaks 
upfield. Figure 3.3 shows the general pattern of resonance signals that was observed. The 
three methylene signals resonating at chemical shifts (δ) ranging between δH 2-4 ppm 
displayed the expected multiplicities i.e. two triplets and a quintet with vicinal coupling 
 






J, around 7 Hz. For derivatives 3.1b (X= SMe) and 3.1c (X= COCH3), the methyl 
resonance peaks were observed as singlets at δH 2.28 ppm and 2.43 ppm, respectively. Some 
of the signals were not well-resolved presumably due to salt/D2O/H2O solvent effects.  
Resonance signals in the aromatic region integrated for the correct number of protons i.e. 












Figure 3.3:  
1
H NMR spectrum of 3.1d (DS0034) to illustrate the general pattern of resonances for NCE 3.1a-e. 
 
The number resonances in 
13
C NMR spectra of all five derivatives (3.1a-e) were in 
accordance with 
1
H NMR spectra observations. For 3.1e (DS0035) only 6 resonance signals 
were observed downfield owing to an existing plane of symmetry.  Derivatives 3.1b 















presence of thiomethyl and acetyl groups, respectively. Also distinct in the spectrum of 3.1c 
(DS0033), was a deshielded carbonyl signal resonating at δC 201.88 ppm. The NMR 
observations were further corroborated by LCMS thereby confirming the structures of the 
compounds and their purity. An accurate mass spectrum of 3.1d (DS0034) with a molecular 
ion peak [M]
+ 
of 377.9991 calculated for C15H13ClNNaO3S2 (m/z) 377.9957 [M]
+ 
is given in 
Figure 3.4 as an example. The base peak ion 356.0180 corresponded to [(M + 2H) – Na]
+
. 
The doubling of peaks (intensity ratio 3:1) in the mass spectrum of 3.1d is indicative of the 















Figure 3.4: An accurate mass spectrum of 3.1d (DS0034) from LCMS analysis showing isotope peaks due to 
the presence of chlorine. Molecular ion peak of [M]
+ 
of 377.9991 calculated for C15H13ClNNaO3S2 (m/z) 
377.9957 [M]
+ 




Chemical Formula: C15H13ClNNaO3S2 
Exact Mass: 376.9923 
Molecular Weight: 377.8414 
m/z: 376.9923 (100.0%), 378.9894 (32.0%), 
377.9957 (16.2%), 378.9881 (9.0%), 379.9927 
(5.2%), 380.9852 (2.9%), 377.9917 (1.6%), 
379.9915 (1.5%), 378.9990 (1.2%) 
[(M+2H) -Na]+ 
[M]+ 




3.3 N-butylsulfonates of phenothiazines 
Application of same strategy used to obtain N-propylsulfonates 3.1a-e afforded remodelled 
phenothiazines 3.5a-e with an extended alkyl linker (Figure 3.5).  
 
 
Figure 3.5: Remodelled phenothiazines with an extended alkyl linker. 
 
3.3.1 Synthesis and analytical characterization  
The synthesis of N-butylsulfonates NCEs 3.5a-c was envisaged as achievable using the same 
approach described in section 3.2.1, similar reaction conditions and purification method were 
employed. However, the electrophilic alkylating agent used to afford a butyl linker was 1,4-
butane sultone (3.8) (Scheme 3.3). Due to butane sultone being a more stable ring system 
than propane sultone, the rate nucleophilic attack was much slower than the competing 
sultone hydrolysis, hence lower yields were obtained. Sufficient materials were obtained for 
bio-activity testing and yield optimization using THF as a solvent was not attempted. 
 




Scheme 2.3: Reagents and conditions: (i) NaH (60% dispersion in mineral oil, 1.1 eq), dry DMF, rt to 50 °C, 
N2, 1.5 h; (ii) 3.8 (1.1 eq) in dry DMF, rt, N2, 20 h. 3.5a (19%), 3.5b (20%), 3.5c (14%). 
 
A thorough analysis of 
1
H NMR spectra of 3.5a (DS00369), 3.5b (DS00370) and 3.5c 
(DS00366) revealed the same pattern of resonance signals as observed earlier for N-
propylsulfonates 3.1a-e. The only noticeable distinction was the presence of an extra 
methylene resonance in the upfield region belonging to the butyl moiety (Figure 3.6). 
Additional support from 
13
























3.4. N-propylsulfonates of ring expanded phenothiazine-like scaffolds 
A ring-expansion strategy was applied to create phenothiazine-like scaffolds that mimic 
atypical neuroleptic drugs shown in Figure 3.7. 
 
 
Figure 3.7: Remodelled phenothiazines mimicking structures of atypical neuroleptic drugs. 
 
3.4.1 Synthesis of ring-expanded scaffolds 
Tricyclic/ tetracyclic ring systems with central seven-membered rings are common scaffolds 
in numerous therapeutic agents. CNS drugs such as clozapine, imipramine, quetiapine and 
loxapine possess such scaffolds.
5,6,7 
Accessibility of these scaffolds is in most cases hindered 
by multistep synthetic routes and/ or low-yielding nature of the reactions.  Significant efforts 
were put into designing routes that could afford scaffolds which closely resemble those found 
in the above-mentioned atypical antipsychotics. 
 




3.4.1.1 Synthesis of a clozapine scaffold 
The synthesis of azaheterocycles was first reported in the mid-1960s.
8,9 
The routes designed 
for the preparation of clozapine scaffolds were inspired by traditional clozapine synthesis 
methods reported in literature.
10
 Retrosynthetic approaches to synthesis of these are depicted 
in Scheme 2.4. Route A shows the traditional route to synthesis of azaheterocycles involving 
copper-catalyzed N-arylation and intramolecular cyclization. Route B was of interest as it 
involved fewer steps to the synthesis of scaffold 3.19 and 3.20 that closely resemble 
clozapine (Scheme 3.4). 
 
 
Scheme 3.4: Possible routes to preparation of clozapine scaffolds via Cu-catalyzed N-arylation or thionation. 




(i) Initial approach: Copper-catalyzed N-arylation 
Documented routes to the synthesis of dibenzodiazepines generally rely on multi-step 
reactions including copper-catalyzed intramolecular N-arylation or cross couplings under 
Buchwald-Hartwig conditions, iron-catalyzed nitro-group reduction as well as amide 
coupling.
11,8,12
 Initially,  the preparation of clozapine scaffold 3.25 was conceived as 
achievable  from an adaptation of a dibenzodiazapinones synthesis procedure reported by 
Zhang et al.
12
  The reaction proceeded via copper-catalyzed cross coupling of diamine 3.23 
and benzoic ester 3.22 (Scheme 3.5). Apart from the route being shorter, the readily available 
starting materials made the reaction worthwhile.   
 
 
Scheme 3.5: Reagents and conditions: (i) 3.21, EtOH, HCl (aq), reflux; (ii) 3.22 (1.0 eq), 3.23 (2.0 eq), Na2CO3 
(2.,0 eq), CuI (10 mol%); ethylene glycol, 100 °C, 4 h; (iii)
 
Lawsesson‘s reagent (1.0 eq), THF, reflux.  
  
The esterification reaction was conducted successfully to give benzoate 3.22. However, the 
subsequent step did not afford the desired product 3.24 and hydrolysed starting material 3.21 
was recovered.  Failure of the N-arylation might be that the benzoate moiety of 3.22 is not 
sufficiently electron-withdrawing to favour SNAr substitution at the ortho position.  
Additionally, Zhang et al. observed this reaction with iodo-/bromo-substituted benzoates and 
not with poorer leaving groups like chlorides (Scheme 3.5).  
 
 




ii) Second approach: Acid-catalyzed N-arylation 
The second approach was also inspired by Route B depicted in Scheme 3.4. The first step of 
preparation of thioamide 3.29 involved a process reported by Meshram et al, (US Patent 
2010/0228023 Al).
13
 This process appeared desirable in that formation of the clozapine 
scaffold 3.28 would occur in one step using inexpensive starting materials via an in situ 
condensation subsequently followed by cyclization.  The preparation involved a reaction 
between isatoic anhydride 3.26 with diamine 3.27 in aqueous acetic acid heated at 75 °C for 
3h (Scheme 3.6).  
 
Scheme 3.6: Reagents and conditions: (i) 3.26 (1.0 mmol), 3.27 (1.1 mmol), Glacial acetic acid, 75 °C, 3 h; (ii)
 
Lawesson‘s reagent (1.0 eq), THF, reflux.  
 
1
H NMR analysis of the solid precipitate revealed multiple products based on the number of 
resonance signals observed. None of these signals corresponded to either one of the starting 
materials (3.26 and 3.27). Therefore it was presumed that the isolated precipitate was a 
mixture of uncyclized intermediates and product 3.28. No purification was attempted as the 
precipitate appeared as a single spot on TLC using different solvent systems and no further 
characterization was carried out to identify components of the mixture. Consequently, this 
method was not pursued any further. 
 




(iii) Third approach: intramolecular amidine synthesis 
Given the failure of the first two approaches, the focus was shifted to clozapine scaffold 3.35 
(Scheme 3.7). The synthesis was envisaged as achievable from an adaptation of an 
intramolecular amidine synthesis procedure reported by Aicher and co-workers as illustrated 





Scheme 3.7: Reagents and conditions: (i)NH2OH.HCl, H2O , reflux, 1h, 96%; (ii) Na2CO3 (0.10 eq), DMF, 135 
°C, 2.5 h, 82%; (iii) 3.32 (1.0 eq), 3.33 (1.1 eq), K2CO3 (1.1 eq), DMF, 120 °C, 16 h,  20% ; (iv) SnCl2.2H2O 
(3.0 eq) in 1N HCl, absolute EtOH, reflux, 8 h, 93%. 
 
The reaction proceeded via nucleophilic aromatic substitution between aminobenzonitrile 
3.32 with 1,4-dichloronitrobenzene 3.33. The N-arylation in this case was successful due to 
the presence of a strong electron-withdrawing nitro group ortho to a chloro leaving group. 
Moreover, the reaction was conducted at a relatively high temperature of 120 ° C.  The 
subsequent step involved nitro-reduction followed by intramolecular amidine formation. The 
possible mechanism of this latter step is similar to the Pinner reaction whereby a protonated  
 




nitrile group is subjected to an intramolecular nucleophilic attack.
15,16
 Apart from aromatic 
resonances observed in the 
1
H NMR spectrum, three distinct broad signals were observed 
downfield thus confirming presence of three NH protons of the tautomeric form 3.35. The 
structure was further confirmed by 
13
C NMR and LCMS analysis.  
 
3.4.1.2 Synthesis of a ‘loxapine-like’ scaffold 
The traditional method for synthesis of dibenzoxazepine is via a multi-step synthetic route 
that involves a key intramolecular N-arylation using either copper-based or palladium-based 
catalyst/ligand systems.
17
 Herein two approaches were explored for the synthesis of 
dibenzoxazepine 3.39 (Scheme 3.8). 
 
 (i) Initial approach: Copper/L-proline-catalyzed intramolecular aryl amination  
Initially, the synthesis of dibenzoxazepine scaffold 3.39 was conceived as achievable from a  
procedure reported by Guo and his co-workers.
18
 The key step of this two-step procedure was 
intramolecular aryl amination catalyzed by a copper/L-proline system (Scheme 3.8). 
 
Scheme 3.8: Reagents and conditions: (i) (a) 2.37 (2.0 eq), Na2CO3 (4.0 eq), DMF (b) 2.36 (1.0 eq) 0°C to rt, 4 








The etherification reaction was successful but the subsequent aryl amination step could not 
afford the desired product 3.39 even after the reaction was allowed to continue for prolonged 
hours. Guo et al. only isolated the desired dibenzoxazepine 3.39 in poor yields under reaction 
conditions represented in Scheme 3.8.
18
 As difficulties were encountered with copper-
catalysed N-arylations before, it was decided to consider palladium/ligand systems. 
 
(ii) Second Approach: Palladium-catalyzed intramolecular N-arylation 
The second approach involved a catalytic Pd2(dba)3/P(t-Bu)3 system as reported by Margolis 
and co-workers.
9
 The first step was etherification, subsequently followed by nitro-reduction 
and then Pd-catalyzed N-aryl amination as depicted in Scheme 3.9.  
 
 
Scheme 3.9: Reagents and conditions: (i) (a) 3.41 (2.0 eq), K2CO3 (2.5 eq), 3.40 (1.1 eq), 70°C, 3 h, 64%; (ii)   
Fe filings (15.0 eq), 10 N HCl, Isopropanol,  60 °C , 17 h, 88%; (iii) 3.43 (1.0 eq)  NaO-t-Bu (2.0 eq), K2CO3 
(2.0 eq), Pd2(dba)3 (10 mol%), P(t-Bu)3 (0.5 mol%), 95 °C, N2, 10 h, 22%.  
 
The first two steps of the reaction afforded product 3.42 and 3.43 in relatively good yields 
(Scheme 3.9). The subsequent N-aryl amination yielded the desired cyclized 
dibenzooxazepine 3.44 in a yield of 22% and unreacted starting material 3.43 was recovered.  




Structure confirmation was achieved by NMR and LCMS analysis. The expected number of 
resonance signals was observed downfield along with a benzyl methylene resonating at δH 
5.03 ppm. A broad resonance signal at δH 5.93 ppm integrated for only one NH proton as 
confirmation of a successful cyclization.  
 
3.4.1.3 Synthesis of a dibenzothiazepine scaffold 
Synthetic approaches to thiazepine-based ring systems vary from cross couplings to 
rearrangements of existing rings.
9,19,20
  Approaches that were attempted for preparation of 
dibenzothiazepine to mimic a quetiapine scaffold are discussed below. 
 
(i) Schmidt rearrangement Approach 
The Schmidt reaction is a useful method of insertion of nitrogen next to a carbonyl group. It 
involves reaction of azides with electrophilic carbonyls in the presence of an acid catalyst to 
form an amide. This goes via an azidohydrin intermediate which rearranges with expulsion of 
nitrogen.
21,22,23 
  The preparation of thiazepine 3.47 was conceived as achievable using this 
reaction followed by reductive deoxygenation using BH3.THF complex (Scheme 3.10).
24
  
Due to the symmetrical nature of 3.45, regioselectivity issues would be avoided. 
 
 
Scheme 3.10: Reagents and conditions: (i) NaN3 (3 eq), conc. H2SO4, CH3CN, 0 °C to rt (12 h); (ii) BH3.THF 
complex, dry THF, -10 °C, reflux,  N2.  
 
 








NMR spectrum of the isolated compound was consistent with that of pure starting 
material 3.45 hence, no reaction took place. Other attempts using different reaction 
conditions, i.e. changing the source of azide (trimethylsilyl azide) and varying the solvent 
(e.g. THF and DCM), were also not successful. 
 
(ii) Beckmann rearrangement approach 
The second approach chosen involved the use of oximes to form amides via the Beckmann 
rearrangement. The rearrangement is envisioned to proceed via alkyl migration induced by an 
electropositive oxime nitrogen under acid conditions.
21,25
 An attempt to synthesize the desired 
thiazepine 3.51 under the conditions outlined in Scheme 3.11 was futile and starting material 
3.48 was recovered. 
 
 
Scheme 3.11: Reagents and conditions: (i) NH2OH.HCl (5.0eq) NH4OAc (5.0 eq), EtOH, reflux, 10h; (ii) conc. 
H2SO4, ∆. (iii) BH3.THF complex, dry THF, -10 °C, reflux, N2. 
 
The first two approaches to dibenzothiazepine i.e. via Beckmann rearrangement or Schmidt 
rearrangement were unsuccessful presumably due to the limited accessibility of the 
thioxanthone keto-group to nucleophilic addition.   
 
 




(iii) S-arylation approach 
After futile attempts to synthesize the desired thiazepine scaffold via rearrangement 
approaches, another route was designed as shown in Scheme 3.12. The first step of the route 
involved one-pot imine formation and S-arylation. The subsequent step was a facile reduction 
of imine 3.54 using sodium borohydride in methanol. 
 
 
Scheme 3.12: Reagents and conditions: (i) 3.52 (1.0 eq), 3.53 (1.0 eq), K2CO3 (0.80 eq), DMF, 100 °C, 20 h, 
53%; (ii) NaBH4 (1.0 eq), MeOH, 0 °C → rt, 91%. 
 
The S-arylation route successfully afforded thiazepine 3.55. The structures were confirmed 
by NMR and LCMS analysis. 
1
H NMR of 3.54 revealed a characteristic imine signal 
downfield resonating at δH 8.92 ppm. After reduction, the imine resonance signal disappeared 
and a methylene resonance of 3.55 was observed at δH 4.85 ppm. 
 
3.4.2 Synthesis of N-alkylsulfonates of ring-expanded phenothiazine-like scaffolds 
NCEs 3.9-3.12 were prepared from the ring-expanded scaffolds (3.35, 3.44, 3.55 & 
commercially available 10,11-dihydro-5H-dibenzoazepine (3.56) via the general sultone ring-
opening procedure described in section 3.2.1 (Scheme 3.13). For NCE 3.9, the alkylation was 
envisaged as achievable via thionation as illustrated in Scheme 3.4 (Route B). However a 
direct sultone ring-opening attempt under mild basic conditions was successful using sodium  
 




carbonate as a base. The reactions were all extremely low yielding due to a competing sultone 
hydrolysis side reaction. However, the amounts isolated were sufficient for bio-activity 
screening. Optimization of yields was not prioritized and unreacted starting materials were 
recovered. 
 
Scheme 3.13: Reagents and conditions: (i) NaH (60% dispersion in mineral oil, 1.1 eq), dry DMF, rt → 50 °C, 
N2, 1.5 h; 1,3-propane sultone 3.3 (1.1 eq) in dry DMF, rt, N2, 16 h → 18 h. 3.10 (22%), 3.11 (18%), 3.12 
(18%); (ii) Na2CO3 (1.1 eq), dry DMF, rt → 50 °C, N2, 1.5 h; 1,3-propane sultone 3.3 (1.1 eq) in dry DMF, rt, 
N2, 12 h 3.9 (11%). 
 
The structures and purity were confirmed by NMR and LCMS analysis. Figure 3.8 
exemplifies the general pattern of resonances observed in the 
1
H NMR spectrum of oxazepine 
3.10. The distinctive feature in the spectrum is the methylene resonance at δH 5.40 ppm 
indicative of a central seven-membered ring. The rest of the NCEs 3.9, 3.11 and 3.12 also 
displayed similar patterns of resonances in the upfield and downfield regions. 
 
 
















H NMR spectrum of DS003125 (3.10) to illustrate the pattern of resonance signals observed. 
 
3.5 N-propylsulfonates of quinolines 
As discussed in chapter 2, quinolines are of interest to this research study owing to their 
structural resemblance to neuroleptic phenothiazines. The strategy that was applied in 
remodelling phenothiazines in section 3.2.1 was also used generate N-propylsulfonates of 




















Figure 3.9: N-propylsulfonates of bicyclic quinolines. 
 
3.5.1 Synthesis of N-propylsulfonates of quinolines 
The approach described in section 3.2.1 was employed in preparation of quinoline and 
isoquinoline-based N-propylsulfonates (Scheme 3.14). Contrary to the appreciable retention 
displayed by phenothiazine-based N-alkylsulfonates (3.1a-e), the quinoline-based derivatives 
(3.57-3.62) showed poor retention on reversed-phase columns. Consequently, co-elution with 
sultone hydrolysis product 3.3a occurred. Repeated chromatography was necessary to afford 
NCEs 3.57-3.62 in pure form. The compounds were obtained in low yields due to a 













Scheme 3.14: Reagents and conditions: (i) NaH (60% dispersion in mineral oil, 1.1 eq), dry dioxane, rt to 40 
°C, N2, 1 h; (ii)  propane sultone 3.3 (1.0 eq) in dry dioxane, rt, N2, 14 h. 3.58 (10%), 3.59 (11%), 3.60 (16%), 





C NMR spectra corroborated by LCMS analysis confirmed the structures of the 
desired NCEs 3.57-3.62. A thorough analysis of 
1
H NMR spectra further confirmed that all 
the derivatives were mono-alkylated as the resonance signals integrated for the expected 
number of protons.  The resonance patterns differed based on the position of the quinoline 
nitrogen and the side chain (Figure 3.10). Given the nature of the structures, intramolecular/ 
intermolecular hydrogen bonding is expected to affect chemical shifts of the amine protons in 













                                                                              
 







H NMR spectra of 3.61 and 3.57 to illustrate the differing patterns of resonance signals.  
 
3.6 Propylsulfonates of scaffolds without a thiazine central ring 
Replacement of the central thiazine ring of phenothiazines with a thiane and acridine ring 
afforded NCEs shown in Figure 3.11.  
 
 
Figure 3.11: Propylsulfonates of non-thiazine phenothiazine-like scaffolds. 
 




3.6.1 Thiane ring from reductive deoxygenation of thioxanthone 
Conversion of ketones to the corresponding hydrocarbons is traditionally achieved via the use 
of methods such as Clemmensen reduction and Wolff-Kishner reduction.  Clemmensen 
reduction of ketones occurs at the surface of a zinc metal catalyst under very strong acidic 
conditions with heating.
21
 The alternative Wolff-Kishner reduction occurs under strong basic 
conditions via the formation of a hydrazone using hydrazine.
21
 Reductive deoxygenation of 
ketones/aldehydes has been reported under milder conditions using reducing agents such as 
borane complexes or copper-based catalyst systems.
24
 Herein, a BH3.THF complex method 
was employed for preparation of thioxanthene 3.67 from thioxanthone 3.66 (Scheme 3.15).  
 
 
Scheme 3.15: Reagents and conditions: (i) 1M BH3.THF complex (2.0 eq), dry THF, -10 °C, rt → reflux, 14h, 
3.67 51%, alcohol 3.68 (15%) + unreacted starting material 3.66. 
 
The reductive deoxygenation reaction afforded desired product 3.67 including alcohol 3.68. 
The structure of product 3.67 was confirmed by 
1
H NMR and 
13
C NMR analysis which 
revealed a methylene signal resonating at δH 3.89 ppm and disappearance of a ketone 











3.6.1 Propylsulfonates of thioxanthene and acridone 
The preparation of NCEs 3.64 and 3.65 was conceived as achievable via the general sultone 
ring-opening procedure described in section 3.2.1. However, a much stronger base, n-butyl 
lithium (pKa ~ 50), was chosen to facilitate C-alkylation of thioxanthene 3.66 (Scheme 3.16).  
 
 
Scheme 3.16: Reagents and conditions: (i) n-BuLi (1.0 eq), dry THF, -20 °C → rt, N2, 0.5 h; (ii) 3.3 (1.3 eq) in 
dry THF, rt, N2, 16 h. 3.64 (24%), 3.65 (12%). 
 
The purification was carried out using reversed-phase chromatography which was 
advantageous in that the sulfonate product (3.64 or 3.65) was eluted before unreacted starting 
material. NMR and LCMS analysis confirmed structures of desired products 3.64 and 3.65. 
In the 
1
H NMR spectrum of 3.65, a triplet resonating at δH 3.85 ppm with a 
3
J of 6.9 Hz 
confirmed C-alkylation. 
 
3.7 Molecular hybrids of phenothiazines 
3.7.1 Phenothiazine-isoniazid hybrids 
The synthesis of phenothiazine-isoniazid hybrids was envisaged as achievable from a two-
step synthesis route. This included an N-alkylation with 1-bromo-3-chloropropane followed 
by nucleophilic substitution on the side chain. The reaction conditions employed to achieve  
 




this are outlined in Scheme 3.17. In chapter 2, the isoniazid dimers were predicted to have 
poor drug-like properties and were thus of least priority. However, step (ii) of the synthesis 
yielded both monomers 3.72a-c and dimers 3.73a-c.  Therefore, the dimers were also isolated 
for biological evaluation. 
 
Scheme 3.17: Reagents and conditions: (i) NaH (1.1 eq), dry DMF, N2, 0 °C → rt, 1.5 h, 1-bromo-3-
chloropropane (1.0 eq), rt, 21 h. 3.70a (38%), 3.70b (79%), 3.70c (26%) ; (ii) Isoniazid (1.0 eq), NaH (1.0 eq), 
dry DMF, N2, 0 °C → rt, 0.5 h, 3.71a-c (1.0 eq), rt, 36 h. 3.72a (20%), 3.72b (22%), 3.72c (26%)., 3.73a (13%), 
3.73b (15%), 3.73c (18%). 
 
1
H NMR spectra of the hybrids displayed two distinct sets of deshielded signals resonating in 
the δH range 7.70-8.73 ppm which were assigned to the pyridine ring. Integrals for all 
methylene and phenothiazine resonances doubled for the dimers.  The structures were further 
confirmed by 
13
C NMR and LCMS analysis. 
 




3.7.2 Ortho- and para- nitrobenzenesulfonamides of phenothiazines 
The synthesis of nitrobenzenesulfonamides of phenothiazines 3.74a-c and 3.76a-c was 
envisaged as achievable from a direct condensation of ortho- or para-nitrobenzenesulfonyl 
chlorides with the respective phenothiazines as illustrated in Scheme 3.18. 
 
 
Scheme 3.18: Reagents and conditions: (i) 3.75a-c (1.0 eq), ortho- or para-nitrobenenzesulfonyl chloride (1.0 




H NMR and 
13
C NMR spectra revealed aromatic resonances with differing patterns 
depending on the type of substitution.  For ortho-nitro derivatives 3.74a-c, the aromatic 
resonances were observed in the range δH 6.75-9.22 ppm and for the para-nitro derivatives 
3.76a-c the range was δH 7.37-8.92 ppm. The formation of the sulfonamide bond was 
confirmed with IR spectra showing sulfonamide absorption bands in the frequency range 
1344-1351 cm
-1










3.7.3 Pyrazole- and isoxazole-linked phenothiazine derivatives 
The synthesis of pyrazole-linked and isoxazole-linked phenothiazines (3.79 & 3.80, 
respectively) was achieved from adaptation  of a  procedure reported by Mekky et al.
26
 The 
reaction conditions are outlined in Scheme 3.19.  
 
 
Scheme 3.19: Reagents and conditions: (i) 3.77 (1.0 eq), Dimethylformamide-dimethylacetal (DMF-DMA) (2.0 
eq), dry toluene, reflux, N2, 47%; (ii) 3.78 (1.0 eq), NH2NH2.H2O (excess), EtOH, rt, 14h, 83%; (iii) 3.78 (1.0 




H NMR spectrum of enaminone 3.78 revealed two ethylenic protons resonating at δH 
7.69 and 5.69 ppm with a 
3
J of 12.3 Hz which is indicative of an E-configuration. In addition 
two singlets were observed at δH 3.14 ppm and 2.90 ppm, which were assigned to the N,N-
dimethyl protons. The 
1
H NMR spectra of pyrazole 3.79 and isoxazole 3.80 revealed 
aromatic resonances in the ranges δH 7.71-6.56 ppm and 8.62-6.70 ppm respectively. 
13
C 








3.8 Phenothiazines with non-basic side chains 
Apart from N-propylsulfonates of phenothiazines, other derivatives with non-basic side 
chains were designed as described in chapter 2 (Scheme 3.20). 
 
3.8.1 Retrosynthetic analysis and synthesis details 
Scheme 3.20 illustrates the retrosynthetic plan undertaken which involved four key one-step 
routes to afford desired NCEs 3.82a-d and 3.83-3.84. Three of the routes (B-C) were 
designed from aza-Michael addition product 3.82a as depicted in Scheme 3.20.  
 
 
Scheme 3.20: The retrosynthetic plan for preparation of desired NCEs 3.82a-d and 3.83-3.84 
 
 




3.8.1.1 Synthesis of nitrile 3.82a-c via aza-Michael addition 
The aza-Michael addition was achieved by a reaction of the phenothiazines 3.81a-c with 





confirmed the addition by showing aromatic resonances along with two triplets resonating in 
the range δH 2.92 – 4.23 ppm. These were assigned to the two methylene groups derived from 
the Michael acceptor. 
1
H NMR results were corroborated by 
13
C NMR and LCMS analysis. 
 
 
Scheme 3.21: Reagents and conditions: (i) Acrylonitrile (excess), Triton B (10 mol%), 0 °C, 0.5 h; Dioxane, 
reflux, 1h, 3.82a (67%), 3.82b (54%), 3.82c (60%).  
 
3.8.1.2 Synthesis of tetrazole 3.84 
The preparation of tetrazole derivative 3.84 was achieved using sodium azide in the presence 
of ammonium chloride (Scheme 3.22).  In comparison to the 
1
H NMR of the unsubstituted 
nitrile derivative 3.82a, a clear shift of methylene resonances from δH 4.23  & 2.93 ppm to δH  
4.35 & 3.32 ppm, respectively, was observed. This was ascribed to strong electron-
withdrawing inductive effects exhibited by the tetrazole ring. 
 
Scheme 3.22: Reagents and conditions: (i) NaN3 (3.0 eq), NH4Cl (3.0 eq), DMF, 125 °C, 16 h, 3.84 (45%). 
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3.8.1.3 Synthesis of dibromo-10H-phenothiazine propanenitrile 3.82d 
A monobrominated product was initially of interest to this study to evaluate the effect of 
halogen substitution, at a position other than the usual 2-position, on bio-activity. However, 
attempts to synthesize the mono-brominated product yielded dibromo 3.82d as the major 
product. Interestingly, dibromo product 3.82d bears structural resemblance to DNA 
intercalators such as ethidium bromide, thus was also of interest to this study.
28 
Consequently, 
the reaction conditions were optimized and the dibromo derivative 3.82d was obtained after 
recrystallization from a mixture of ethyl acetate and hexane (Scheme 3.23).  
 
 
Scheme 3.23: Reagents and conditions: (i) N-bromosuccinimide (2.3 eq; optimized for dibromination), dry 
THF, 0 °C, 1 h → rt 12 h, 3.82d (65%). 
 
Dibromo 3.82d was the major product presumably due to ortho, para-directing effects of the 
thiazine ring. Selectivity amongst the available positions is known to be determined by steric 
hindrance.
29,30
 Two sets of aromatics resonances at δH 7.41 ppm & 7.04 ppm integrated for 
four and two protons, respectively. This was a confirmation that the electrophilic 
disubstitution was successful.  
 
3.8.1.4 Synthesis of amide 3.83 via the Ritter reaction 
The amide derivative 3.83 was prepared via an acid-catalyzed nucleophilic addition of nitrile 
3.82a to a carbenium ion generated from t-butyl acetate (Scheme 3.24). This reaction is 
known as the Ritter reaction.
31
 Nitriles are known to be poor nucleophiles and weak bases  





Scheme 3.24: Reagents and conditions: (i) tert-butyl acetate, conc. H2SO4, rt → 42 °C., 12 h, 3.83 (20%). 
 
due to the lone pair on the nitrogen atom being in a low-energy sp orbital.
30 
The carbocation 
generated in this reaction is reactive enough to combine with the weakly nucleophilic nitrile. 
The proposed mechanism of this reaction is illustrated in Figure 3.12. 
 
Figure 3.12: Proposed mechanism of the Ritter reaction illustrating the series of intermediates involved. 




The Ritter product 3.83 was characterized by NMR and LCMS. The 
1
H NMR spectrum 
showed a characteristic tert-butyl resonating upfield at δH 1.23 ppm. An amide proton was 
observed downfield at δH 7.46 ppm. 
13
C NMR revealed a carbonyl signal resonating at δC 
169.66 ppm. One of the methylene resonances appeared to overlap with the DMSO-d6 peak at 
δH 2.48 ppm, thus the signal integration was ambiguous. This ambiguity was resolved using 
an 
13
C-APT (Attached Proton Test) NMR experiment for distinguishing between carbons 
based on the number of protons attached. The 
13
C-APT spectrum of 3.83 showed two positive 
resonance peaks at δC 34.17 ppm and 43.32 ppm, thus confirming the presence of two 














C-APT NMR for confirmation of two methylenes in the chemical structure of 3.83 (DS00385). 
Quaternary and methylene carbons point upwards whereas CH‘s and CH3‘s point downwards. 
 
3.83 




3.8.1.5 N-propylphosphonate ester 3.87 from the Michaelis-Arbuzov reaction 
The Michaelis-Arbuzov reaction is a useful method for preparing phosphonates from alkyl 
halides.  One of the drawbacks from this classical synthetic method is the need for elevated 
temperatures for the reaction to occur. Adaptations of the original method have been reported 
including the use of Lewis acid-catalysts.
32
 The synthesis of the N-propylphosphonate ester 
3.87 was conceived as achievable using the Michaelis-Arbuzov reaction method under the 
conditions outlined in Scheme 3.25. 
 
Scheme 3.25: Reagents and conditions: (i) NaH (1.1 eq), dry DMF, N2, 0 °C → rt, 1.5 h, 1-bromo-3-
chloropropane (1.0 eq), rt, 26 h. 53 %; (ii) 3.86 (1.0 eq), triethyl phosphite (5.0 eq), ZnCl2 (1M in DCM) (1.2 
eq), dry toluene, 75 °C, N2, 18 h. 10%. 
 
The Michaelis-Arbuzov reaction proceeded via an SN2 reaction between nucleophilic 
triethylphosphite and an alkyl halide followed by an SN2 dealkylation to form phosphonate 
ester 3.87. The proposed mechanism is depicted in Figure 3.14. 
 
Figure 3.14: Proposed mechanism of Michaelis-Arbuzov reaction illustrating the formation of phosphonate 
ester 3.87 from an alkyl halide. 















Figure 3.15:  
31




H NMR spectrum of phosphonate ester 3.87 revealed the right number of aromatic 
resonating in the range δH 7.20-6.96 ppm along with sets of methylene and methyl resonances 
in the upfield region. Furthermore, a resonance peak was observed at δP 31.48 ppm in the 
31
P 



















3.9 Concluding remarks 
Adaptation of well-known organic reactions and literature reported synthetic methods led to 
the design of shorter and concise routes to the library of desired NCEs. The attachment of 
side chains was afforded via reactions such as nucleophilic ring-opening N-alkylation and 
aza-Michael addition. Other mechanistically interesting reactions such as the Arbuzov-
Michaelis reaction and Ritter reaction also afforded desired NCEs. In cases where the 
tricyclic-ring system had to be assembled from functionalized benzenes, the Buchwald-
Hartwig reaction conditions were employed. In general, most of the chemical reactions were 
low yielding particularly due to incomplete consumption of starting materials and/or 
competing side reactions (e.g. sultone hydrolysis). However, the amount of products isolated 
was sufficient for bio-activity screening thus optimization of yields was not prioritized.  
 
Isolation and purification techniques common in organic synthesis were employed with 
reversed-phase chromatography being an exception for purification of alkylsulfonate NCEs. 
This method involved the use of aqueous-based mobile phase and introduction of organic 
modifiers where necessary.  Spectroscopic techniques such as NMR, LCMS and IR were 
employed for structure elucidation, confirmation and purity analysis. 
 
The next two chapters (Chapter 4 & 5) report on the biological evaluation of the library of 
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Structurally remodelled phenothiazines as potential antitubercular agents 
without neuroleptic effects 
 
Preface 
Various strategies were applied in remodelling phenothiazines and related neuroleptic drugs. 
The strategies were rationally selected to ensure deviation from minimum structural 
requirements for neuroleptic action of phenothiazines. In so doing, a focused library 
comprising remodelled phenothiazines that are less likely to exhibit neuroleptic effects was 
generated.  In the previous chapter, remodelled phenothiazines and related drugs were 
chemically synthesized for biological evaluation. 
 
Tuberculosis remains one of the leading causes of death from an infectious disease, 
worldwide. In this chapter, the library of remodelled phenothiazines including parent drugs 
was evaluated against drug-susceptible Mycobacterium tuberculosis. Moreover, a selected 
series was screened for binding to serotonin and dopamine receptors to corroborate in silico 
predictions. Furthermore, in vitro and in vivo preclinical evaluation studies are also reported 
herein. This chapter thus addresses one of the key objectives of this research study i.e. to 
identify potential antitubercular agents from remodelled phenothiazines with less likelihood 










4.1 The Tuberculosis scourge  
4.1.1 Tuberculosis and HIV co-epidemics: global statistics 
The prevalence of Tuberculosis (TB) is a grave global concern. An estimated 9.0 million new 
TB cases were reported in 2013 of which 16% resulted in death and 13% tested positive for 
Human Immunodeficiency Virus (HIV) (Figure 4.1). Significant progress has been made 
over the years since TB was declared a global public health emergency by the World Health 
Organization (WHO) in 1993. The TB mortality rate has gone down by 45% since 1990 and 





Figure 4.1: 2013 Global statistics of HIV co-infection with TB. Data and map courtesy of WHO Global 
Tuberculosis Report, 2014.
 
Key Facts: HIV-positive people are 29 times more likely get infected with TB; 13% 
of 9 million TB patients  tested positive for HIV in 2013;  There is a decrease in the  number of people dying 












Emergence of drug resistance continues to be a threat to the management of TB. More than 
480 000 cases of multidrug-resistant TB (MDR-TB) occur annually across the globe. Of 
these, 9% is associated with extensively drug-resistant TB (XDR-TB).
2
 In 2014, the WHO 
reported 54 countries that confirmed treating XDR-TB patients in 2013.  Amongst these are   
Ukraine (1006 XDR-TB cases), South Africa (612 XDR-TB cases), India (364 XDR-TB 
cases) and Kazakhstan (305 XDR-TB cases).
1 
 
4.1.2 Mycobacterium tuberculosis: the causative agent of TB 
Mycobacterium tuberculosis (M.tb) typically affects the lungs to cause pulmonary TB or 
other sites of the body (extrapulmonary).
3
 TB infection is acquired from inhalation of micro-
droplets of sputum from a TB patient. These micro-droplets are about 2.5 μm in diameter 
with 1-3 bacilli. Once the bacteria reach the alveolar sacs of the pulmonary system, they get 
phagocytosed by macrophages. The host responds to this infection by apoptosis of infected 
macrophages.  
Virulent strains may escape apoptosis by subversion of the immune system resulting in 
prolonged survival in host cells.  The bacteria may remain dormant in the macrophages and 
this is referred to as latent TB. The latent stage of TB infection is asymptomatic and non-
infectious.
3 
Poor hygienic conditions, poverty, immune system suppression and co-infection 
with other diseases, e.g. HIV, may lead to active TB.
  
A simplified depiction of TB infection 
is given in Figure 2.2. 
Diagnosis of TB is commonly carried out via sputum smear microscopy, a method that was 
developed over a century ago. Diagnosis may also be done using culture methods especially 
in regions where there is a more developed laboratory infrastructure.
1,4 
 







 Figure 4.2: A simplified depiction of TB infection cycle caused by Mycobacterium tuberculosis. 
 
4.1.3 Treatment of TB infections and drug resistance as a setback 
Prior to the discovery of M.tb in 1882 by Robert Koch, a German physician and scientist, 
different types of collapse therapy and surgical interventions e.g. thoracoplasty were used for 
TB treatment. By the early 1950s, surgical interventions for TB treatment began to recede as 
antitubercular drugs were introduced.
3 
The principal issue with the management of TB is the 
necessity to have lengthy drug treatment regimens of six to nine months. The lengthy 




Amongst these drawbacks, drug resistance remains the major setback in TB treatment. The 
Direct Observed Treatment (DOT) of drug-susceptible TB involves a four-drug regimen of 
first-line anti-TB drugs. The first phase (intensive phase – rate of bacteria growth very high) 
includes isoniazid, pyrazinamide, rifampicin and ethambutol for a period of two months. 
Subsequently, a continuation phase (bacilli in slow growth persister form) including only 
isoniazid and rifampicin follows for at least 4 months.
3 
 






The existence of drug-resistant M.tb strains was first reported in 1944 right after streptomycin 
was introduced. Subsequently, resistance to other TB drugs was demonstrated.
7
 M.tb strains 
resistant to first-line anti-TB drugs are termed multidrug-resistant (MDR), while those 
resistant to second-line anti-TB drugs e.g. fluoroquinolones and aminoglycoside injectables 
like amikacin are termed extremely drug-resistant (XDR) (Figure 4.3).
8,9
 Treatment of drug-





Figure 4.3: Resistance of Mycobacterium tuberculosis - a threat to management of TB. 
 






More recently, totally-drug resistant (TDR) M.tb strains have been reported as a serious 
threat to TB therapy. TDR-TB is virtually untreatable and shows resistance to all first-line 
and second line anti-TB drugs. The earliest observation of TDR-TB was in Italy over a 
decade ago followed by Iran in the late 2000s.
10,11
  In 2011, Udwadia et al. reported patients 
with TDR-TB in India.
12 
 Additionally, in 2013, the Center for Disease Control and 
Prevention reported first incidents of TDR-TB in South Africa.
11
 
Anti-TB chemotherapeutics are categorized into five groups on the basis of factors such as 
efficacy, mode of administration (oral or injectable) and structural identity (Table 4.1).
2 
 
Table 4.1: Classification of anti-TB drugs 
Group 1 Group 2  Group 3 Group 4 Group 5 
Oral Injectable Oral & Injectable 
(Fluroquinolones) 
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As discussed in chapter 1, novel therapeutic drug classes are urgently required to curb the 
rising tide of antibiotic resistance.  Several drug candidates with novel modes of action are in 
late-stage clinical development or have been approved for TB chemotherapy (Figure 4.4).
13
 
Examples include bedaquiline (a diarylquinoline), delamanid (a nitroimidazo-oxazole), 
sutezolid (an oxazolidinone) and SQ109 (a 1,2-diamine).
10,13,14
  








Figure 4.4: The tuberculosis drug pipeline. OBR - optimised background regimen; DS-TB: drug-susceptible   




Drug repurposing (chapter 1) has garnered significant research interest as an alternative 
strategy for the management of antimicrobial drug resistance. A number of drugs, including 
neuroleptic thioridazine and linezolid, have been repurposed and are under investigational use 




4.1.4 Drug targets in TB drug discovery 
The cell wall is crucial for survival of M.tb particularly under unfavourable conditions post-
phagocytosis by the host. Its biosynthesis is appealing for discovery of new drugs for several 
reasons. It is absent in the mammalian system and many enzymes involved in this pathway  
 
 






are attractive biomolecular targets. An illustration of processes targeted by the majority of 
anti-TB agents is given in Figure 4.5. The bacterial cell wall synthesis is targeted by first-line 
anti-TB drugs, ethambutol and isoniazid.
5
 The newly developed nitroimidazo-oxazole, 
delamanid, also targets cell wall synthesis by blocking the synthesis of mycolic acids.
14
  
Inhibition of calcium-dependent enzymes interferes with processes such as ATP hydrolysis 
which is essential for cellular energy.
7,8 
Bedaquiline targets the proton pump of ATP 






Figure 4.5: Examples of biological processes targeted by the majority of anti-TB drugs. InhA (2-trans-enoyl-




A number of biosynthetic pathways have been well documented as potential anti-TB drug 
targets. Mycothiol and ergothioneine are primary low molecular weight thiols that play a 
crucial role in maintaining cellular redox homeostasis thereby ensuring the survival and  
 






persistence of M.tb. Therefore, enzymes involved in the biosynthesis of small molecule thiols 
and the associated detoxification pathways are appealing targets.
18
 Another pathway that is 
appealing is amino acid biosynthesis which involves synthesis of aromatic and non-aromatic 
amino acids.
5
 Other attractive targets include enzymes involved in the respiratory chain of 
M.tb.
19
 Oxidoreductases such as type II NADH:menaquinone odixoreductase (NDH-2) are 
viable anti-TB drug targets.
8
 Mutations of genes associated with processes such as cell wall 
synthesis and DNA metabolism play a major role in drug resistance. They may cause 
upregulation of bacterial efflux pumps thus decreasing its susceptibility to several drug 





Phenothiazines have been reported to interfere with some of the above-mentioned biological 
processes.
8
 In particular, thioridazine and other phenothiazines, have been reported as 
inhibitors of M.tb NDH-2 and bacterial efflux pumps.
9,21,22
 Moreover, they have also been 
reported to inhibit
  




4.1.5 Reports of antimycobacterial properties of phenothiazines 
There is a growing interest in the antimycobacterial properties of native phenothiazine drugs 
and their derivatives (Chapter 1).
24,25,26 








 and phenothiazines 
bearing a triphenylphosphonium moiety.
16
 These reports reveal the great potential of 
phenothiazines as antitubercular agents through minimal structural remodelling.  
 






4.2 Biological evaluation of a focused library of remodelled phenothiazines 
4.2.1 Brief overview 
Phenothiazines produce adverse side effects in addition to their inherent neuroleptic effects at 
clinically effective concentrations. Therefore, their extended clinical use as antimycobacterial 
agents is limited. In this study, it was postulated that these drugs could be remodelled such 
that their inherent neuroleptic effects are abrogated whilst antimycobacterial activity is 
retained. The overall rationale applied in the remodelling involved deviating from structural 
traits and properties associated with their neuroleptic action (Chapter 2). The library of the 
new chemical entities generated was taken through several stages to identify potential 
antitubercular agents with reduced likelihood of neuroleptic effects (Figure 4.6). 
 
Figure 4.6: Biological evaluation of new chemical entities from remodelling phenothiazines and related drugs.  






4.2.2 Antimycobacterial evaluation against M.tbH37Rv 
The biological screening against M.tb was conducted in collaboration with University of 
Cape Town (UCT) Institute of Infectious diseases and Molecular Medicine (IIDMM). 
Detailed assay methods are provided in Chapter 7. Neuroleptic drugs with unknown 




Figure 4.7: Parent neuroleptic drugs that were structurally remodelled for antimycobacterial evaluation. 
  
The library of NCEs (Figure 4.8) and commercially available parent drugs (Figure 4.7) were 
evaluated in vitro against virulent M.tbH37Rv using the Green Fluorescent Protein 
Microplate Assay (GFPMA) in a GAST/Fe medium.
30
 The minimum inhibitory 
concentrations (MICs) were determined at 14 days (Table 4.2).  






Figure 4.8: Library of new chemical entities derived from phenothiazines and related neuroleptics for 
evaluation as antitubercular agents. 





Table 4.2: in vitro activity of remodelled phenothiazines against M.tbH37Rv in comparison to parent 
neuroleptic drugs and their in silico predicted CNS activity  




   MIC90 
   (µM) 
M.tbH37Rv 
   MIC99 




MIC90 & MIC99 
         (µM) 
a
lit MIC    (µg/mL) 
N-propylsulfonates       





DS0032 -1 (inactive) > 125 > 125 Thioridazine 9.9  & 12.9 
DS0033 -2 (inactive) > 125 > 125 Acepromazine 




DS0034 -1 (inactive) > 125 > 125 Chlorpromazine 
a
  4-32 (Bactec)
33
 
DS0035 -1 (inactive) > 125 > 125 Promazine 




N-butylsulfonates          
DS00369 -2 (inactive) > 125 > 125 Thioridazine 9.9  & 12.9 
DS00370 -1 (inactive) > 125 > 125 Chlorpromazine  





Ring-expanded scaffolds      






75.1  &  99.6 
DS003123  -2 (inactive) > 125 > 125 Clozapine > 125 
DS003125   -1 (inactive)              > 125 > 125 Loxapine > 125 
DS00380     -1 (inactive) > 125 > 125 Trimipramine > 125 
Non-thiazine scaffolds         
DS00386 -1 (inactive) > 125 > 125 Thiothixene 30.8  &  40.6 
DS00387  -2 (inactive) > 125 > 125   
Quinoline scaffolds     (Antimalarial drugs)  
DSQ1 -2 (inactive) > 125 > 125 Primaquine  
DSQ2 -2 (inactive) > 125 > 125  Chloroquine  
DSQ3 -2 (inactive) > 125 > 125  Primaquine   
DSQ4 -2 (inactive) > 125 > 125  Chloroquine   
DSQ5 -2 (inactive) > 125 >125  Chloroquine  
DSQ6 -2 (inactive) > 125 > 125  Primaquine  
 





Table 4.2 continued…     




   MIC90 
   (µM) 
M.tbH37Rv 
   MIC99 




MIC90 & MIC99 
         (µM) 
a
lit MIC (µg/mL) 
Isoniazid  hybrids     
DS00362b                                   -2 (inactive)  92.8 120 Acepromazine




DS00362 (dimer) -2 (inactive) 10.6 11.3 Acepromazine      




DS00364a 0 (moderate) > 125 > 125 Chlorpromazine   
a
  4-32 (Bactec)
33
  
DS00364  (dimer) 0 (moderate) >125 >125 Chlorpromazine   
a
  4-32 (Bactec)
33
 





DS00365 (dimer) 0 (moderate) > 125 > 125 Promazine            
a 
 > 25 (Bactec) 
34
 
Nitrobenzenesulfonamides     
DS00325 0 (moderate) > 125 > 125 Promazine            
a
 > 25 (Bactec)
34
 
DS00342 -1 (inactive) > 125 > 125 Promazine            
a
 > 25 (Bactec)
34
 










DS00329 0 (moderate) 66.2 73.8 Chlorpromazine   
a
  4-32 (Bactec)
33
 
DS00341 -2 (inactive) >125 >125 Acepromazine      




Pyrazole & Isoxazole derivatives     
DS00397 1 (moderate) > 125 > 125 Promazine             
a
  > 25 (Bactec)
34
 
DS00398 1 (moderate) 90.9 117 Promazine             




Other non-basic side chains     
DS00385 1 (moderate) > 125 > 125 Promazine             
a
  > 25 (Bactec)
34
 





DS00393 0 (moderate) > 125 > 125 Chlorpromazine    
a
  4-32 (Bactec)
33
 
DS00394 0 (moderate) > 125 > 125 Promazine             
a
 > 25 (Bactec)
34
 
DS00395 -1 (inactive) 38.1  44.4 Promazine             
a
  > 25 (Bactec)
34
 
DS00396 1 (moderate) 11.4  15.4 Promazine             
a 
 > 25 (Bactec)
34
 
DS00390 1 (moderate) > 125 > 125 Promazine            
a
  > 25 (Bactec)
34
 
MIC-minimum inhibitory concentration; MIC90 –concentration that inhibits 90% of bacterial isolates; MIC99- concentration 
that inhibits 99% of bacterial isolates; Positive control-Rifampicin MIC90 (0.003129) & MIC99 (0.00503) µM; Concentration 
range tested 0.244-125 µM, MIC less than 125 are highlighted; 
a
 MICs from literature and system used for determination of 
direct antitubercular activity; cfu- colony-forming units; QikProp predicted CNS activity scale: -2 (inactive) to +2 (active). 






The evaluation of the library of remodelled phenothiazines including native neuroleptic drugs 
against virulent M.tbH37Rv led to identification of several interesting hits from each subclass 
(Table 4.2). The library displayed MICs ranging from as low as 9.9 µM to 125 µM, the 
highest concentration tested. The remodelled phenothiazines as well as neuroleptic drugs that 
displayed MIC90 values less than 125 µM are shown in Figure 4.9. 
 
 
Figure 4.9: Remodelled phenothiazines and neuroleptic drugs with MIC90 below 125 µM. The MICs were 
determined using the GFPMA in a GASTE/Fe medium.  
 






Alkyl chain extension, from propyl to butyl, yielded a hit compound, DS00366 (Figure 4.9). 
The butylsulfonate NCE DS00366 displayed a lower MIC90 of 23.5 µM relative to its 
analogue DS0035 (> 125 µM). The parent thioridazine drug had the lowest MIC90, 9.9 µM. 
Amitriptyline and thiothixene displayed MIC90 of 75.1 and 30.8 µM, respectively. It is 
important to note that the aforementioned antidepressants, amitriptyline and thiothixene, have 
not been previously evaluated as antitubercular agents. Therefore, their potential use as 
adjuvants or drug resistance-reversal agents in TB chemotherapy remains to be investigated.  
 
Introduction of ring-expanded scaffolds did not lower MIC90 values in comparison to parent 
drugs and six-membered phenothiazine tricyclic systems. Moreover, replacement of the 
phenothiazine ring system with bicyclic quinolines and non-thiazine scaffolds had no effect 
on MICs. Substitution patterns in bicyclic quinolines and isoquinolines also had no effect on 
MICs as all NCEs displayed MICs greater than 125 µM.  
 
Of the isoniazid hybrids, only DS00365a, DS00362 and DS00362b displayed MIC90 less 
than 125 µM (Figure 4.9). Interestingly, DS00362 whose molecular weight (699.88 Da) lies 
out of the conventional oral drug space (300-500 Da), displayed the lowest MIC90 of 10.6 µM 
(Table 4.2). The presence of an acetyl group at C-2 of the phenothiazine appeared to have an 
effect on MICs as observed for isoniazid hybrid dimer DS00362 (10.6 µM) and monomer 
DS00362b (92.8 µM). Nitrobenzenesulfonamide DS00329 and pyrazole DS00398 also 















Dibromo-substituted NCE DS00396 emerged as the most active of the N-alkyl nitrile series 
with the lowest MIC90 of 11.4 µM (Figure 4.9). Furthermore, the MIC is 2-fold lower than 
that of NCE DS00366 (23.5 µM) from the N-alkylsulfonates series. Another NCE, tetrazole 
DS00395, also displayed a relatively low MIC90 of 38.1 µM (Figure 4.9). 
 
It is noteworthy that the hit compounds identified from the antimycobacterial screening were 
predicted to be CNS-inactive and also less likely to cross the blood/brain barrier. Therefore, 
these hit compounds hold great potential for further development as antitubercular agents that 
are devoid of neuroleptic effects. 
 
Although N-propylsulfonates (DS0031, DS0032, DS0034 & DS0035) displayed MIC90 and 
MIC99 values greater than 125 µM, they were of particular interest to this study for various 
reasons. They are analogous to clinically approved neuroleptics trifluoperazine, thioridazine, 
chlorpromazine and promazine, which have known physical and pharmacological properties.  
Additionally, the replacement of the alkylamine moiety with an alkylsulfonate as the only 
structural modification, created the greatest contrast between the parent neuroleptic drugs and 
the NCEs. Contrary to the lipophilic chromophore/basic side chain paradigm, an alkyl 
sulfonate functionality is expected to impart aqueous solubility and to exist as negatively 
charged species at physiological pH. It was therefore decided to carry out further 
investigations to establish their structure-antimycobacterial activity relationships and 














4.2.3 Investigation of N-propylsulfonates as non-neuroleptic antitubercular agents 
4.2.3.1 Inhibition of M.tb growth and determination of cell viability 
The N-propylsulfonates (DS0031, DS0032, DS0034 & DS0035) were selected for further 
evaluation against M.tbH37Rv (UCT IIDMM). The GFPMA was used to evaluate 
bactericidal/ bacteriostatic activity against extracellular M.tb in a Middlebrook 7H9 
medium.
36
 Isoniazid and the neuroleptic thioridazine were selected as positive controls. 
Additionally, their ability to inhibit intracellular M.tb replication was assessed. For 
intracellular inhibition of M.tb growth, bone marrow-derived macrophages infected with M.tb 
were treated for five days with the respective remodelled phenothiazines. Furthermore, cell 
viability was determined using CellTiter-Blue® Reagent as an indicator of cytotoxicity in 
infected macrophages. 
 
The remodelled phenothiazines displayed a concentration-dependent inhibitory effect on 
replication of M.tbH37Rv.gfp (Figure 4.10). Interestingly, the order of antimycobacterial 
activity of the NCEs (i.e. DS0035 & DS0034 > DS0032 & DS0031) did not follow the order 
of potency of the neuroleptic drugs they are analogous to i.e. trifluoperazine > thioridazine > 
chlorpromazine > promazine.
8
 The structures of NCEs only varied from each other by 
substituents at C-2 of the tricyclic ring system.  Unsubstituted NCE (DS0035) and a chloro-
substituted NCE (DS0034) displayed MICs of 12.5 µg/mL.  The MICs of the other two NCEs 
(trifluoromethyl-substituted DS0031 and thiomethyl-substituted DS0032) were 2-fold higher 
(Table 4.3).  These observations demonstrate that although MICs of the NCEs were higher 































Figure 4.10: Direct antibacterial activity of the four remodelled phenothiazines (DS0031, DS0032, DS0034 & 
DS0035) against M.tbH37Rv using the GFPMA in a Middlebrook 7H9 medium. Isoniazid (INH) and 
neuroleptic thioridazine (TZ) were used as positive controls and were evaluated at concentration ranges of 
0.0125-0.1 and 0.7812-25 µg/mL, respectively. The fluorescence of M.tbH37Rv.gfp was measured for 12 days 












Table 4.3: In vitro antimycobacterial activity of remodelled phenothiazines in comparison to literature-reported 
MICs of parent neuroleptic drugs 
Remodelled Phenothiazine MIC against  
M.tbH37Rv.gfp 
(µg/mL) 




























































   5-8 (cfu)
39
 
   4-16 (cfu)
40
 




MIC- minimum inhibitory concentration; Isoniazid and neuroleptic thioridazine were used as positive controls 
and were evaluated at concentration ranges of 0.0125-0.1 and 0.7812-25 µg/mL, respectively; * MIC obtained 
from literature, system used for determination of direct antitubercular activity is given in brackets; cfu- colony-
forming units.  
 






The NCEs with the lowest MICs showed between 40% and 60% inhibition against 
intracellular M.tb at 25µg/mL thus demonstrating their ability to transverse cell membrane 
systems (Figure 4.11). Furthermore, it is possible that the NCEs also retained the capacity to 




Figure 4.11: The activity of phenothiazine derivatives (DS0034 & DS0035) against intracellular M.tbH37Rv to 
evaluate efficacy and cell viability. A- Bone marrow-derived macrophages infected with M.tbH37Rv were 
treated for five days with the respective NCEs. They were then lysed and plated for cfu determination. Isoniazid 
(INH) and thioridazine (TZ) were used as positive controls. B- Post treatment, cell viability was determined 
using CellTiter-Blue® Reagent as measure of cytotoxicity in infected macrophages. 
 
Moreover, infected macrophages were almost completely viable (> 95%) post-treatment with 
the respective remodelled phenothiazines, thus pointing to their lack of cytotoxicity. The 
percentages of cell viability for all four NCEs are tabulated in Table 4.4. It is important to 
note that at the highest concentration tested, 25 µg/mL, thioridazine was cytotoxic whereas its 
analogue DS0032 was not. Furthermore, at the same concentration, the rest of the NCEs 
displayed negligible cytotoxicity.  
 
 
         INH          TZ         DS0035      DS0034                                INH           TZ        DS0035   DS0034   Untreated                                                                                                                                             



































Table 4.4: Cell viability as a measure of cytotoxicity, bone marrow-derived macrophages were treated for five 
days, after which cell viability was determined using CellTiter-Blue® Reagent. TZ- thioridazine 
 
Concentration 
Cell Viability (%) 
TZ DS0035 DS0034 DS0031 DS0032 
25.00 µg/mL 0.00 98.36 98.05 98.41 100.00 
12.50 µg/mL 0.00 100.00 97.87 100.00 100.00 
6.25 µg/mL 0.00 100.00 97.92 100.00 99.54 
3.13 µg/mL 87.45 99.95 97.96 100.00 98.85 
1.56 µg/mL 98.75 100.00 100.00 96.620 100.00 
0.78 µg/mL 99.93 100.00 99.13 98.36 100.00 
0.39 µg/mL 99.15 98.80 98.72 98.93 100.00 
0.20 µg/mL 99.89 100.00 99.78 96.86 100.00 
 
4.2.3.2 Investigation of the neuroleptic potential of N-propylsulfonates 
Having established the ability of the four NCEs (DS0031, DS0032, DS0034 & DS0035) to 
inhibit both extracellular and intracellular M.tb replication, their neuroleptic potential was 
investigated next. The NCEs were screened in dopamine and serotonin receptor radioligand 
binding assays to corroborate in silico predicted CNS activity results (Perkin Elmer, formerly 
Caliper Life Sciences, Maryland USA). They were evaluated for binding to dopaminergic 
receptor subtypes D1, D2 and D3 as well as serotonergic receptor subtypes 5-HT1A, 5-HT2A 
and 5-HT2C (Figure 4.12). 
 
 







Figure 4.12: Results from dopamine and serotonin receptor radioligand binding assay showing percentage 
inhibition of binding for remodelled phenothiazines (DS0031, DS0032, DS0034 & DS0035); Table embedded 
lists ligands used in the assay; NovaScreen radio-ligand binding assay standard baseline range -20% to + 20% ; 
Inhibition of binding -20% to + 20% (inactive); 20% to 49%  ( marginal activity) ; > 50% (active); h- human 
recombinant; All the remodelled phenothiazines displayed no binding to the respective receptors except 
DS0031which exhibited marginal serotonin receptor (5-HT1A)  binding . 
 
The results demonstrated that there was no dopamine and serotonin receptor binding by any 
of the remodelled phenothiazines except for DS0031 which displayed marginal serotonin 
receptor (5-HT1A) binding. It is known that substitution at C-2 of phenothiazines influences 
CNS receptor binding affinity. In particular, the presence of a trifluoromethyl substituent at 
C-2 in conjunction with an alkylamine moiety is known to increase CNS receptor binding 
affinity.
41,42
 It is therefore possible that DS0031 retained marginal serotonin receptor binding 
due to the presence of a trifluoromethyl group at C-2 position. 
 






Overall, these observations demonstrated that it is possible to abolish binding of 
phenothiazines to CNS receptors whilst retaining antimycobacterial activity through 
rationalized structural remodelling. Successfully switching off CNS receptor binding without 
losing antimycobacterial activity is a challenge in itself. Others have reported remodelled 




Herein, the key to successful abolishment of dopamine and serotonin receptor binding 
involved increasing polarity by introducing a sulfonate functionality at a critical receptor 
recognition site. Furthermore, the polar sulfonate moiety imparts aqueous solubility thus 
deviating from the lipophilic chromophore/basic side chain obeyed by native phenothiazine 
drugs. This strategy also relied on the change of charge i.e. at physiological pH the distal 
amine moiety (pKa 8-9.5) of phenothiazine drugs acquires a positive charge whereas 
sulfonates ((pKa ~ 2) would be negatively charged (Chapter 2). These findings were 
fundamental to this study and encouraged further investigation of the NCEs (Salie, S.; Hsu, N.; 
Semenya, D.; Jardine, A.; Jacobs, M. Novel Non-Neuroleptic Phenothiazines Inhibit Mycobacterium 




4.2.3.3 Preclinical evaluation of N-propylsulfonates of phenothiazines 
4.2.3.3.1 In vitro microsomal metabolic stability and kinetic solubility 
Preclinical evaluation of the NCEs was inspired by the positive outcomes from 
antimycobacterial screening as well as dopamine and serotonin receptor binding studies. To 
corroborate in silico predicted ADMET properties, in vitro microsomal metabolic stability 
and kinetic solubility studies were conducted (UCT Division of Clinical Pharmacology) 
(Table 4.5). 



















































































































* FaSSIF- bio-relevant buffer that simulates the small intestine juices in fasted state; **A single time point assay 
(30 min) was used to establish ranking of the NCEs for prediction of half-life; Quality control standards for 
validation of metabolic stability include (i) Propanolol (8.1; 8.3) (ii) Midazolom (6.9, 7.8) (iii) MMV390048 
(96.1, > 100)  [ % remaining (first value) and projected half-life (second value)]. 
 
As discussed in Chapter 2, solubility is a key determinant of absorption and oral 
bioavailability.
44
 The kinetic solubility of the NCEs was measured at pH 2 and pH 6.5 in  





fasted state simulated intestinal fluid (FaSSIF) medium.
45
  All compounds had solubility 
values greater than 100 which were interpreted as highly soluble (Table 4.5). These 
observations were anticipated as the presence of a highly polar sulfonate moiety is expected 
to impart aqueous solubility. 
 
Early assessment of microsomal stability provides crucial information on metabolic liabilities 
of potential drug candidates. Low metabolic stability is associated with high hepatic 




metabolic stability of the NCEs was assessed in 
mouse liver microsomes using a single time point assay that involved 30 min incubation and 
measurement of the percentage of compound remaining.
46
 The metabolic stability of the 
NCEs was comparable to the positive control MMV390048 (Table 4.5). The percentage 
residual NCE ranged between 72.4 and 90.0. These NCEs do not have any apparent highly 
reactive groups excluding DS0032 which might be more susceptible to sulfoxidation.  This 
could potentially explain why NCE DS0032 displayed the lowest percentage NCE remaining 
(72.4) and a shorter half-life (64.9).  
 
4.2.3.3.2 In vivo toxicity in mice 
The toxicity potential of two N-propylsulfonates NCEs (DS0034 & DS0035) was evaluated 
in a small animal model at a dose of 100mg/kg as the maximum starting dose and outcomes 
were measured against thioridazine or against no treatment. For this purpose, 6-8 week old 
adult female C57Bl/6 mice were used.  Preliminary observations revealed that while a daily 
dose administration of either 100mg/kg or 40mg/kg thioridazine caused 100% mortality 
within 48h, all the animals challenged with 100mg/kg of DS0034 or DS0035 survived. 
Moreover, mice that were treated with DS0034 or DS0035 lost approximately 10% of their 
body weight.  Of the body organs assessed, brains, livers, lungs, kidneys and hearts showed 
normal weight distribution whereas spleens were significantly reduced.  Overall, the 





comparative toxicity profiles of DS0034 and DS0035 were significantly better than that of 
thioridazine even when the latter was tested at a dose 10-fold lower. The full details of the in 
vivo toxicity evaluation will be reported elsewhere at a later stage as the investigation is still 
in progress. 
 
4.4 Concluding remarks 
Phenothiazines possess desirable antitubercular properties including multi-drug resistance 
reversal properties. At clinically relevant doses, their extended use may lead to adverse side 
effects, hence the resistance to their application in TB chemotherapy. Thioridazine, a milder 
phenothiazine, has recently been successfully repurposed for XDR-TB therapy.  
Herein, rationalized remodelling strategies were employed to generate a focused library of 
NCEs that would less likely exhibit neuroleptic effects, but still retain antimycobacterial 
properties.  The general remodelling approach was to eliminate minimum structural 
requirements for neuroleptic action. The library comprised N-propylsulfonates of 
phenothiazines; N-butylsulfonates phenothiazines; N-propylsulfonates of quinolines; N-
propylsulfonates of ring-expanded scaffolds & non-thiazine scaffolds; molecular hybrids and 
N-alkyl phenothiazines with other non-basic terminal moieties. 
Chapter 4 addressed one of the key objectives of this study by identifying interesting hits 
through screening the library against virulent M.tbH37Rv and probing their neuroleptic 
potential. The hit compounds with MIC90 (GAST/Fe) less than 25 µM included N-
butylsulfonate DS00366 (23.5 µM), nitrile DS00396 (11.4 µM) and isoniazid hybrid dimer 
DS00362 (10.6 µM). Furthermore, a lower MIC90 of butylsulfonate DS00366 (23.5 µM) in 
comparison to its analogue propylsulfonate DS0035 (MIC90 > 125 µM), indicated that 
efficacy could be improved through alkyl chain extension. Moreover, for the first time, the 
antitubercular activity of the neuroleptics amitriptyline and thiothixene was demonstrated. 





Further evaluation of N-propylsulfonates (DS0031, DS0032, DS0034 & DS0035) also gave 
interesting results. The conclusions drawn from the observations include: (i) The remodelled 
phenothiazines retained antitubercular properties against M.tbH37Rv.gfp (7H9 MIC 12.5- 25 
µg/mL); (ii) They displayed between 40% and 60% inhibition of intracellular M.tbH37Rv 
thus demonstrating their ability to transverse cell membrane systems and access intracellular 
bacilli; (iii) Cell viability measurements indicated that in contrast to the parent neuroleptic 
thioridazine which was toxic to bone-marrow derived macrophages at higher concentrations 
(6.25-25 µg/mL, Table 4.4), the remodelled phenothiazines were not toxic.  
The neuroleptic potential of this series of N-propylsulfonates was investigated through 
dopamine and serotonin receptor radioligand binding assays. The results demonstrated that, 
through careful structural manipulation undesirable CNS receptor binding could be abolished. 
Additionally, preclinical evaluation of the N-propylsulfonates revealed favourable in vitro 
metabolic stability, kinetic solubility and in vivo toxicity profiles. These observations led to a 
conclusion that these NCEs possess promising drug-like properties, thus evaluation of their in 
vivo efficacy against M.tb in mice is currently underway. 
Overall, this chapter reports on subclasses of remodelled phenothiazines that hold potential 
for further development as non-neuroleptic antitubercular agents. Lowering MICs and hit-to-
lead optimization would require standard medicinal chemistry approaches that involve 
iterative structural modification processes.  
 
The anticancer properties of phenothiazines have been demonstrated in various literature 
reports.
47,48,49,50
 Therefore, it was decided to evaluate the same library of compounds as 
potential anticancer agents, to evaluate whether their anticancer effects were retained post-
remodelling. A report on the anticancer screening is given in the next chapter. 
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Structurally remodelled phenothiazines as potential anticancer 
chemotherapeutics  
Preface 
In the previous chapter, the antimycobacterial activity of remodelled phenothiazines and 
related drugs was reported. The screening led to the identification of several 
antimycobacterial hits with reduced likelihood of neuroleptic effects. Additionally, 
preclinical evaluation revealed favourable in vitro microsomal stability, kinetic solubility and 
in vivo toxicity profiles of selected new chemical entities (NCEs).  
 
Phenothiazines are known to exhibit broad-spectrum biological activities and their anticancer 
potential has been demonstrated in multiple tumor cell lines. The key findings in chapter 4 
demonstrated that careful structural manipulation of native phenothiazine drugs could lead to 
abrogation of unwanted neuroleptic effects whilst antimycobacterial activity was retained. 
Herein, a preliminary investigation of the library of remodelled phenothiazines reported in 
chapter 4 was carried out, to test whether application of the same principles could potentiate 
their anticancer effects.  
 
5.1 Overview of Cancer 
5.1.1 Brief overview and global statistics 
Cancer is undoubtedly among the most devastating non-communicable diseases known to 
humankind and has been claiming millions of lives for years. There is mounting evidence that 
links the development of cancer to a rare population of cells termed cancer stem cells 
(CSCs).
1,2
 CSCs are found within tumors and they possess characteristics similar to that of 






normal stem cells such as self-renewal and the ability to differentiate into various cell types.
3
 
Moreover, they have the unique ability to initiate and sustain the disease.
1,4 
As an example, a 
comparison of stem cell self-renewal during haematopoiesis (the formation of blood cellular 




Figure 5.1: The transformation of stem cells in normal and leukaemic haematopoiesis. The signalling pathways 





Over half of cancer deaths that occur annually are attributable to the most common types 
including lung, breast, colorectal, liver and stomach cancers. In 2012, an estimated 14.1 
million new cancer cases and 8.2 million deaths occurred. Of the various malignancies, lung 
cancer remains the most prevalent with an estimated 1.8 million cases in 2012. In the same 
year, brain and central nervous system cancers accounted for 1.8% of the new cases and 2.3%   
 








The percentage contribution to deaths caused by the most commonly 
diagnosed cancers is represented in Figure 5.2. Types of cancer treatment include radiation, 




Figure 5.2: Estimated percentage contribution to deaths caused by various types of cancers in 2012.
5 
 
5.1.2 Cancer chemotherapy 
The normal functioning of the cell cycle is regulated by multiple mechanisms and their 
dysregulation is implicated in the development of tumors.
8
 The phases of the cell cycle 
include resting stage (G0 phase), growth phase 1 (G1), DNA synthesis (S phase), growth 
phase 2 (G2) and mitosis (M). It also involves critical checkpoints that are regulated by  






complex mechanisms such as cyclin-dependent kinases (CDKs). The cell cycle represents an 
opportunity for development of new chemotherapeutics, thus the majority of antineoplastics 
target the proliferation cycle of cells.
9
 Due to the inability of anticancer drugs to differentiate 
between healthy cells and tumor cells, cancer chemotherapy is associated a plethora of side 
effects including gastrointestinal tract lesions, bone marrow suppression and hair loss.
10
 
Various classes of drugs are in clinical use for cancer chemotherapy including alkylating 
agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, mitotic inhibitors and 
corticosteroids (Figure 5.3).  
 




Chemotherapeutics such as cytarabine, 5-fluorouracil, fludarabine and pentostatin inhibit 
DNA synthesis.
11
 Other anticancer agents including paclitaxel or docetaxel and vinca 
alkaloids such as vinblastine, vincristine, vindesine, and vinorelbine interfere with the normal  
 








 Reportedly, antimitosis drugs bind at three major sites of tubulin 
(a component of microtubules) namely the vinca, taxane and colchicine sites.
14
 Other 
examples of potent antimitotic agents include combretastatin A-4 (a natural product extracted 
from a South African tree, Combretum caffrum) and epothilones.
12
 An illustration of the cell 
cycle events that are targeted by most anticancer drugs is given in Figure 5.4. 
 
 













5.2 Phenothiazines as promising anticancer chemotherapeutic agents 
As alluded to in chapter 1, the anticancer chemotherapeutic properties of phenothiazines have 
been extensively studied for decades. Native phenothiazines and their derivatives have been 
reported to display cytotoxic activities against various tumor cell lines including colon, 




Trifluoperazine has been reported to augment the cytotoxicity of bleomycin against human 
non-small cell lung carcinoma U1810. Additionally, it was reported to sensitize H23 cells to 
DNA-damaging antineoplastics, bleomycin and cisplatin. Triflupromazine and fluphenazine 
were also reported as sensitizers and enhanced cytotoxicity of cisplatin to U1810.
21
 The 
cytotoxicity of five native phenothiazines (thioridazine, chlorpromazine, trifluoperazine, 
perphenazine and fluphenazine) was demonstrated against human neuroblastoma SH-SY5Y 
and rat glioma C6 cells with IC50 ranges of 11-15 and 13-22 µM, respectively.
22
 Others 
reported thioridazine as a potent antiglioblastoma and antiglioblastoma stem cells agent.
23
 




Motohashi and co-workers were among the first to report the anticancer effects of 
functionalized phenothiazines including benzophenothiazines, phenothiazines bearing 
naphthalenes and ―half-mustard type‖ phenothiazines.
25
 Other reports include phenothiazine-
based thiazole derivatives which displayed cytotoxicity against cancer cell lines MCF-7 and 
HT29.
26
 Phenothiazines and dibenzazepines with neutral polar side chains were also reported 
to display activity against H1650 lung adenocarcinoma cells.
27
 Prinz et al. reported a series of 
N-benzolyated phenoxazine and phenothiazine derivatives with cytotoxicity against human  
 
 






chronic myelogenous leukemia K562 cells.
28
 Another series of phenothiazine analogues 
bearing a 1,2,3-triazole motif was reported to exhibit cytotoxicity against different human 
tumor cell lines.
19
 Abuhaie et al. demonstrated the anticancer activities of  phenstatin 
analogues bearing a phenothiazine ring against various cancer cell types including leukemia, 




The phenothiazine cancer chemopreventive effect is accounted for by their anti-calmodulin 
activity, inhibition of protein kinase C, inhibition of P-glycoprotein and anti-proliferative 
effects.
29,30,31 
Resistance to anticancer chemotherapeutics poses severe limitations on their 
efficacy. Therefore, the chemosensitizing properties possessed by phenothiazines hold 
significant promise for cancer chemotherapy regimens.
21
 Amongst the various anticancer 
properties possessed by phenothiazines, they also show great potential as chemotherapeutics 




5.2.1 Potentiating non-neuroleptic CNS-related effects of phenothiazines 
Phenothiazines are notably unselective  and they elicit adverse side effects in addition to 
neuroleptic effects through binding to multiple CNS receptor subtypes including 
dopaminergic and serotonergic receptor subtypes.
34,35 
In this study, the general remodelling 
approach involved elimination of structural traits associated with neuroleptic activity 
(Chapter 2-4). The cytotoxicity of phenothiazines has been demonstrated against different 
cell lines.
14,19
 Herein, brain cancer was first to be investigated given that phenothiazines are 
native CNS agents. Furthermore, in consideration of the structural remodelling strategies 
employed in this study, brain cancer was considered an interesting avenue for exploration 
(Figure 5.5). To potentiate cytotoxicity of phenothiazines against brain cancer, the challenge 
 






would be carrying out the remodelling such that their ability to cross the blood-brain barrier 
is not compromised whereas neuroleptic-related structural traits are eliminated. Therefore, as 
a starting point, the library of NCEs reported in chapter 4 was evaluated against the U-251 
glioblastoma cell line. The preliminary investigation would reveal whether the anticancer 
properties of the remodelled phenothiazines were retained after structural remodelling.  
 
 
Figure 5.5: The pharmacophore of phenothiazines in clinical use for psychosis and their remodelling for 
evaluation as anticancer agents. BBB - Blood brain barrier. 
 
5.2.2 Epidemiology of glioblastoma 
Classification of brain tumors may be based on their anatomical location or histophathologic 
characteristics. Gliomas are the most common type of brain tumors including 
astrocytomas,ependymomas and oligodendrogliomas.
36,37 
The types of gliomas that are not of  






glial tissue origin include schwannomas, craniopharyngiomas, meningiomas and germ cell 
tumors.
37
 Glioblastoma is one of the most aggressive and lethal type of malignant 
astrocytoma.
36
 The highly invasive nature of the tumor cells renders surgical interventions 
virtually impossible. Glioblastoma and related malignant gliomas only infiltrate the 
surrounding brain parenchyma and metastasis does not occur. Moreover, resistance to 




Gliomas are more prevalent among white rather than black populations and also in males than 
females. A family history of glioma only increases the risk of developing glioma by 2-
fold.
39,40
 Post-surgery, adjuvant radiotherapy in combination with chemotherapy is usually 
considered for glioblastoma patients.
39
 Frequently used glioblastoma chemotherapy regimens 
include a DNA alkylating agent, temozolomide, concomitant with radiotherapy.
41
 Virtually 
all glioblastoma patients experience tumor progression after first-line chemotherapy. Apart 
from surgical resection for treatment of recurrent glioblastoma, salvage chemotherapy 
options include the use of temozolomide, bevacizumab and various alkylating agents such as 
nitrosoureas and carboplatin.  No treatment options are available in case of unsuccessful 
salvage chemotherapy and the median survival is 3 to 4 months.
39,42
 This points to an urgent 
need for novel chemotherapeutic treatment approaches for glioblastoma. 
 
 5.3 Evaluation of remodelled phenothiazines against glioblastoma cell line  
The anticancer potential of remodelled phenothiazines in this study and parent neuroleptic 
drugs was assessed by an MTT assay,
43
 to determine their effects on U-251 glioblastoma 
cells after 48 h exposure. Of the various subclasses evaluated, nitrobenzenesulfonamides 
(DS00325, DS00326, DS00329, & DS00341) and two native phenothiazines (thioridazine 
and thiothixene) displayed potent inhibition effects against the glioblastoma cell line (Table  






5.1). At the highest concentration tested, 15 µM, the rest of the remodelled phenothiazines 
and parent neuroleptic drugs were not cytotoxic to the U-251 glioblastoma cells.  
 
Table 5.1: The anticancer effects of phenothiazines on U-251 glioblastoma cell line after 48 h exposure. (NC- 
Not cytotoxic at the highest concentration tested, 15 µM) 
NCE/ parent neuroleptic  
drug 
U-251 glioblastoma 
IC50  (µM) 
NCE/ parent neuroleptic 
drug 
U-251 Glioblastoma 


















































Table 5.1 continued…    
NCE/ parent neuroleptic  
drug 
U-251 glioblastoma 
IC50  (µM) 
NCE/ parent neuroleptic  
drug 
U-251 Glioblastoma 























































IC50- Half maximal inhibitory concentration; NC- Not cytotoxic at the highest concentration tested, 15 µM; *A 
dose-dependent decrease in cell viability was observed but 50% cell death was not observed at 15 µM. 
 






In chapter 4, N-propylsulfonates DS0034 & DS0035 displayed negligible cytotoxicity against 
bone marrow-derived macrophages (Table 5.1). Interestingly, herein they also displayed no 
cytotoxicity against the U-251 glioblastoma cells. The compounds with potent inhibition 

















Figure 5.6: The anticancer effects of remodelled phenothiazines and native neuroleptic drugs on U-251 































































































































Thioridazine (IC50 8.32 µM)  






The IC50 values ranged from 4.51-12.43 µM. Furthermore, the remodelled phenothiazines 
(DS00325, DS00326, DS00329) were more potent than the native neuroleptics, thioridazine 
and thiothixene. Thiothixene and thioridazine also displayed interesting effects on the cells. 
At lower concentrations, there was no significant effect on the cells followed by a drastic 
decrease in cell viability at higher concentrations, 9-15 µM. The cytotoxic effect of native 
phenothiazines including thioridazine on neuroblastoma and glioma cell lines was reportedly 
mediated by apoptosis.
22
 Herein, the mode of action of the remodelled phenothiazines 
remains to be ascertained. Although conclusive structure-activity relationships could not be 
established, these preliminary observations demonstrate that the anticancer effects of native 
phenothiazines could be retained after structural remodelling. 
 
5.4 Concluding Remarks  
In this chapter, the preliminary results demonstrated that it is possible to potentiate the 
anticancer effects of phenothiazines through structural remodelling. In particular, the 
remodelled phenothiazines [DS00325 (IC50 8.06 µM), DS00326 (IC50 4.51 µM), DS00329 
(IC50 6.63 µM)] displayed more potent cytotoxic effects than the native neuroleptics 
[thioridazine (IC50 8.32 µM), thiothixene (IC50 12.43 µM)]. Furthermore, the remodelled 
phenothiazines are devoid of structural traits associated with neuroleptic action i.e. a 
lipophilic chromophore in conjunction with a basic alkylamino moiety. In silico predictions 
(Chapter 2) also revealed that they are less likely to exhibit CNS activity. The ability to cross 
the blood-brain barrier is a crucial characteristic of therapeutics that target CNS-related 
indications. Therefore, further development of the remodelled phenothiazines as 
antiglioblastoma agents would require introduction of some degree of lipophilicity to 
facilitate blood-brain barrier penetration.  
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Summary, Conclusions and Recommendations 
6.1 Overall Summary and Conclusions 
The emergence of drug resistance in both communicable and non-communicable diseases 
threatens the effectiveness of chemotherapy options as pharmaceutical drug pipelines are 
drying up. Innovative strategies such as drug repurposing, drug repositioning and drug rescue 
have garnered significant research interest in efforts to rejuvenate drug pipelines. 
Phenothiazines and related neuroleptic drugs exhibit broad spectrum biological activities 
including antibacterial, antimalarial, antiemetic, anticancer, antihistaminic and many more 
(Chapter 1). However, there is resistance to their wider clinical application in non-neuroleptic 
indications due to potential adverse side effects in addition to inherent neuroleptic effects. 
Amongst neuroleptic drugs, thioridazine is the only phenothiazine that has been successfully 
repurposed for the treatment of XDR-TB due to its milder side effects.  
 
The primary objective of this research study was to demonstrate that phenothiazines and 
related drugs could be structurally remodelled such that their inherent neuroleptic effects are 
abrogated whilst their antitubercular or anticancer properties are retained. Neuroleptic 
phenothiazines are native central nervous system (CNS) agents with a well-defined 
pharmacophore (Figure 6.1). The structural traits associated with their neuroleptic action 
include conformational resemblance to dopamine, high degree of lipophilicity for blood-brain 
barrier penetration and presence of a proton accepting distal amine moiety. In full knowledge 
of the aforementioned structural traits, the remodelling strategies employed in this study were 
rationally selected to generate new chemical entities (NCEs) with reduced likelihood of 
neuroleptic effects (Figure 6.1). 







Figure 6.1: Summary of remodelling strategies employed in this research study. 
 
The following aims and objectives were addressed herein: 
(i) A diverse focused library of modified phenothiazines and related neuroleptics was 
generated through rationalized structural remodelling. The library comprised N-
propylsulfonates of phenothiazines; N-butylsulfonates phenothiazines; N-propylsulfonates of 
quinolines; N-propylsulfonates of ring-expanded scaffolds & non-thiazine scaffolds; 
molecular hybrids and N-alkyl phenothiazines with other non-basic terminal moieties such as 
nitriles. In silico predictions tools were integrated into the structural remodelling to assess 
drug-likeness of the NCEs on the basis of Lipinski‘s rule of five. Moreover, the in silico 
assessment included the prediction of blood-brain partition coefficients and CNS activity to 
determine their likelihood of exhibiting neuroleptic effects. In silico predictions also included 
ADMET properties such as aqueous solubility, Caco-2 & MDCK cell permeability, number 
of likely metabolic reactions and hERG inhibition (Chapter 2).   
 
 






(ii) The remodelled phenothiazines were chemically synthesized via adaptation of well-
known organic reactions and literature reported synthetic methods. The chemical synthesis 
mainly involved N-alkylations, cross coupling reactions under Buchwald-Hartwig conditions 
and other mechanistically interesting reactions such as the Ritter reaction and the Michaelis-
Arbuzov rearrangement. Several synthetic challenges were encountered, in particular, the 
assembly of tricyclic scaffolds from functionalized benzenes as highlighted in Chapter 3. 
Moreover, intricate precautions had to be taken in handling and performing chemical 
reactions with phenothiazines so as to avoid air oxidation as well as radical reactions under 
exposure to light. Isolation and purification techniques common in organic synthesis were 
employed including reversed-phase chromatography. In this study, purification via reversed-
phase chromatography was advantageous from a commercial and ―green‖ perspective as the 
mobile phase was primarily aqueous. Spectroscopic techniques such as NMR, IR and LCMS 
were used for structure elucidation, confirmation and purity analysis (Chapter 3 & 7).  
 
(iii) The focused library of remodelled phenothiazines including commercially available 
neuroleptic drugs was screened for in vitro Mycobacterium tuberculosis (M.tb) H37Rv 
growth inhibition using the Green Fluorescent Protein Microplate Assay (GFPMA) in a 
GAST/Fe medium or Middlebrook 7H9 medium (Chapter 4). Selected NCEs were further 
evaluated for intracellular M.tbH37Rv growth inhibition using bone marrow-derived 
macrophages. The observations demonstrated that the antimycobacterial properties were 
retained post-remodelling. The hits with MIC90 (GAST/Fe) less than 25 µM included N-
butylsulfonate DS00366 (3.56) (23.5 µM), nitrile DS00396 (3.82d) (11.4 µM) and isoniazid 
hybrid dimer DS00362 (3.74a) (10.6 µM). Moreover, the antitubercular activity of the 
neuroleptics amitriptyline and thiothixene was demonstrated for the first time with MIC90   of 
75.1 µM and 30.8 µM, respectively. Further evaluation of N-propylsulfonates {DS0031 






(3.1a), DS0032 (3.1b), DS0034 (3.1d) & DS0035 (3.1e)} using the GFPMA in a 
Middlebrook 7H9 medium demonstrated that they also retained their antitubercular 
properties, with MIC (7H9) of 12.5-25 µg/mL. Furthermore, the N-propylsulfonates 
displayed between 40% and 60% inhibition of intracellular M.tbH37Rv thus demonstrating 
their ability to transverse cell membrane systems and access intracellular bacilli. Moreover, 
determination of cell viability indicated that in contrast to the parent neuroleptic thioridazine, 
the N-propylsulfonates were not cytotoxic to bone-marrow derived macrophages at higher 
concentrations (6.25-25 µg/mL).  
 
(iv) The neuroleptic potential of four N-propylsulfonates {DS0031 (3.1a), DS0032 (3.1b), 
DS0034 (3.1d) & DS0035 (3.1e)}  was evaluated using dopamine and serotonin receptor 
radioligand binding assays to corroborate the tentative conclusions drawn from in silico CNS 
activity predictions (Chapter 4). The NCEs were screened for binding to dopaminergic 
receptor subtypes D1, D2 and D3 as well as serotonergic receptor subtypes 5-HT1A, 5-HT2A 
and 5-HT2C. All the NCEs displayed no binding to the aforementioned receptor subtypes 
except for DS0031 (3.1a) which displayed marginal serotonin receptor (5-HT1A) binding. 
These findings were fundamental to this research study as they demonstrated conclusively 
that through rationalized structural remodelling, it is possible to abolish inherent neuroleptic 
effects of phenothiazines whilst their antimycobacterial properties are retained. The 
replacement of the distal amine moiety of phenothiazines with a sulfonate functionality was 
one of the key remodelling strategies employed in this study. The rationale behind 
successfully abolishing neuroleptic properties of the N-propylsulfonates involved introducing 
the polar sulfonate group at a critical post-synaptic receptor recognition site. As mentioned 
previously, phenothiazines are known to obey a lipophilic chromophore/basic side chain 





paradigm, therefore the replacement with a sulfonate moiety is expected to alter the charge of 
the molecule at physiological pH. 
 
(v) Preclinical studies of the N-propylsulfonates {DS0031 (3.1a), DS0032 (3.1b), DS0034 
(3.1d) & DS0035 (3.1e)} were carried out to elucidate their pharmacokinetic profiles. The 
evaluation revealed favourable in vitro microsomal metabolic stability, kinetic solubility and 
in vivo toxicity profiles. Preliminary observations indicated that the in vivo toxicity profiles of 
DS0034 (3.1d) and DS0035 (3.1e) were superior to that of the clinically approved neuroleptic 
drug, thioridazine. These NCEs with promising properties are currently undergoing further 
preclinical development and are being evaluated for in vivo efficacy against M.tb in mice.  
 
(vi) The library of remodelled phenothiazines was also subjected to an MTT cell viability 
screen against the U-251 glioblastoma cell line to evaluate their anticancer potential (Chapter 
5). In Chapter 4, the subclass of nitrobenzenesulfonamides displayed poor MIC90 against 
M.tbH37Rv. When evaluated against the U-251 glioblastoma cell line, they displayed potent 
cytotoxic effects i.e. DS00325 (3.74a) (IC50 8.06 µM), DS00326 (3.74b) (IC50 4.51 µM) and 
DS00329 (3.74c) (IC50 6.63 µM).  Furthermore, their cytotoxic effects were more potent than 
that of the native neuroleptics i.e. thioridazine (IC50 8.32 µM) and thiothixene (IC50 12.43 
µM). Also noteworthy was the lack of cytotoxicity of N-propylsulfonates DS0034 (3.1d) and 
DS0035 (3.1e) against the U-251 glioblastoma cell line, which was observed previously using 
bone-marrow derived macrophages (Chapter 4). These preliminary findings demonstrated 
that the anticancer properties of phenothiazines could be retained after structural remodelling. 
It is noteworthy that in silico predictions (Chapter 2) revealed that the nitrobenzene- 
sulfonamides are less likely to exhibit CNS activity or cross the blood-brain barrier. 
Therefore, further development should address these liabilities whilst still deviating from 
structural traits that are associated with neuroleptic action. 






6.2 Recommendations for future work 
Overall, this research study presented subclasses of remodelled phenothiazines that hold great 
potential for further development as either non-neuroleptic antitubercular or anticancer 
agents. Iterative standard medicinal chemistry approaches can be applied for their further 
development into viable drug candidates.  
 
In this study, N-alkylsulfonates of phenothiazines have shown great potential as 
antitubercular agents that are devoid of neuroleptic effects and that have promising toxicity 
profiles. Further development may include the transformation of the sulfonate group into 
functionalities such as sulfonamides or sulfonate esters to evaluate the effects on their 




Figure 6.2: Possible structural modifications for further development of N-propylsulfonates of phenothiazines. 
 
The rising tide of drug resistance calls for novel drug classes with unexplored modes of 
action for the treatment of microbial infections. As discussed previously (Chapter 1), native 
phenothiazines including thioridazine are multi-targeting agents with promising antimicrobial 
properties. The majority of existing anti-TB drugs target processes such as cell wall  
 






biosynthesis and DNA metabolism which have acquired resistance. Type II NADH: 
menaquinone odixoreductase in M.tb has recently been validated as a biomolecular target of 
phenothiazines. Moreover, phenothiazines have been reported as efflux pump inhibitors in 
various pathogens. Herein, the probable mode of action of the remodelled phenothiazines has 
not been established. Therefore, further studies should include elucidation of plausible 
mechanisms. In addition to evaluation against drug-susceptible M.tb, the remodelled 
phenothiazines could also be screened against drug-resistant M.tb strains. The remodelled 
phenothiazines reported herein hold great promise for further development as agents in TB 
adjuvant chemotherapy. This in view of the fact that they have reduced neuroleptic potential 
as well as promising toxicity profiles relative to native phenothiazine drugs. 
  
In Chapter 5, preliminary results indicated that anticancer properties of phenothiazines could 
be retained after structural remodelling. The cancer cell type investigated in this study was 
the U-251 glioblastoma cell line. To potentiate the antiglioblastoma effects of remodelled 
phenothiazines, liabilities such as blood-brain barrier penetration would have to be addressed. 
Native neuroleptics have displayed cytotoxic effects against multiple cancer cell types. 
Further evaluation of the remodelled phenothiazines could be performed against other cancer 
cell types such as breast cancer, colon cancer, prostate cancer, non-small cell lung cancer and 
renal cancer. Moreover, the chemosensitizing effect of phenothiazine neuroleptics has been  
reported to enhance the activity of antineoplastics such as bleomycin and cisplatin. Therefore, 
further assessment could include screening the remodelled phenothiazines in combination 













6.3 Final remarks 
Phenothiazines and related antipsychotics have attracted notable research interest owing to 
their multiple biological properties. However, at clinically relevant doses, potential adverse 
side effects in addition to inherent neuroleptic effects preclude their extended clinical use in 
non-neuroleptic indications. Amongst clinically approved neuroleptics, thioridazine is the 
only phenothiazine that has been successfully repurposed as therapy for XDR-TB. Although 
the benefits of repurposing thioridazine seem to outweigh the inherent neuroleptic effects and 
potential side effects, clinical application of phenothiazines that are non-neuroleptic is also an 
attractive avenue to explore. The research undertaken herein has demonstrated that it is 
possible to enhance the selectivity of phenothiazines for non-neuroleptic effects through 
rational structural remodelling. It is hoped that the findings presented herein would encourage 
further investigations in terms of clinical application of phenothiazines that are devoid of 
neuroleptic effects.  
 







7.1 In silico profiling 
Chemical structures were imported from ChemBioDraw Ultra 11.0 in smiles format and used 
in either Stardrop 5.5 (http://www.optibrium.com/stardrop/stardrop-features.php)
1
 or QikProp 
(http://www.schrodinger.com/QikProp/)
2
 for in silico prediction of physicochemical 
properties and ADMET properties. 
 
7.2 General chemical synthesis information   
7.2.1 Chemical Reagents and Solvents 
Commercially available chemical reagents, neuroleptic drugs (thioridazine, thiothixene, 
trimipramine, amitriptyline, clozapine and loxapine), anhydrous solvents and deuterated 
solvents were purchased from Sigma-Aldrich (United States or Schelldorf, Germany), Merck 
(South Africa or Darmstadt, Germany) or AK Scientific (United States). AR grade general 
solvents such as EtOAc, MeOH, and Et2O were purchased from Kimix (Cape Town, South 
Africa) or Protea Chemicals (Milnerton, South Africa) and were used without any further 
distillation. Most of the chemical reactions were performed under an inert atmosphere of 
nitrogen or argon in oven-dried glassware.  
7.2.2 Purification Methods 
All reactions were monitored by thin-layer chromatography (TLC) using Merck PF254 
aluminium-backed pre-coated silica gel plates (with a fluorescent indicator) and viewed 
under ultraviolet light (UV) at 254 nm and 360 nm. TLC spots were further visualized by 
spraying with ceric ammonium sulfate solution (CAS) followed by heating, or using iodine 
vapour. Merck Kieselgel silica gel 60 (0.040-0.063 mm) was used for column  






chromatography and appropriate solvent mixtures were used for elution of compounds. 
Reversed-phase chromatography was carried out using Biotage KP-C-18-HS Sorbent; ultra-
filtered water (purified by Millipore Synergy water purification system) and AR grade MeOH 
were used in appropriate ratios for elution of compounds. All compounds were dried under 
high vacuum or by lyophilisation before determination of reaction yields or spectroscopic 
characterization.  
7.2.3 Analytical techniques 
Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope and are 
uncorrected. Infrared spectra were recorded on a PerkinElmer Spectrum 100 FT-IR 
spectrometer in the 4500 - 400 cm-
1
 frequency range, with samples as KBr pellets. 
Liquid chromatography-mass spectrometry (LCMS) analyses were carried out using 
Agilent® UHPLC 1290 Infinity Series and Agilent® 6530 Accurate-Mass Q-TOF system 
equipped with an Agilent® jet stream ionization source (ESI); or using an Agilent® 1260 
Infinity Series and Agilent® 6120 Quadrupole (Single) mass spectrometer equipped with 





C and APT) nuclear magnetic resonance spectra (NMR) were 
recorded on Varian Mercury 300 MHz (75 MHz for 
13
C), Varian Unity 400 MHz (101 MHz 
for 
13
C) or Bruker  Unity 400 MHz (101 MHz for 
13
C & 162 MHz for 
31
P) spectrometers. 
Deuterated solvents of choice were CDCl3, DMSO-d6, CD3OD or D2O. NMR chemical shifts 
are expressed in parts-per-million (ppm) relative to the internal solvent peak or 
trimethylsilane (TMS at δ 0 ppm). Coupling constants (J) are reported in Hertz (Hz). Spin 
multiplicities are denoted by the following lower-case letters: s (singlet); d (doublet); dd 
(doublet of doublets); t (triplet); td (triplet of doublets); q (quartet); qt (quintet); m ( 
unresolved multiplet). 






7.3 Chemical synthesis details 
General procedure for preparation of N-propylsulfonates of phenothiazines {3.1a 
(DS0031), 3.1b (DS0032), 3.1c (DS0033), 3.1d (DS0034) & 3.1e (DS0035)} 
 
(i) Method A: Synthesis using DMF as the solvent 
To a suspension of NaH (60% dispersion in mineral oil, 1.1 eq) in anhydrous DMF (1 mL) 
under an inert atmosphere of nitrogen, was added a solution of phenothiazine 3.2a-e (1.0 eq) 
in anhydrous DMF (2 mL). The mixture was allowed to stir at room temperature for 30 min 
and then heated at 50 °C for 1 h, during which the colour got darker indicating formation of 
phenothiazinium anion. After cooling to room temperature, 1,3-propane sultone 3.3 (1.3 eq) 
in anhydrous DMF (1 mL) was added and the mixture was allowed to stir for 16 h. A few 
drops of water were added to quench unreacted NaH. Subsequently, toluene was added and 
the solvents were removed by azeotropic distillation under reduced pressure. The resulting 
crude material was chromatographed on a C-18 reversed-phase column (H2O; 9:1 
H2O/MeOH) to afford the desired products 3.1a-e. 
 
(ii) Method B: Large-scale synthesis using THF as the solvent 
To a suspension of NaH (60% dispersion in mineral oil, 1.1 eq) in anhydrous THF (200 mL), 
was added a solution of phenothiazine (3.2a, 3.2b, 3.2d, 3.2e) (8.0 g, 1.0 eq) in anhydrous 
THF (40 mL) under argon through a cannula. The mixture was allowed to stir under an inert 
atmosphere of argon for 1 h at room temperature and then for 30 min at 50 °C. The mixture 
acquired a dark orange colour, following the formation of the phenothiazine anion. After the 
suspension had cooled to 0°C, a solution of 1,3-propane sultone 3.3 (1.0 eq) in anhydrous 










immediately to clear yellow. The mixture was allowed to stir at 0°C for thirty minutes after 
the addition of sultone 3.3 and then at room temperature for another 30 min.  Subsequently, 
the precipitate was filtered, washed with THF and triturated with EtOAc to give the desired 
product (3.1a, 3.1b, 3.1d or 3.1e) in greater than 90% yield. 
  
Sodium 3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propane-1-sulfonate 3.1a 
(DS0031) 
Pale-pink solid (0.62 g, 27%); Rf 0.40 (1.5:8.5 MeOH/ 
EtOAc); Mp 189-191 °C; 
1
H NMR (300 MHz, D2O) δ 7.07 
(t, J = 6.9 Hz, 1H, H-8), 6.94 (s, 1H, H-1), 6.79 (m, 5H, 
(H-9. H-6, H-4, H-7 & H-3), 3.73 (t, J = 7.2 Hz, 2H, 2 x H-
11), 2.87 (t, J = 7.2 Hz, 2H, 2 x H-13), 2.06 (qt, J = 7.2 Hz,  
2H, 2 x H-12); 
13
C NMR (75 MHz, D2O) δ 145.31, 143.64, 129.54, 129.25, 128.82, 127.95, 
127.43, 126.21, 123.49, 122.60, 119.00, 116.18, 111.97, 48.27, 45.41, 21.85; HRMS (ESI+): 
m/z 412.0265 [M+H]
+ 




Sodium 3-(2-(methylthio)-10H-phenothiazin-10-yl)propane-1-sulfonate 3.1b (DS0032) 
Turquoise solid (0.40 g, 17 %) ; Rf  0.40 (1.5:8.5 MeOH/ 
EtOAc); Mp 194-196 °C; 
1
H NMR (300 MHz, D2O) δ 7.05 
(t, J = 7.5 Hz, 1H, H-8), 6.89 (d, J = 7.5 Hz, 1H, H-9), 6.72 
(m, 3H, H-7, H-6 & H-4), 6.62 (s, 1H, H-1), 6.47 (d, J = 
7.4 Hz, 1H, H-3), 3.68 (t, J = 7.5 Hz, 2H, 2 x H-11), 2.88 
(t, J = 7.5 Hz, 2H, 2 x H-13), 2.28 (s, 3H, 3 X H-14), 2.08 (qt, J = 7.5 Hz, 2H, 2 x H-12); 
13
C 











120.66, 120.48, 116.24, 114.08, 48.67, 45.47, 21.94, 15.35 (C-14); HRMS (ESI+): m/z 
390.0268 [M+H]
+




Sodium 3-(2-acetyl-10H-phenothiazin-10-yl)propane-1-sulfonate 3.1c (DS0033) 
Bright yellow solid (0.55 g, 23%); Rf 0.40 (1.5:8.5 MeOH/ 
EtOAc); Mp 182-184 °C;
1
H NMR (300 MHz, D2O) δ 7.11 
(m, 1H, H-3), 7.03 (d, J = 7.8 Hz, 1H, H-4), 6.96 (s, 1H, H-
1), 6.80 (m, 3H, H-8, H-9 & H-6), 6.57 (d, J = 7.7 Hz, 1H, 
H-7), 3.73 (t, J = 7.0 Hz, 2H, 2 X H-11), 2.91 (t, J = 7.0 
Hz, 2H, 2 x H-13), 2.43 (s, 3H, 3 x H-15), 2.05 (qt, J =7.0 Hz, 2H, 2 X H-12); 
13
C NMR (75 
MHz, D2O) δ 201.88 (C-14), 144.09, 143.65, 135.58, 132.09, 128.25, 127.33, 126.85, 123.33,  
123.19, 122.53, 116.07, 113.89, 48.47, 45.35, 26.17, 21.67; HRMS (ESI+): m/z 386.0497 
[M+H]
+




Sodium 3-(2-chloro-10H-phenothiazin-10-yl)propane-1-sulfonate 3.1d (DS0034) 
Pale-purple solid (0.98 g, 40 %); Rf 0.40 (1.5:8.5 MeOH/ 
EtOAc); Mp 192-194 °C; 
1
H NMR (300 MHz, D2O) δ 7.06 
(t, J = 7.4 Hz, 1H, H-8), 6.86 (d, J = 7.4 Hz, 1H, H-9), 6.75 
(m, 2H, Ar-H, H-6 & H-4), 6.63 (s, 1H, H-1), 6.55 (m, 2H, 
H-7 & H-3), 3.65 (t, J = 6.9 Hz, 2H, 2 x H-11), 2.88 (t, J = 
6.9 Hz, 2H, 2 x H-13), 2.07 (qt, J = 6.9 Hz, 2H, 2 x H-12);  
13
C NMR (101 MHz, D2O) δ 
146.01, 143.74, 132.83, 127.89, 127.66, 127.50, 124.22, 123.13, 122.98, 122.32, 116.09, 
115.61, 48.46, 45.34, 21.85; HRMS (ESI+): m/z 378.0001 [M+H]
+
 calculated for 












Sodium 3-(10H-phenothiazin-10-yl)propane-1-sulfonate 3.1e (DS0035) 
Purple-grey solid (0.99 g, 38 %); Rf 0.40 (1.5:8.5 MeOH/ 
EtOAc); Mp 287-289 °C; 
1
H NMR (300 MHz, D2O) δ 6.98 
(t, J = 7.6 Hz, 2H, H-2 & H-8), 6.84 (d, J = 7.6 Hz, 2H, H-
1 & H-9), 6.68 (m, 4H, H-4, H-6, H-3 & H-7), 3.70, (t, J = 
7.0 Hz,  2H, 2 x H-11), 2.91 (t, J = 7.0 Hz, 2H, 2 x H-13), 
2.08 (qt, J =  7.0 Hz, 2H, 2 x H-12); 
13
C NMR (101 MHz, D2O) δ 144.69, 127.63, 127.43, 
124.33, 122.74, 115.80, 49.01, 48.54, 45.19, 21.98; HRMS (ESI+): m/z 344.0391 [M+H]
+
 




General procedure for the preparation N-butylsulfonates of phenothiazines {3.5a 
(DS00369), 3.5b (DS00370) & 3.5c (DS00366)} 
To a suspension of NaH (60% dispersion in mineral oil, 1.1 eq) in anhydrous DMF (0.5 mL) 
under an inert atmosphere of argon, was added a solution of phenothiazine 3.6a-c (1.0 eq) in 
anhydrous DMF (1 mL). The mixture was allowed to stir at room temperature for 30 min and 
then heated at 50 ° C for 1 h, during which the colour got darker indicating formation of 
phenothiazinium anion. After cooling to room temperature, 1,4-butane sultone 3.8 (1.1 eq) in 
anhydrous DMF (1 mL) was added and the mixture was allowed to stir for 20 h. A few drops 
of water were added to quench unreacted NaH. Subsequently, toluene was added and the 
solvents were removed by azeotropic distillation under reduced pressure. The resulting crude 
material was chromatographed on a C-18 reversed-phase column (H2O; 9:1 H2O/MeOH) to 
afford the desired products 3.5a-c. 
 
 






Sodium 4-(10H-phenothiazin-10-yl)butane-1-sulfonate 3.5c (DS00366) 
Dark purple solid (0.030 g, 14%); Rf  0.51 (2:8 MeOH/ 
EtOAc); Mp 184-186 °C; 
1
H NMR (400 MHz, DMSO-d6) δ 
7.17 (m, 2H, H-2 & H-8), 7.11 (d, J = 6.6 Hz, 2H, H-1 & H-9), 
7.00 (d, J = 7.4 Hz, 2H, H-4 & H-6), 6.91 (t, J = 7.3 Hz, 2H, 
H-3 & H-7), 3.83 (t, J = 6.8 Hz, 2H, 2 x H-11), 2.44 (t, J = 7.5 
Hz, 2H, 2 x H-14), 1.72 (m, 4H, 2 x H-12 & 2 x H-13); 
13
C NMR (101 MHz, DMSO-d6) δ 
145.24, 128.07, 127.52, 123.88, 122.84, 116.21, 51.41, 46.95, 26.07, 23.15; MS (ESI+): m/z 
336.0 [(M-Na) + 2H]
+




Sodium 4-(2-(methylthio)-10H-phenothiazin-10-yl)butane-1-sulfonate 3.5a (DS00369) 
Dark brown solid (0. 040 g, 20%); Rf  0.51 (2:8 MeOH/ 
EtOAc); Mp 179-181 °C; 
1
H NMR (400 MHz, DMSO-d6) δ 
7.19 (dd, J = 8.1, 1.3 Hz, 1H, H-8), 7.13 (dd, J = 7.6, 1.3 Hz, 
1H, H-7), 6.99 (m, 4H, H-6, H-4, H-9 & H-1), 6.83 (m, 1H, 
H-3), 3.87(t, J = 6.6 Hz, 2H, 2 x H-11), 2.47 (s, 3H, 3 x H-
15), 2.45 (m, 2H, 2 x H-14), 1.74 (m, 4H, 2 x H-12 & 2 x H-13); 
13
C NMR (101 MHz, 
DMSO-d6) δ 145.88, 144.99, 138.22, 128.05, 127.72, 127.53, 124.15, 122.99, 120.61, 
120.51, 116.50, 114.02, 51.42, 46.96, 26.13, 23.14, 15.55 (C-15); HRMS (ESI+): m/z 
381.0527 [(M-Na) + H]
+



















Sodium 4-(2-chloro-10H-phenothiazin-10-yl)butane-1-sulfonate 3.5b (DS00370) 
Light brown solid (0.040 g, 19%); Rf  0.51 (2:8 MeOH/ 
EtOAc); Mp 216-218 °C; 
1
H NMR (400 MHz, DMSO-d6) δ 
7.21 (t, J = 7.7 Hz, 1H, H-8), 7.14 (m, 2H, H-9 & H-6), 7.04 
(m, 2H, H-4 & H-7), 6.98 (m, 2H, H-1 & H-7), 3.86 (t, J = 
6.5 Hz, 2H, 2 x H-11), 2.45 (t, J = 7.0 Hz, 2H, 2 x H-14), 
1.71 (m, 4H, 2 x H-12 & 2 x H-13); 
13
C NMR (101 MHz, DMSO-d6) δ 146.84, 144.51, 
132.95, 128.51, 128.26, 127.65, 123.71, 123.39, 122.98, 122.49, 116.71, 116.12, 51.36, 
47.01, 25.99, 23.07 ; MS (ESI+):  m/z 370.0 [(M-Na) + 2H]
+
, calculated for C16H17ClNO3S2, 





General procedure for preparation of N-propylsulfonates of quinolines and 
isoquinolines {3.61 (DS-Q1), 3.60 (DS-Q2), 3.59 (DS-Q3), 3.57 (DS-Q4), 3.62 (DS-Q5) & 
3.58 (DS-Q6)} 
A mixture of aminoquinoline 3.63a-f (1.0 eq) and NaH (60% dispersion in mineral oil, 1.1 
eq) in anhydrous dioxane (1 mL) was allowed to stir at 40 ° C under an inert atmosphere of 
nitrogen for 1 h. After cooling to room temperature, 1,3-propane sultone 3.3 (1.1 eq) in 
anhydrous dioxane (1 mL) was added and then allowed to stir at room temperature for 14 h. 
A few drops of water were added to quench unreacted NaH. The solvent was removed under 
reduced pressure and the resulting crude material was chromatographed on a C-18 reversed-














Sodium 3-(quinolin-8-ylamino)propane-1-sulfonate 3.61 (DS-Q1) 
Pale yellow solid (0.080 g, 22%); Rf 0.33 (2:8 MeOH/ 
EtOAc); Mp 180-182 °C; 
1
H NMR (300 MHz, D2O) δ 8.56 
(dd, J = 4.3, 1.6 Hz, 1H, H-2), 8.05 (dd, J = 8.3, 1.6 Hz, 1H, 
H-7), 7.36 (m, 2H, H-4 & H-3), 7.08 (m, 1H, H-6), 6.74 (d, J 
= 7.7 Hz, 1H, H-5), 3.31 (t, J = 7.1 Hz, 2H, 2 x H-9), 3.09 (m, 
2H, 2 x H-11), 2.15 (m, 2H, 2 x H-10);
 13
C NMR (101 MHz, D2O) δ 147.64, 143.47, 137.29, 
137.21, 128.58, 127.71, 121.70, 115.91, 107.39, 48.99, 42.12, 23.89; MS (ESI+): m/z 267.1 
[(M-Na) + 2H]
+





Sodium 3-(isoquinolin-1-ylamino)propane-1-sulfonate 3.60 (DS-Q2) 
Light yellow solid (0.060 g, 16%); Rf 0.33 (2:8 MeOH/ 
EtOAc); Mp 219-221 °C; 
1
H NMR (300 MHz, D2O) δ 7.80 
(d, J = 8.5 Hz, 1H, H-3), 7.71 (t, J = 7.5 Hz, 1H, H-8), 7.51 (t, 
J = 7.5 Hz, 2H, H-6 & H-7), 7.20 (d, J = 7.2 Hz, 1H, H-5), 
6.73 (d, J = 8.5 Hz, 1H, H-4), 4.09 (t, J = 6.6 Hz, 2H, 2 x H-
9), 3.04 (t, J = 6.6 Hz, 2H, 2 x H-11), 2.20 (qt, J = 6.6 Hz, 2H, 2 x H-10);
 13
C NMR (101 
MHz, D2O) δ 153.61, 135.03, 133.92, 131.43, 128.70, 127.19, 124.07, 118.49, 111.52, 51.15, 
47.40, 22.59; MS (ESI+): m/z 267.1 [(M-Na) + 2H]
+
, calculated for C12H15N2O3S, found  















Sodium 3-(isoquinolin-5-ylamino)propane-1-sulfonate 3.59 (DS-Q3) 
Bright orange solid (0.040 g, 11%); Rf 0.34 (2:8 MeOH/ 
EtOAc); Mp 281-283 °C; 
1
H NMR (300 MHz, D2O) δ 9.41 
(s, 1H, H-1), 8.31 (d, J = 7.0 Hz, 1H, H-3), 8.20 (dd, J = 7.0, 
2.8 Hz, 1H, H-4), 7.70 (m, 2H, H-6 & H-8), 7.29 (m, 1H, H-
7), 4.78 (t, J = 7.0 Hz, 2H, 2 x H-9), 3.01 (t, J = 7.0 Hz, 2H, 2 
x H-11), 2.49 (qt, J = 7.0 Hz, 2H, 2 x H-10);
 13
C NMR (101 MHz, D2O) δ 149.23, 143.16, 
132.41, 132.06, 128.51, 126.77, 121.29, 119.97, 119.79, 59.44, 47.42, 26.21; MS (ESI+):  
m/z 267.1 [(M-Na) + 2H]
+




Sodium 3-(7-chloroquinolin-4-ylamino)propane-1-sulfonate 3.57 (DS-Q4) 
Bright orange solid (0.030 g, 13%); Rf  0.34 (2:8 MeOH/ 
EtOAc); Mp 256-258 °C; 
1
H NMR (300 MHz, D2O) δ 8.28 
(dd, J = 6.8, 2.1 Hz, 1H, H-3), 8.06 (m, 1H, H-2), 7.68 (m, 
1H, H-8), 7.17 (m, 1H, H-6), 6.80 (dd, J = 7.3, 3.7 Hz, 1H, 
H-5), 4.64 (m, 2H, 2 x H-9), 3.06 (t, J = 7.2 Hz, 2H, 2 x H-
11), 2.37 (m, 2H, 2 x H-10); 
13
C NMR (101 MHz, D2O) δ 146.81, 141.39, 135.33, 127.89, 
126.17, 124.28, 122.53, 117.75, 103.55, 53.44, 48.07, 24.66; MS (ESI+): m/z 301.0 [(M-Na) 
+ 2H]
+




Sodium 3-(quinolin-6-ylamino)propane-1-sulfonate 3.62 (DS-Q5) 
Pale yellow solid (0.040 g, 11 %); Rf 0.31 (2:8 MeOH/ 
EtOAc); Mp 265-267 °C; 
1
H NMR (300 MHz, D2O) δ 8.86 
(d, J = 6.5 Hz, 1H, H-7), 8.66 (d, J = 8.4 Hz, 1H, H-2), 8.16 
(d, J = 6.0 Hz, 1H, H-4), 7.81 (dd, J = 8.4, 6.0 Hz, 1H, H-
3), 7.63 (d, J = 6.5 Hz, 1H,  H-8), 7.22 (s, 1H, H-5), 5.06 (t,  
 






J = 7.2 Hz, 2H, 2 x H-9), 3.12 (t, J = 7.2 Hz, 2H, 2 x H-11), 2.52 (qt, J = 7.2 Hz, 2H, 2 x H-
10); 
13
C NMR (101 MHz, D2O) δ 149.10, 144.94, 144.11, 132.95, 128.05, 122.13 (2 x C), 
119.74, 109.20, 56.51, 48.03, 25.51; MS (ESI+): m/z 267.1 [(M-Na) + 2H]
+
, calculated for 




Sodium 3-(quinolin-5-ylamino)propane-1-sulfonate 3.58 (DS-Q6) 
Bright orange solid (0.036 g, 10%); Rf 0.33 (2:8 MeOH/ 
EtOAc); Mp 295-297 °C; 
1
H NMR (300 MHz, D2O) δ 9.02 
(m, 2H, H-2 & H-4), 7.76 (m, 2H, H-6 & H-7), 7.47 (d, J = 
9.0 Hz, 1H, H-3 ), 7.01 (d, J = 8.0 Hz, 1H, H-8), 4.97 (m, 
2H, 2 x H-9), 3.05 (t, J = 7.2 Hz, 2H, 2 x H-11), 2.44 (m, 2H, 
2 x H-10); 
13
C NMR (101 MHz, D2O) δ 148.64, 147.70, 142.48, 138.54, 138.03, 119.10, 
112.99, 107.57, 106.47, 56.90, 48.05, 25.04; MS (ESI+): m/z 267.1 [(M-Na) + 2H]
+
, 




Preparation of sodium 3-(10,11-dihydro-5H-dibenzoazepin-5-yl) propane-1-sulfonate 
3.12 (DS00381) 
 To a suspension of NaH (60% dispersion in mineral oil, 
0.034 g, 1.40 mmol) in anhydrous DMF (0.5 mL) under an 
inert atmosphere of nitrogen, was added dibenzoazepine 3.56 
(0.25 g, 1.28 mmol) in anhydrous DMF (1 mL). The mixture 
was allowed to stir at 0 °C for 30 min and at room 
temperature for a further 30 min. 1,3-propane sultone 3.3 (0.16 g, 1.28 mmol) in anhydrous 
DMF (0.5 mL) was then added and the mixture was allowed to stir for 18 h.  A few drops of 
water were added to quench unreacted NaH. Subsequently, toluene was added and the  
 






solvents were removed by azeotropic distillation under reduced pressure. The crude material 
was chromatographed on a reverse phase C-18 column to afford the desired product 3.12 as a 
light brown solid (0.080 g, 18%); Rf  0.38 (1:9 MeOH/ EtOAc); Mp 180-182 °C; 
1
H NMR 
(300 MHz, D2O) δ 6.94 (m, 4H, H-9, H-1, H-7 & H-3), 6.76 (m, 4H, H-8, H-2, H-6  & H-4), 
3.53 (m, 2H, 2 x H-12), 2.75 (m, 6H, 2 x H-14, 2 x H-10 & 2 x H-11), 1.89 (m, 2H, 2 x H-
13); 
13
C NMR (101 MHz, D2O) δ 147.95, 134.19, 129.87, 126.58, 122.70, 120.03, 49.15, 
48.70, 31.70, 22.86; HRMS (ESI+): m/z 317.1086 [(M-Na)+H]
+
, calculated for C17H19NO3S, 




Preparation of dibenzo-1,4-thiazepine 3.54 
To a mixture of 2-aminothiophenol 3.53 (1.00 g, 8.0 mmol) 
and K2CO3 (0.88 g, 6.40 mmol) in DMF (4 mL), was added 
2-fluorobenzaldehyde 3.52 (1.00 g, 8.0 mmol). The mixture 
was heated at 100 °C and allowed to stir for 20 h. After 
cooling to room temperature, water was added to the mixture followed by extraction of the 
product with diethyl ether (3 x 40 mL). The organic extracts were washed with brine and then 
dried over magnesium sulfate. After removing diethyl ether under reduced pressure, the 
resulting solid was triturated with hexane and recrystallized from ethyl acetate to afford a 





H NMR (300 MHz, CDCl3) δ 8.92 (s, 1H, H-10), 7.40 (m, 7H, Ar-H), 7.19 (m, 1H, Ar 
H); 
13
C NMR (101 MHz, CDCl3) δ 162.22 (C-10), 148.59, 139.44, 137.28, 132.76, 131.62, 














Preparation of 10,11-dihydrodibenzo-1,4-thiazepine 3.55 
 To a solution of dibenzo-1,4-thiazepine 3.54 (1.20 g, 5.66 
mmol) in dry MeOH (4 mL), was added NaBH4 (0.21 g 5.60 
mmol) portion-wise under an inert atmosphere of nitrogen at 
0 °C. The mixture was allowed to stir for 8 h and then 
quenched with diluted HCl. Water was added to the mixture, followed by extraction of the 
product with EtOAc (2 x 40 mL). The organic extracts were combined, washed with brine 
and dried over magnesium sulfate.  EtOAc was removed under reduced pressure and the 
resulting solid was triturated with hexane to give the product 3.55 as a pale brown solid. (1.10 




H NMR (300 MHz, 
CDCl3) δ 7.55 (m, 1H, H-6), 7.28 (m, 3H, H-7, H-4 & H-8), 7.19 (m, 1H, H-9), 6.93 (m, 1H, 
H-2), 6.58 (dd, J = 7.3, 1.3 Hz, 1H, H-3), 6.39 (dd, J = 8.1, 1.2 Hz, 1H, H-1 ), 4.85 (s, 2H, 2 x 
H-10); 
13
C NMR (101 MHz, CDCl3) δ 146.88, 142.89, 137.18, 132.36, 131.44, 128.59, 
128.34, 128.23, 127.92, 118.34, 117.65, 116.26, 48.99. 
 
 
Preparation of sodium 3-(dibenzo-1,4-thiazepin-10(11H)-yl)propane-1-sulfonate 3.11 
(DS00380) 
 To a suspension of NaH (60% dispersion in mineral oil) 
(0.072 g, 3.0 mmol) in anhydrous DMF (1.0 mL) under an 
inert atmosphere of nitrogen, was added dibenzothiazepine 
3.55 (0.50 g, 2.3 mmol) in anhydrous DMF (0.5 mL). The 
mixture was allowed to stir at 0 °C for 30 min, and at room 
temperature for a further 30 min. 1,3-propane sultone (0.28 g, 
2.30 mmol) in anhydrous DMF (0.5 mL) was then added and the mixture was allowed to stir 
for 16 h. A few drops of water were added to quench unreacted NaH. Subsequently, toluene  
 






was added and the solvents were removed by azeotropic distillation under reduced pressure. 
The crude material was chromatographed on a reverse phase C-18 column to afford the 
desired product 3.11 as a light brown crystalline solid. (0.15 g, 18 %); Rf 0.35 (1:9 
MeOH/EtOAc); Mp 180-183 °C; 
1
H NMR (300 MHz, D2O) δ 7.11 (m, 3H, H-6, H-7 & H-4), 
6.96 (m, 3H, H-8, H-9 & H-2), 6.67 (d, J = 8.2 Hz, 1H, H-1), 6.49 (m, 1H, H-3), 4.33 (s, 2H, 
2 x H-10), 3.01 (t, J = 6.5 Hz, 2H, 2 x H-12), 2.77 (t, J = 6.5 Hz, 2H, 2 x H-14), 1.93 (m, 2H, 
2 x H-13); 
13
C NMR (101 MHz, D2O) δ 149.42, 140.14, 135.54, 130.35, 129.43, 128.22, 
127.75, 127.49, 127.20, 121.56, 119.66, 119.60, 53.61, 52.42, 48.54, 22.37;  HRMS (ESI+):  
m/z 336.0728 [(M-Na)+2H]
+




Preparation of 2-aminobenzonitrile 3.32 
Step (i): Preparation of 3-(hydroxyimino)indolin-2-one 3.31 
A mixture of isatin 3.30 (4.0 g, 27.0 mmol) and hydroxylamine 
hydrochloride in water (13.6 mL) was allowed to reflux for an 
hour. After cooling to room temperature, the precipitate was 
filtered off, washed with cold water and then dried to give the 





Step (ii) Preparation of aminobenzonitrile 3.32 
A mixture of the oxime 3.31 (2.00 g, 12.35 mmol) and sodium 
carbonate (0.1eq) in DMF (4 mL) was heated at 135 °C for 2.5 h 
and then allowed to cool to room temperature. Water was added to 
the mixture, followed by extraction of the product with EtOAc (2 x 
50 mL). The organic extracts were combined and the solvent was removed under reduced  
 






pressure. The resulting solid was dried to afford aminobenzonitrile 3.32 as a light yellow 




H NMR (300 
MHz, DMSO-d6) δ 7.37 (dd, J = 7.8, 6.4 Hz, 1H, H-4), 7.30 (d, J = 8.4 Hz, 1H, H-6), 6.79 
(dd, J = 8.4, 7.8 Hz, 1H, H-5), 6.59 (dd, J = 6.4 Hz, 1H, H-3), 5.98 (s, 2H, 2 X NH-8).  
 
Preparation of 2-(4-chloro-2-nitrophenylamino)benzonitrile 3.34
7 
 To a mixture of aminobenzonitrile 3.32 (1.09 g, 9.19 
mmol) and K2CO3 (1.1 eq) in DMF (4 mL), was added 
1,4-dichloronitrobenzene 3.33 (1.94 g, 10.11 mmol). The 
resulting mixture was heated at 120 °C and allowed to 
stir for 16 h. After cooling to room temperature, water 
was added the product was extracted with EtOAc (2 x 50 mL). The organic extracts were 
combined and the solvent was removed under reduced pressure. The resulting crude material 
was triturated with hexane to afford the desired product 3.34 as a light brown solid (0.50 g, 
20%); Rf 0.50 (3:7 EtOAc/Hex); Mp 180-183 °C; 
1
H NMR (300 MHz, CDCl3) δ 9.53 (s, 1H, 
NH), 8.27 (d, J = 2.5 Hz, 1H, H-9), 7.75 (dd, J = 7.8, 1.3 Hz, 1H, H-11), 7.64 (m, 1H, H-4), 
7.45 (m, 2H, H-2 & H-3), 7.32 (m, 1H, H-12), 7.20 (m, 1H, H-5); 
13
C NMR (101 MHz, 
CDCl3) δ 141.97, 139.08, 135.73, 135.18, 134.06, 134.02, 126.19, 125.42, 124.71, 123.17, 
118.19, 116.11, 107.84. 
 
Preparation of 8-chloro-5H-dibenzo-1,4-diazepin-11-amine hydrochloride 3.35
7 
 To a solution of 2-(4–chloro-2nitrophenylamino)benzo- 
nitrile 3.34 (0.40 g, 1.46 mmol) in absolute EtOH, was a 
solution of stannous chloride dihydrate (0.99 g, 4.38 
mmol) in 10 N HCl. The reaction mixture was allowed to 
stir and reflux for 8 h, thereafter allowed to cool to room  
 
 






temperature. The mixture was concentrated followed by addition of water to precipitate the 
product. The precipitate was collected by vacuum filtration, washed with water and dried to 
give the desired amine hydrochloride 3.35 as a light brown solid (0. 38 g, 93 %); Rf 0.51 (2:8 
MeOH/EtOAc); Mp 174-176 °C; 
1
H NMR (300 MHz, DMSO-d6) δ 9.67 (s, 1H, NH-5), 9.19 
(s, 1H, NH-10), 8.38 (s, 1H, NH-11), 7.61 (m, 2H, Ar-H), 7.19 (m, 5H, Ar-H); 
13
C NMR 
(101 MHz, DMSO) δ 166.03, 153.09, 142.53, 136.80, 131.97, 129.72, 127.78, 127.59, 
123.18, 122.92, 122.58, 121.23, 117.08. 
 
Preparation of sodium 3-(8-chloro-5H-dibenzo-1,4-diazepin-11-ylamino)propane- 1-
sulfonate 3.9 (DS3123) 
A mixture of 8-chloro-5H-dibenzo-1,4-diazepin-
11-amine hydrochloride 3.35 (0.10 g, 0.36 mmol)  
and Na2CO3 (0.050 g, 0.47 mmol) in anhydrous 
DMF (0.5 mL) was allowed to stir at room 
temperature for 30 min and then at 50 ° C for 1 h. 
After cooling to room temperature, 1,3-propane-sultone (0.044 g, 0.36 mmol) in anhydrous 
DMF (0.5 mL) was added and then allowed  stirred at room temperature for 12 h. The crude 
mixture was concentrated under reduced pressure and then chromatographed on a C-18 
reversed-phase column using water as the eluent to give the desired product as a brown solid 
(0.015 g,  11%) ; Rf 0.26 (2:8 MeOH/EtOAc); Mp 284-286 °C; 
1
H NMR (300 MHz, D2O) δ 
7.57 (m, 2H, Ar-H), 7.03 (m, 5H, Ar-H), 4.19 (m, 2H, 2 x H-12 ), 2.92 (m, 2H, 2 x H-14), 
2.08 (m, 2H, 2 x H-13); HRMS (ESI+): m/z 364.0523 [M-Na]
+
, calculated for 














Preparation of 1-bromo-2-((2-nitrophenoxy)methyl)benzene 3.42
8 
To a mixture of 2-nitrophenol 3.41 (0.53 g, 3.80 mmol 
and K2CO3 (1.31 g, 9.50 mmol) in anhydrous acetonitrile 
(7.5 mL), was added mixture of 2-bromobenzyl bromide 
3.40 (1.00 g, 4.0 mmol). The resulting mixture was heated 
at 70 ºC and allowed to stir for 3h. After the reaction went 
to completion, it was quenched with water followed by extraction with EtOAc (2 x 50 mL). 
The organic extracts were combined, washed with brine and dried over Na2SO4. The solvent 
was removed under reduced pressure and the resulting solid was recrystallized from a 
mixture of EtOAc/Hex (2:8) to afford product 3.42 faint-yellow crystals (0.84 g, 64 %); Rf 
0.42 (1:9 EtOAc/Hex); Mp 91-93 °C; 
1
H NMR (400 MHz, CDCl3) δ 7.89 (dd, J = 8.0, 1.7 
Hz, 1H, H-9), 7.69 (dd, J = 7.7, 1.1 Hz, 1H, H-11), 7.58 (dd, J = 8.0, 1.1 Hz, 1H, H-10), 7.54 
(d, J = 8.0 Hz, 1H, H-6), 7.38 (dd, J = 7.5, 1.7 Hz, 1H, H-4), 7.21 (td, J = 8.0, 1.7 Hz, 1H, H-
5), 7.15 (d, J = 7.5 Hz, 1H, H-3), 7.07 (d, J = 7.7 Hz, 1H, H-12), 5.28 (s, 2H, 2 X H-7); 
13
C 
NMR (101 MHz, CDCl3) δ 151.68, 140.39, 134.94, 134.21, 132.50, 129.48, 128.60, 127.91, 
125.82, 121.52, 120.94, 115.02, 70.46 (C-7). 
 
Preparation of 2-(2-bromobenzyloxy)aniline hydrochloride 3.43
8 
To a solution of 1-bromo-2-((2-nitrophenoxy)methyl) 
benzene 3.42 (1.10 g, 3.57 mmol)  in isopropanol at 60 
°C, 10 N HCl  was added, followed by Fe filings (4.0 eq). 
The mixture was allowed to stir for 17 h at 60 °C and then 
filtered hot through a pad of celite. The filtrate was 
concentrated, 2 N HCl and diethyl ether were added until a precipitate formed. The resulting 










white solid. (0.72 g, 88%) ; Rf 0.40 (2:8 EtOAc/Hex); Mp 190-192 °C; 
1
H NMR (400 MHz, 
CD3OD) δ 7.66 (m, 2H, H-4 & H-6), 7.43 (m, 3H, H-3, H-5 & H-12), 7.26 (m, 2H, H-10, H-
9), 7.11 (dd, J = 7.7, 1.2 Hz, 1H, H-11), 5.36 (s, 2H, 2 x H-7); 
13
C NMR (101 MHz, MeOD) 
δ 152.90, 136.50, 133.96, 131.60, 131.17, 130.81, 128.95, 125.10, 123.83, 122.79, 120.87, 
114.61, 71.50 (C-7). 
 
Preparation of 5,11-dihydrodibenzo-1,4-oxazepine 3.44 
Anhydrous toluene was added to 2-(2-bromobenzyloxy) 
aniline hydrochloride 3.43 (0.650 g, 2.07 mmol), potassium 
tert-butoxide (0.46 g, 4.14 mmol), K2CO3 (0.57 g, 4.14 
mmol) and bis(dibenzylideneacetone)palladium (0) (0.12 g, 
0.21 mmol) under an inert atmosphere of nitrogen. This was followed by addition of tri-tert-
butyl phosphine (0.020 g, 0.10 mmol) and the mixture was allowed to stir at 95 °C for 10 h. 
The reaction was cooled to room temperature, concentrated and then chromatographed on a 
silica gel column (3:7 CH2Cl2/Hex) to give 3.44 as a white solid (0.088 g, 22%); Rf 0.43 (2:8 




H NMR (400 MHz, CDCl3) δ 7.17 (dd, J = 
7.7, 1.4 Hz, 1H, H-3), 7.08 (d, J = 7.4 Hz, 1H, H-1), 6.96 (dd, J = 7.9, 1.1 Hz, 1H, H-9), 6.89 
(dd, J = 7.4, 1.2 Hz, 1H, H-7), 6.79 (m, 1H, H-2), 6.73 (m, 3H, H-4, H-6 & H-8), 5.94 (s, 1H, 
NH-5), 5.03 (s, 2H, 2 X H-11); 
13
C NMR (101 MHz, CDCl3) δ 149.03, 143.36, 134.58, 














Preparation of sodium 3-(dibenzo[1,4]oxazepin-5(11H)-yl)propane-1-sulfonate 3.10 
(DS003125) 
To a suspension of NaH (60% dispersion in mineral oil, 
0.014 g, 0.52 mmol) in anhydrous DMF (0.5 mL) under 
an inert atmosphere of nitrogen, was added dibenzo-1,4-
oxapine 3.44 (0.10 g, 0.52 mmol) in anhydrous DMF (1 
mL). The mixture was allowed to stir at 0 °C for 30 min 
and at room temperature for a further 30 min. 1,3-propane sultone (0.090 g, 0.52 mmol) in 
anhydrous DMF (0.5 mL) was then added and the mixture was allowed to stir for 26 h.  A 
few drops of water were added to quench unreacted NaH. Subsequently, toluene was added 
and the solvents were removed by azeotropic distillation under reduced pressure. The crude 
material was chromatographed on a reversed-phase C-18 column to afford the desired 
product 3.10 as a light brown solid (0.21 g, 12%); Rf 0.36 (1:9 MeOH/EtOAc);  Mp 198-200 
°C; 
1
H NMR (300 MHz, D2O) δ 7.44 (m, 2H, H-3 & H-1), 7.28 (d, J = 8.1 Hz, 1H, H-9), 7.19 
(m, 2H, H-7 & H-2), 7.01 (t, J = 8.1 Hz, 1H, H-8), 6.91 (m, 2H, H-4 & H-6), 5.40 (s, 2H, 2 x 
H-11), 3.93 (t, J = 6.5 Hz, 2H, 2 x H-12), 2.95 (m, 2H, 2 x H-14), 2.10 (m, 2H, 2 x H-13); 
13
C 
NMR (101 MHz, D2O) δ 149.93, 148.29, 136.24, 131.41, 129.94, 128.78, 123.63, 122.86, 
122.27, 120.85, 120.25, 119.24, 69.80, 48.73, 48.33, 22.35. HRMS (ESI+): m/z 342.0776 
[M+H]
+




Preparation of 9H-thioxanthene 3.67 
 To a solution of thioxanthone 3.66 (0.50 g, 2.36 mmol) in dry 
THF under nitrogen, was added 1M BH3.THF complex (2 eq) 
drop-wise at -10 °C. The mixture was allowed to warm to room 
temperature and then heated to reflux for 14h. Water was slowly  
 






added to the reaction mixture, followed by extraction with EtOAc (2 x 30 mL). The organic 
extracts were combined, washed with brine and dried over Na2SO4. The resulting solid was 
recrystallized from DCM (0.24 g, 51%); Rf 0.57 (2:8 EtOAc/Hex);
 





H NMR (400 MHz, CDCl3) δ 7.47 (m, 2H, H-4 & H-5), 7.34 (m, 2H, H-3 & H-6), 
7.22 (m, 4H, H-2, H-7, H-1 & H-8), 3.89 (s, 2H, 2 x H-9); 
13
C NMR (101 MHz, CDCl3) δ 
139.25, 134.71, 127.66, 126.70, 125.87, 114.10, 31.87 (C-9). 
 
 
General procedure for alkylation with propane sultone using n-BuLi as a base 
To a solution of acridone 3.69 or thioxanthene 3.67 (1.0 eq) in anhydrous THF (2 mL) under 
an inert atmosphere of nitrogen at -20 °C, was added n-BuLi (1.0 eq) drop-wise. The mixture 
was allowed to slowly warm to room temperature followed by addition of 1,3-propane 
sultone 3.3  (1.3 eq) in anhydrous THF (1 mL). The resulting mixture was allowed to stir at 
room temperature for 16 h, followed by slow addition of water to quench unreacted n-BuLi. 
The crude mixture was concentrated under reduced pressure and then chromatographed on a 
C-18 reversed phase column (H2O; 8:2 H2O/MeOH) to afford the desired products 3.64 and 
3.65. 
 
Lithium 3-(9H-thioxanthen-9-yl)propane-1-sulfonate 3.65 (DS00386) 
Pale yellow solid (0.030 g, 12%); Rf 0.46 (1.5:8.5 MeOH/ 
EtOAc); Mp 298-301 °C ; 
1
H NMR (300 MHz, D2O) δ 7.22 
(d, J = 7.7 Hz, 2H, H-4 & H-5), 7.12 (m, 4H, H-3, H-6, H-2 
& H-7), 7.03 (m, 2H, H-1 & H-8), 3.85 (t, J = 6.9 Hz, 1H, H-
9), 2.66 (m, 2H, 2 x H-10), 1.54 (m, 4H , 2 x H-12 & 2 x H-
11); 
13
C NMR (101 MHz, D2O) δ 137.04, 131.07, 128.60, 128.47, 126.25, 126.01, 50.34, 
47.66, 30.18, 21.86; HRMS (ESI+):  m/z 319.0463 [M-Li]
+










Lithium 3-(9-oxoacridin-10(9H)-yl)propane-1-sulfonate 3.64 (DS00387) 
 Bright yellow solid (0.050 g, 24 %); Rf 0.42 (1.5:8.5 
MeOH/ EtOAc); Mp 270-272 °C; 
1
H NMR (300 MHz, 
D2O) δ 7.97 (dd, J = 8.1, 1.2 Hz, 2H, H-4 & H-5), 7.67 (m, 
2H, H-2 & H-7), 7.42 (d, J = 8.8 Hz, 2H, H-1 & H-8), 7.17 
(t, J = 7.5 Hz, 2H, H-3 & H-6), 4.13 (m, 2H, 2 x H-11), 
3.05 (t, J = 7.0 Hz, 2H, 2 x H-13), 2.01 (m, 2H, H-12); 
13
C 
NMR (101 MHz, D2O) δ 178.20 (C-9), 140.57, 134.53, 126.03, 121.50, 120.10, 114.78, 
47.68, 44.00, 21.85; HRMS (ESI+): m/z 316.0649 [M-Li]
+





General procedure for preparation of 10-(3-chloropropyl)-10H-phenothiazine 
derivatives 3.71a-c 
To a suspension of NaH (60% dispersion in mineral oil, 1.1 eq) in anhydrous DMF (2 mL) 
under an inert atmosphere of nitrogen, phenothiazine 3.70a-c (1.0 eq) in anhydrous DMF (2 
mL) was added. The mixture was allowed to stir at 0 °C for 30 min, and at room temperature 
for a further 30 min. 1-bromo-3-chloropropane (1.0 eq) was then added and the mixture was 
allowed to stir for 21 h. Water was added to quench unreacted sodium hydride. Subsequently, 
toluene was added and the solvents were removed by azeotropic distillation under reduced 
pressure. The resulting solid was dissolved in EtOAc and subsequently washed with brine. 
The organic layer was concentrated and then chromatographed on a silica gel column (100 % 













 Yellow solid (0.25 g, 38%); Rf 0.51 (2:8 EtOAc/Hex); Mp 
53-54 ºC; 
1
H NMR (400 MHz, CDCl3 ) δ 7.48 (m, 2H, Ar-
H), 7.17 (m, 3H, Ar-H), 6.94 (m, 2H, Ar-H), 4.13 (t, J = 
6.5 Hz, 2H, 2 x H-11), 3.67 (t, J = 6.1 Hz, 2H, 2 x H-13) , 
2.57 (s, 3H, 3 x H-15), 2.28 (m, 2H, 2 x H-12). 
13
C NMR 
(101 MHz, CDCl3) δ 197.26 (C-14), 145.35, 144.35, 136.43, 132.71, 127.77, 127.65, 127.22, 




 White solid (0.52 g, 79%); Rf 0.51 (2:8 EtOAc/Hex); Mp 
51-52 ºC; 
1
H NMR (400 MHz, CDCl3) δ 7.17 (m, 2H, Ar-
H), 7.05 (m,1H, Ar-H), 6.96 (m, 1H, Ar-H), 6.92 (m, 2H, 
Ar-H), 6.88 (m, 1H, Ar-H), 4.06 (t, J = 6.5 Hz, 2H, 2 x H-
11), 3.67 (t, J = 6.5 Hz, 2H, 2 x H-13), 2.27 (m, 2H, 2 x 
H-12); 
13
C NMR (101 MHz, CDCl3) δ 146.42, 144.37, 133.38, 128.11, 127.73, 127.51, 




 White solid (0.18 g, 26%); Rf 0.51 (2:8 EtOAc/Hex); Mp 
58-59 ºC; 
1
H NMR (400 MHz, CDCl3) δ 7.17 (m, 4H, H-
2, H-8, H-1 & H-9), 6.93 (m, 4H, H-4, H-6, H-3 & H-7), 
4.09 (t, J = 6.5 Hz, 2H, 2 x H-11), 3.63 (m, 2H, 2 x H-
13), 2.27 (m, 2H, 2 x H-12); 
13
C NMR (101 MHz, 










General procedure for preparation of isoniazid hybrids [monomers 3.72a (DS00362b), 
3.72b (DS00364) & 3.72c (DS00365a); dimers 3.73a (DS00362), 3.73b (DS00364) & 3.73c 
(DS00365)] 
To a suspension of NaH (60% dispersion in mineral oil, 1 eq) in anhydrous DMF (1 mL) 
under an inert atmosphere of nitrogen, was added isoniazid (1 eq) and the resulting mixture 
was allowed to stir at 0 °C for 30 min. After warming to room temperature, alkylated 
phenothiazine 3.71a-c (1 eq) in anhydrous DMF (1 mL) was added and the mixture was 
allowed to stir at room temperature for 36 h. Water was added to quench unreacted sodium 
hydride. Subsequently, toluene was added and the solvents were removed by azeotropic 
distillation under reduced pressure. EtOAc (50 ml) was then added to the crude material, and 
this was washed with brine. The organic layer was concentrated and then chromatographed 




N'-(3-(2-acetyl-10H-phenothiazin-10-yl)propyl)isonicotinohydrazide 3.72a (DS00362b) 
Dark yellow solid (0.028 g, 20%); Rf 0.55 (8:2 
EtOAc/Hex); Mp 49-50 °C; 
1
H NMR (400 MHz, 
CDCl3) δ 8.72 (d, J = 5.9 Hz, 2H, H-16 & H-17), 
7.72 (dd, J = 5.9, 1.6 Hz , 2H, H-15 & H-18), 
7.47 (m, 2H, Ar-H), 7.14 (m, 3H, Ar-H), 6.94 
(m, 2H, Ar-H), 4.48 (t, J = 6.6 Hz, 2H, 2 x H-
11), 4.14 (t, J = 6.6 Hz, 2H, 2 x H-13), 2.54 (s, 3H, 3 x H-20), 2.27 (qt, J = 6.6 Hz, 2H, 2 x 
H-12);
 13
C NMR (101 MHz, CDCl3) δ 197.19, 164.98, 150.55, 145.27, 144.25, 137.23, 
136.38, 132.79, 127.74, 127.68, 127.20, 124.45, 123.42, 123.16, 122.78, 115.89, 115.78, 
114.19, 113.89, 63.09, 43.89, 26.50, 25.84; HRMS (ESI+): m/z 419.1542 [M+H]
+
, calculated 
for C23H23N4O4S, found 419.1505 [M+H]
+
.  






N'-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)isonicotinohydrazide 3.72b (DS00364a)      
                                                                     
Pale yellow solid (0.034g, 22%); Rf 0.55 (8:2 
EtOAc/Hex); Mp 54-56 °C; 
1
H NMR (400 MHz, 
CDCl3)  δ 8.73 (d, J = 6.0 Hz, 2H, H-16 & H-
17), 7.71 (d, J = 6.0 Hz, 2H, H-15 & H-18), 7.14 
(m, 2H, Ar-H), 7.02 (d, J = 8.0 Hz, 1H, Ar-
H),6.95 (dd, J = 7.6, 1.2 Hz, 1H, Ar-H), 6.88 (m, 
3H, Ar-H), 4.49 (t, J = 6.6 Hz, 2H, 2 x H-11), 4.05 (t, J = 6.6 Hz, 2H, 2 x H-13), 2.26 (p, J = 
6.6 Hz, 2H, 2 x H-12); 
13
C NMR (101 MHz, CDCl3) δ 164.97, 150.58, 146.28, 144.27, 
137.22, 133.32, 128.13, 127.75, 127.49, 125.51, 124.27, 123.25, 122.75, 122.62, 115.87, 
115.77, 111.25, 109.76, 63.02, 43.90, 25.95; HRMS (ESI+): m/z 411.1046 [M+H]
+
, 





N'-(3-(10H-phenothiazin-10-yl)propyl)isonicotinohydrazide 3.72c (DS00365a) 
Pale yellow solid (0.024 g, 26%); Rf 0.55 (8:2 
EtOAc/Hex); Mp 89-90 °C;  
1
H NMR (400 MHz, 
CDCl3) δ 8.71 (d, J = 5.9 Hz, 2H, H-17 & H-16), 
7.69 (d, J = 5.9 Hz, 2H, H-15 & H-18), 7.15 (m, 
4H, Ar-H), 6.91 (m, 4H, Ar-H), 4.48 (t, J = 6.6 
Hz, 2H, 2 x H-15), 4.08 (t, J = 6.6 Hz, 2H, 2 x H-
17), 2.26 (m, 2H, 2x H-16). 
13
C NMR (101 MHz, CDCl3) δ 164.99, 150.53, 145.02, 137.34, 
127.68, 127.27, 125.86, 122.77, 115.51, 63.25, 43.76, 26.08; HRMS (ESI+): m/z 377.1436 
[M+H]
+









N',N'-bis(3-(2-acetyl-10H-phenothiazin-10-yl)propyl) isonicotinohydrazide 3.73a 
(DS00362) 
Dark yellow solid (0.022 g, 13%); Rf 0.68 (8:2 
EtOAc/Hex); Mp 42-44 °C;  
1
H NMR (400 MHz, 
CDCl3) δ 8.64 (d, J = 6.1 Hz, 2H, H-16 & H-17), 
7.55 (d, J = 6.1 Hz, 2H, H-15 & H-18), 7.29 (dd, J 
= 7.9, 1.6 Hz, 2H, Ar-H), 7.23 (d, J = 1.7 Hz, 2H, 
Ar-H), 7.06 (m, 6H, Ar-H), 6.88 (m, 2H, Ar-H), 
6.79 (dd, J = 8.1, 1.1 Hz, 2H, Ar-H), 3.79 (t, J = 
6.9 Hz, 4H, 2 x H-11 & 2 x H-11´), 2.43 (s, 6H, 3 
x H-20 & 3 x H-20´), 1.91 (m, 4H, 2 x H-13 & 2 x 
H-13´), 1.26 (m, 4H, 2 x H-12 & 2 x H-12´);
 13
C NMR (101 MHz, CDCl3) δ 176.88, 165.60, 
150.15, 145.12, 143.77, 141.13, 135.77, 131.60, 130.01, 129.77, 127.74, 127.32, 126.59, 
123.37, 122.78, 122.61, 121.21, 115.52, 113.34, 52.21, 44.13, 26.34, 23.35; HRMS (ESI+): 
m/z 700.2416 [M+H]
+




(DS00364)   
Pale yellow solid (0.028g, 15%); Rf 0.68 (8:2 
EtOAc/Hex); Mp 43-45 °C;  
1
H NMR (400 MHz, 
CDCl3) δ 8.64 (d, J = 5.9 Hz, 2H, H-16 & H-17), 
7.32 (d, J = 5.9 Hz, 2H, H-15 & H-18), 7.12 (m, 
2H, Ar-H), 7.06 (dd, J = 7.5, 1.3 Hz, 2H, Ar-H), 
6.97 (m, 2H, Ar-H), 6.88 (d, J = 7.5 Hz, 2H, Ar-H), 
6.84 (m, 4H, Ar-H), 6.79 (d, J = 2.0 Hz, 2H, Ar-H), 
3.87 (t, J = 6.3 Hz, 4H, 2 x H-11 & 2 x H-11´), 2.94  





(m, 4H, 2 x H-13 & 2 x H-13´), 1.83 (m, 4H, 2 x H-12 & 2 x H-12´); 
13
C NMR (101 MHz, 
CDCl3) δ 165.04, 150.40, 146.44, 144.59, 140.60, 133.38, 127.94, 127.61, 127.50, 124.78, 
123.62, 123.05, 122.70, 122.42, 120.84, 116.27, 116.21, 116.13, 55.43, 44.56, 24.53; HRMS 
(ESI+): m/z 684.1425 [M+H]
+




N',N'-bis(3-(10H-phenothiazin-10-yl)propyl)isonicotinohydrazide 3.73c (DS00365) 
                                                                                                                                                
Pale yellow solid (0.016 g, 18%); Rf 0.68 (8:2 
EtOAc/Hex); Mp 45-47 °C;  
1
H NMR (400 MHz, 
CDCl3) δ 8.61 (dd, J = 4.4, 1.6 Hz, 2H, H-16 & H-
17), 7.26 (dd, J = 4.4, 1.6 Hz, 2H, H-15 & H-18), 
7.08 (m, 8H, Ar-H), 6.85 (m, 8H, Ar-H), 3.90 (t, J = 
6.2 Hz, 4H, 2 x H-11 & 2 x H-11´), 2.92 (m, 4H, 2 x 
H-13 & 2 x H-13´), 1.84 (m, 4H, 2 x H-12 & 2 x H-
12´); 
13
C NMR (101 MHz, CDCl3) δ 165.07, 150.34, 
145.26, 127.45, 127.33, 125.14, 122.55, 120.86, 115.96, 55.62, 44.46, 24.61; HRMS (ESI+): 
m/z 616.2205 [M+H]
+




General procedure for preparation of 2-Nitro-benzenesulfonyl-10H phenothiazine 
derivatives [3.74a (DS00325), 3.74b (DS00326) & 3.74c (DS00329)] 
To a solution of phenothiazine 3.75 (1 eq) in pyridine (2 mL), was added 2-
nitrobenzenesulfonylchloride (1 eq.). The orange-yellow mixture was allowed to stir at 50 °C 
under an inert atmosphere of nitrogen for 32 h. The reaction mixture formed a brick-red solid 
precipitate, which was macerated with EtOH. The precipitate was filtered off and washed 
with diethyl ether (4 x 20 mL) and then recrystallized from MeOH to give desired 
sulfonamide products 3.74a-c.  






10-(2-Nitro-benzenesulfonyl)-10H-phenothiazine 3.74a (DS00325) 
Orange-brown solid (0.94, 49% yield); Rf 0.22 (2:8 
MeOH/EtOAc); Mp 233-235 ºC;
 1
H NMR (400 MHz, 
DMSO-d6) δ 9.21 (d, J = 5.6 Hz, 1H, H-13), 8.70 (t, J = 7.8 
Hz, 1H, H-15), 8.23 (m, 1H, H-16), 7.85 (m, 1H, H-14), 
7.51 (m, 4H, H-2, H-8, H-1 & H-9), 6.87 (m, 4H, H-4, H-6, 
H-3 & H-7) ; 
13
C NMR (101 MHz, DMSO-d6) δ 146.34, 144.81, 144.62, 140.93, 137.01, 
131.10, 130.33, 129.46, 128.60, 128.47, 126.82, 124.41, 123.36, 122.80, 122.77, 118.62, 
115.52, 114.84; IR νmax (KBr) cm
-1
 1531.34 Strong (NO2), 1471.15 Very Strong (S=O), 
1352.92 Medium {-SO2-N- (S-N)}; HRMS (ESI+): m/z 386.0395 [M+2H]
 + 
, calculated for 





10-(2-Nitro-benzenesulfonyl)-2-trifluoromethyl-10H-phenothiazine 3.74b (DS00326) 
Bright orange solid (0.10 g, 12% yield); Rf 0.20 (2:8 
MeOH/EtOAc); Mp 180-182 ºC; 
1
H NMR (400 MHz, 
DMSO-d6) δ 9.22 (d, J = 6.8 H, 1H, H-13), 8.71 (t, J = 7.8 
Hz, 1H, H-15), 8.25 (m, 1H, H-16), 7.86 (m, 1H, H-14), 
7.53 (m, 3H, H-8, H-9 & H-6), 7.16 (m, 2H, H-4 & H-3), 
6.97 (s, 1H, H-1), 6.85 (dd, J = 8.6, 1.1 Hz, 1H, H-7). 
13
C NMR (101 MHz, DMSO-d6) δ 
146.55, 144.72, 143.68, 141.67, 137.62, 131.10, 130.33, 129.47, 128.49, 127.62, 124.94, 
123.11, 122.78, 119.63, 119.59, 117.74, 115.25, 111.18, 111.14; IR νmax (KBr) cm
-1
 1518.44 
Strong (NO2), 1481.90 Very Strong (S=O), 1350.76 Medium {-SO2-N- (S-N)}; HRMS 
(ESI+): m/z 454.0269 [M+2H]
+













2-Chloro-10-(2-nitro-benzenesulfonyl)-10H-phenothiazine 3.74c (DS00329) 
Orange-brown solid (0.39 g, 22% yield); Rf 0.20 (2:8 
MeOH/EtOAc); Mp 193-195 ºC; 
1
H NMR (300 MHz, 
DMSO-d6) δ 9.19 (m, 2H, H-13 & H-15), 8.70 (t, J = 7.8 
Hz, 1H, H-14), 8.23 (m, 2H, H-16 & H-8), 7.51 (m, 3H, H-
9, H-6 & H-4), 6.97 (d, J = 8.2 Hz, 1H, H-3), 6.86 (m, 1H, 
H-7), 6.75 (d, J = 2.2 Hz, 1H, H-1),
 13
C NMR (101 MHz, DMSO-d6) δ 146.50, 144.71, 
143.90, 142.46, 137.48, 132.81, 131.11, 130.35, 129.47, 128.49, 128.12, 124.67, 123.01, 
122.81, 122.79, 118.43, 115.22, 114.84; IR νmax (KBr) cm
-1
 1522.74 Strong (NO2), 1466.85 
Very Strong (S=O), 1344.31 Medium {-SO2-N- (S-N)} HRMS (ESI+): m/z 420.0005 
[M+2H]
+





General procedure for preparation of substituted 10-(4-nitrophenylsulfonyl)-10H-
phenothiazine derivatives [3.76a (DS00342), 3.76b (DS00338) & 3.76c (DS00341)] 
To a solution of phenothiazine 3.75 (1.0 eq) in pyridine (2 mL), was added 4-
nitrobenzenesulfonylchloride (1.0 eq). The orange yellow mixture was allowed to stir at 50 
°C under an inert atmosphere of nitrogen for 26 h. The reaction mixture formed a brick-red 
solid precipitate, which was macerated with EtOH. The precipitate was filtered off and 
washed with diethyl ether (4 x 20 mL) and then recrystallized from MeOH to afford desired 













10-(4-nitrophenylsulfonyl)-10H-phenothiazine 3.76a (DS00342) 
Orange-brown ‗diamond-shaped‘ crystals; (0.10 g, 21% 
yield); Rf 0.20 (2:8 MeOH/EtOAc); Mp 244-246 ºC; 
1
H 
NMR (400 MHz, DMSO-d6) δ 8.24 (m, 2H, H-13 & H-
15), 7.70 (dd, J = 8.0, 1.3 Hz, 2H, H-12 & H-16), 7.48 (m, 
2H, H-2 & H-8), 7.42 (m, 2H, H-1 7 H-9), 7.37 (m, 4H, H-
4, H-6, H-3 & H-7). 
13
C NMR (101 MHz, DMSO-d6) δ 
151.05, 144.06, 135.01, 132.88, 130.02, 129.30, 129.20, 128.34, 128.04, 124.94; IR νmax 
(KBr) cm
-1
 1531.34 Strong (NO2), 1462.55 Very Strong (S=O), 1357.21 Medium {-SO2-N- 
(S-N)}HRMS (ESI+): m/z 384.0238 [M]
+





10-(4-nitrophenylsulfonyl)-2-(trifluoromethyl)-10H-phenothiazine 3.76b (DS00338) 
Bright orange solid; (0.16 g, 38%); Mp 158-159 °C ;
1
H 
NMR (400 MHz, DMSO- d6) δ 8.92 (d, J = 5.5 Hz, 2H, H-
13 & H-15), 8.58 (m, 2H, H-12 & H-16), 8.19 (m, 2H, H-8 
& H-9), 8.05 (m, 3H, H-4, H-6 & H-7), 7.84 (m, 2H, H-3 
& H-1); 
13
C NMR (101 MHz, DMSO-d6) δ 154.82, 
147.77, 146.23, 144.72, 143.09, 128.51, 127.62, 127.53, 
127.40 (2 x C), 125.03, 124.94, 123.79 (2 X C), 123.09, 115.26; IR νmax (KBr) cm
-1
 1518.44 
Strong (NO2), 1481.90 Very Strong (S=O), 1350.76 Medium {-SO2-N- (S-N)}; HRMS 
(ESI+): m/z 454.0269 [M+2H]
+




















1-(10-(4-nitrophenylsulfonyl)-10H-phenothiazin-2-yl)ethanone 3.76c (DS00341) 
 Dark brown solid; (0.20 g, 46%); Rf 0.20 (2:8 
MeOH/EtOAc); Mp 233-235 °C; 
1
H NMR (400 MHz, 
DMSO-d6) δ 8.21 (m, 1H, H-13), 8.16 (d, J = 1.8 Hz, 1H, 
H-15), 7.93 (dd, J = 8.2, 1.9 Hz, 1H, H-12), 7.71 (dd, J = 
8.0, 1.0 Hz, 1H, H-16), 7.50 (m, 2H, Ar-H), 7.40 (m, 5H, 
Ar-H), 2.62 (s, 3H, 3 x H-18); 
13
C NMR (101 MHz, 
DMSO-d6) δ 196.80 (C-17), 150.43, 143.92, 138.81, 136.84, 135.11, 134.63, 131.73, 130.03, 
129.40, 129.18, 128.68, 128.64, 128.18, 128.05, 127.40, 124.93, 27.11 (C-18); IR νmax (KBr) 
cm
-1
 1632.38 Strong (C=O), 1522.74 Strong (NO2), 1466.85 Very Strong (S=O), 1344.31 
Medium {-SO2-N- (S-N)}; HRMS (ESI+): m/z 427.0422 [M+H]
+
, calculated for 





General procedure for preparation of 3-(10H-phenothiazin-10-yl) propanenitrile 
derivatives [3.82a (DS00394), 3.82b (DS00392) & 3.82c (DS00393)] 
A suspension of phenothiazine 3.81a-c (1 eq) in acrylonitrile (5 mL) was cooled at 0 °C. To 
this was added Triton B (10 mol%) and the mixture was allowed to stir at 0 °C. Once the 
reaction subsided, dioxane (1.0 mL- 2.5 mL) was added and the reaction mixture was heated 
to reflux for 1 h.  The mixture was poured into water, the precipitate was filtered and washed 
several times with diethyl ether (5 x 50 mL). The filtrate was collected and the solvent was 



















3-(10H-phenothiazin-10-yl)propanenitrile 3.82a (DS00394) 
 White flakes (1.70 g, 67 %); Rf 0.33 (2:8 EtOAc/Hex);  




H NMR (300 MHz, 
DMSO-d6) δ 7.23 (m, 4H, H-2, H-8,H-1, H-9), 7.09 (m, 
2H, H-4 & H-6), 7.01 (t, J = 7.6 Hz, 2H, H-3 & H-7), 
4.23 (t, J = 6.6 Hz, 2H, 2 x H-11), 2.93 (t, J = 6.6 Hz, 
2H, 2 X H-12); 
13
C NMR (101 MHz, DMSO-d6) δ 144.42, 128.22, 127.83, 124.84, 123.55, 
119.28, 116.43, 42.79, 16.46; MS (ESI+): m/z 252.1 [M]
+







Faint-pink solid (0.37 g, 60 %); Rf 0.33 (2:8 EtOAc/Hex);   
Mp 165-167 °C; 
1
H NMR (300 MHz, DMSO-d6) δ 7.23 
(m, 4H, Ar-H), 7.06 (m, 3H, Ar-H), 4.25 (t, J = 6.5 Hz, 
2H, 2 x H-11), 2.92 (t, J = 6.5 Hz, 2H, 2 X H-12); 
13
C 
NMR (101 MHz, DMSO-d6) δ 145.62, 143.15, 132.73,  
128.36, 128.01, 127.51, 124.19, 123.61, 123.45, 122.83, 118.75, 116.45, 116.13, 42.51, 
16.10; MS (ESI+): m/z 286.0 [M]
+







Faint-yellow solid (0.16 g, 54 %); Rf 0.33 (2:8 
EtOAc/Hex); Mp 140-142 °C; 
1
H NMR (300 MHz, 
DMSO-d6) δ 7.30 (m, 5H, Ar-H), 7.08 (m, 2H, Ar-H), 
4.32 (t, J = 6.5 Hz, 2H, 2 x H-11), 2.92 (t, J = 6.5 Hz, 2H, 
2 x H-12); 
13
C NMR (101 MHz, DMSO-d6) δ 144.91,  
 
 





143.00, 130.12, 128.22, 128.03, 127.60, 123.83, 123.57, 119.71, 119.68, 118.71, 116.61, 
112.45, 112.42, 42.58, 16.10; MS (ESI+): m/z 320.0 [M]
+





Preparation of 3-(3,7-dibromo-10H-phenothiazin-10-yl)propanenitrile 3.82d (DS00396) 
 To a solution of alkylated phenothiazine 3.82a (0.50 g, 
1.98 mmol) in dry THF (5 mL), NBS (0.85 g, 4.75 mmol) 
in dry THF (5 mL) was added dropwise over a period of 1 
h at 0 °C. The mixture was stirred at room temperature for 
12h.  Water was added to the mixture and the product was 
extracted with DCM (2 x 40 mL). The organic extracts were combined and the solvent was 
removed under reduced pressure. The resulting solid was recrystallized from a mixture of 
EtOAc/hexane (1:1) to afford product 3.82d as a light green solid.  (0.53 g, 65 %); Rf 0.36 
(3:7 EtOAc/Hex); Mp 108-110 °C; 
1
H NMR (300 MHz, DMSO-d6) δ 7.41 (m, 4H, H-2, H-8, 
H-1 & H-9), 7.04 (d, J = 8.5 Hz, 2H, H-4 & H-6), 4.19 (t, J = 6.6 Hz, 2H, 2 x H-11), 2.91 (t, 
J = 6.6 Hz, 2H, 2 x H-12); 
13
C NMR (101 MHz, DMSO-d6) δ 143.50, 130.96, 129.78, 
126.74, 119.03, 118.35, 115.24, 43.05, 16.32. HRMS (ESI+): m/z 409.8911 [M]
+
, calculated 




Preparation of 10-(2-(1H-tetrazol-5-yl)ethyl)-10H-phenothiazine hydrochloride 3.84 
(DS00395)
13 
A mixture of alkylated phenothiazine 3.82a (0.50 g, 1.98 
mmol), sodium azide (0.39 g, 5.94 mmol), NH4Cl (0.32 g, 
5.94 mmol) in DMF was heated at 125 °C and allowed to stir 
for 16 h. Toluene was added to the mixture and the solvents 











pressure. Water was then added to the crude mixture followed by acidification with HCl to 
pH ~2. The resulting solid was washed with hexane and recrystallized from MeOH to afford 
the desired product 3.84 as a dark grey solid. (0.29 g, 45 %); Rf 0.28 (0.5:9.5 MeOH/EtOAc); 
Mp 175-177 °C; 
1
H NMR (300 MHz, DMSO-d6) δ 7.22 (m, 4H, H-2, H-8, H-1 & H-9), 7.04 
(m, 4H, H-3, H-7 , H-4 & H-6), 4.35 (t, J = 6.6 Hz, 2H, 2 x H-11), 3.32 (t, J = 6.6 Hz, 2H, 2 x 
H-12); 
13
C NMR (101 MHz, DMSO-d6) δ 153.37, 144.29, 127.80, 127.30, 123.93, 122.90, 
115.91, 44.50, 21.45; MS (ESI+): m/z 297.1 [M+2H]
+





Preparation of N-tert-butyl-3-(10H-phenothiazin-10-yl)propanamide 3.83 (DS00385) 
 To a solution of nitrile 3.82a (0.20 g, 0.79 mmol) in 
tert-butyl acetate (1 mL), conc. H2SO4 (40 µL) was 
slowly added at room temperature. The resulting 
mixture was allowed to stir at 42 °C for 12 h , thereafter 
poured into ice cold NaHCO3(aq) to neutralize the acid. 
The product was filtered and purified on a preparative 
TLC plate (2:8 EtOAc/Hex) to afford propanamide 3.83 as a white solid. (0.051 g, 20 %); Rf 
0.33 (2:8 EtOAc/Hex); Mp 109-111 °C; 
1
H NMR (400 MHz, DMSO-d6) δ 7.46 (s, 1H, NH), 
7.18 (m, 2H, H-2 & H-8), 7.11 (dd, J = 7.6, 1.5 Hz, 2H, H-1 & H-9), 7.02 (dd, J = 7.3, 1.9 
Hz, 2H, H-4 & H-6), 6.92 (t, J = 7.5 Hz, 2H, H-3 & H-7), 4.05 (m, 2H, 2 x H-11), 2.48 (m, 
2H, 2 x H-12), 1.23 (s, 9H, 2 x H-14, 2 x H-14´, 2 x H-14´´). 
13
C NMR (101 MHz, DMSO-
d6) δ 169.66 (C-13), 144.48, 127.71, 127.08, 123.07, 122.59, 115.54, 50.13, 43.32, 34.17, 
28.61. MS (ESI+): m/z 327.1 [M+H]
+
















Preparation of diethyl 3-(10H-phenothiazin-10-yl)propylphosphonate 3.87 (DS00390)
14 
To a solution of 10-(3-chloropropyl)-10H pheno- 
thiazine 3.86 (0.10 g, 0.36 mmol) in dry toluene, was 
added triethyl phosphite (0.31 mL, 1.80 mmol). This 
was followed by the addition of zinc chloride (1M in 
DCM) (0.065 mL, 0.40 mmol) and the mixture was 
stirred at 75 °C under nitrogen for 18 h. The reaction 
mixture allowed to cool to room temperature and then filtered through a pad of celite. 
Toluene was removed under reduced pressure and the resulting crude material was triturated 
with hexane to give the desired product 3.87 as a colourless oil. (0.014 g,  10 %); Rf 0.29 (5:5 
EtOAc/Hex); 
1
H NMR (300 MHz, DMSO) δ 7.20 (m, 4H, H-2, H-8, H-1 & H-9), 7.05 (d, J = 
7.6 Hz, 2H, H-4 & H-6), 6.96 (dd, J = 7.6, 1.1 Hz, 2H, H-3 & H-7), 3.96 (m, 2H, 2 x H-11), 
3.89 (m, 4H, 2 x H-14 & 2 x H-14´), 1.84 (m, 4H, 2 x H-13 & 2 x H-12), 1.14 (t, J = 7.0 Hz, 
6H, 3 x H-15 & 3 x H-15´).; 
31
P NMR (162 MHz, DMSO-d6) δ 31.48; 
13
C NMR (101 MHz, 
DMSO-d6) δ 145.11, 128.07, 127.67, 124.50, 123.11, 116.49, 61.31, 46.65, 22.58, 21.19, 
16.69. MS (ESI+): m/z 378.1 [M+H]
+




Preparation of (E)-3-(dimethylamino)-1-(10H-phenothiazin-2-yl)prop-2-en-1-one 3.78
15 
 To a solution of 2-acetyl phenothiazine 3.77 (1.20 
g, 4.97 mmol) in anhydrous toluene (15 mL), 
dimethylformamide-dimethylacetal (DMF-DMA) 
(1.3 mL, 10 mmol) was added. The mixture was 
allowed to reflux for 20 h under an inert 
atmosphere of nitrogen, after which the solvent and excess DMF-DMA were removed under  
 






reduced pressure. The resulting solid was washed with diethyl ether and then recrystallized 
from a mixture of MeOH/EtOAc (1:9) to afford enaminone 3.78 as a bright yellow solid. 
(0.70 g, 47 %); Rf 0.20 (7:3 EtOAc/Hex); Mp. 243-245 °C; 
1
H NMR (300 MHz, DMSO-d6) δ 
8.65 (s, 1H, NH-10), 7.69 (d, J = 12.3 Hz, 1H, H-13), 7.29 (dd, J = 8.0, 1.7 Hz, 1H, H-4), 
7.22 (d, J = 1.7 Hz, 1H, H-1), 6.99 (m, 1H, H-8), 6.92 (m, 2H, H-9 & H-3) 6.74 (m, 1H, H-
7), 6.67 (dd, J = 7.9, 1.1 Hz, 1H, H-6), 5.69 (d, J = 12.3 Hz, 1H, H-12), 3.14 (s, 3H, 3 X H-
14), 2.90 (s, 3H, 3 X H-14´); 
13
C NMR (101 MHz, DMSO-d6) δ 185.18 (C-11), 154.64, 
142.28, 142.19, 140.14, 128.23, 126.71, 126.15, 122.33, 121.37, 120.42, 115.98, 114.98, 
113.26, 91.09 , 44.98 (C-14), 37.81 (C14´).  
 
 
Preparation of 2-(1H-pyrazol-3-yl)-10H-phenothiazine 3.79 (DS00398)
15 
 To a solution of enaminone 3.78 (0.20 g, 0.68 
mmol) in EtOH (6 mL), was added excess 
hydrazine hydrate (2 mL). The mixture was 
allowed to stir at room temperature for 14 h. The 
precipitate was filtered off, washed with cold 
EtOH and then dried to afford pyrazole 3.79 as a light yellow solid. (0.15 g, 83%); Rf 0.43 
(7:3 EtOAc/Hex); Mp 209-211 °C; 
1
H NMR (300 MHz, DMSO-d6) δ 12.88 (s, 1H, NH-13), 
8.65 (s, 1H, NH-10), 7.71 (s, 1H, H-1), 7.18 (m, 2H, H-4 & H-12), 7.00 (m, 1H, H-8), 6.93 
(m, 2H, H-9 & H-6), 6.74 (m, 2H, H-7 & H-3), 6.56 (d, J = 2.2 Hz, 1H, H-11); 
13
C NMR 
(101 MHz, DMSO-d6) δ 142.77, 142.39, 128.04 (2C), 126.86, 126.71, 122.24, 119.35 (2C), 
116.80, 115.94 (2C), 115.00, 111.45, 102.11. MS (ESI+): m/z 266.1 [M+H]
+
, calculated for 













Preparation of 5-(10H-phenothiazin-2-yl)isoxazole 3.80 (DS00397)
15 
To a solution of enaminone 3.78 (0.20 g, 0.68 
mmol) in EtOH (6 mL), was added excess 
hydroxylamine hydrochloride (3 eq). The yellow 
solution turned bright orange upon addition of 
hydroxylamine and the resulting mixture was 
allowed to stir at room temperature for 14 h. The precipitate was filtered off, washed with 
cold EtOH and then dried to afford isoxazole 3.80 as a brown solid. (0.15 g, 85%); Rf 0.58 
(7:3 EtOAc/Hex); Mp 178-180 °C; 
 1
H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1H, NH-10), 
8.62 (d, J = 1.9 Hz, 1H, H-12), 7.25 (dd, J = 8.0 Hz, 1H, H-9), 7.12 (d, J = 1.9 Hz, 1H, H-11), 
7.06 (d, J = 7.6 Hz, H-4), 7.00 (dd, J = 8.0 Hz, 1.4 Hz, 1H, H-8), 6.93 (dd, J = 7.6 Hz, 1H, H-
3), 6.87 (d, J = 1.4 Hz, 1H, H-1), 6.78 (dd, J = 8.0 Hz, H-6), 6.70 (dd, J = 8.0 Hz, 1.4 Hz, 1H, 
H-7); 
13
C NMR (101 MHz, DMSO-d6) δ 168.28, 152.14, 143.07, 141.74, 128.35, 127.37, 
126.78, 126.41, 122.68, 119.97, 119.75, 116.17, 115.13, 110.97, 100.05; MS (ESI+): m/z 
269.1 [M+3H]
+


















7.4 Biological assays  
The biological assays were conducted by collaborators or service providers as indicated 
below. Ethical clearance was obtained for the in vivo toxicity study.  
7.4.1 Green Fluorescent Protein Microplate Assay (GAST/Fe) 
The MIC90s and MIC99s determinations were performed at UCT IIDMM. Details of the assay 
have been reported by van der Westhuyzen et al.
16
 In brief, the MICs were  determined in a 
GAST/Fe (glycerol-alanine-salts) medium using the standard broth microdilution method
17,18 
Test compounds were dissolved in DMSO to make up stock solutions to a final concentration 
of 128 mM. A two-fold serial dilution of the test compounds was performed across a 96-well 
microtitre plate from Row 2-11 in GAST/Fe medium with a final DMSO concentration of 5% 
v/v. The minimum growth control was rifampicin (Row 12) and the maximum growth control 
was 5% DMSO in GAST/Fe (Row 1). A M.tbH37Rv.gfp stock culture was grown to an 
OD600-0.6, diluted 1:100 and 50 µL was added to each well. The plates were incubated at 37 
°C followed by measurement of fluorescence (excitation 485 nM; emission 520 nM) using a 
plate reader. (FLUOstar, OPTIMA, BMG LABTECH) at day 14. The concentration range 
tested was 0.244-125 µM. The lowest concentration of drug that inhibits growth of more than 




7.4.2 Green Fluorescent Protein Microplate Assay (Middlebrook 7H9) 
The determination of MICs of selected compounds (DS0031, DS0032, DS0034 & DS0035) 
was performed at UCT IIDMM. Details of the assay have been reported by Salie, S.; Hsu, N.; 
Semenya, D.; Jardine, A.; Jacobs, M. Novel Non-Neuroleptic Phenothiazines Inhibit 
Mycobacterium Tuberculosis Replication. J. Antimicrob. Chemother. 2014, 69 (6), 1551–
1558.
19
 In brief, direct antibacterial activity screening was performed in black 96-well plates  






in a Middlebrook 7H9 medium. Frozen M.tbH37Rv.gfp was thawed, spun down and the 
pellet was resuspended in Middlebrook 7H9 broth with 25 mg/L kanamycin. 100 µL of 
H37Rv.gfp was added to each experimental well at a concentration of 1×10
6
 cfu/mL. Sterile 
water was added to outer to with sterile water to minimize evaporation. Test compounds and 
controls were first dissolved in water followed by 2-fold dilutions using 7H9 broth 
supplemented with 25 mg/L kanamycin. Relative fluorescence readings were measured at 
various timepoints.  
 
7.4.3 Evaluation against Mtb.H37Rv infected macrophages (ex vivo activity) 
Selected compounds (DS0031, DS0032, DS0034 & DS0035) were screened for intracellular 
inhibition of M.tbH37Rv in bone-marrow derived macrophages (BMDMs) (UCT IIDMM). 
Details of the assay have been reported by Salie, S.; Hsu, N.; Semenya, D.; Jardine, A.; 
Jacobs, M. Novel Non-Neuroleptic Phenothiazines Inhibit Mycobacterium Tuberculosis 
Replication. J. Antimicrob. Chemother. 2014, 69 (6), 1551–1558.
19
 Briefly, BMDMs were 
cultured from the femurs of 6–8-week-old C57Bl/6 mice. The cultures were maintained in 
RPMI medium supplemented with 20% fetal calf serum (FCS), 30% L929-conditioned 
medium, 10mM L-glutamine, 100 µg/mL streptomycin and 100 U/mL penicillin for 8–10 
days at 37 °C with 5% CO2. Confluent cells were seeded at a concentration of 1×10
5
 cells per 
well in a 96-well plate. Macrophages were infected with M. tuberculosis (H37Rv) at a 
multiplicity of infection of 5:1 (M. tuberculosis:cells) for 4 h. Infected cells were washed 
with BMDM medium (2 mM L-glutamine, 2% FCS, 10% L929 medium, RPMI) to remove 
extracellular bacteria, then the initial number of intracellular bacilli was determined by lysing 
the macrophages and plating the supernatant on Middlebrook 7H10 agar for cfu enumeration. 
Two sets of cultures were prepared to evaluate intracellular drug activity and cell viability  
 






simultaneously. The infected macrophages were incubated with medium containing isoniazid 
(1 mg/L), thioridazine (3 mg/L), and test compounds (25 mg/L) in triplicate. After 5 days of 
treatment, macrophages were either lysed for cfu determination (% inhibition), or incubated 
with Cell-titer Blue reagent for 4 h then read on a fluorimeter for cell viability. Percentage 
inhibition was calculated relative to untreated macrophages and percentage viability was 
calculated relative to uninfected macrophages. 
 
7.5 Dopamine and serotonin receptor radioligand binding assays 
Selected compounds were sent to Perkin Elmer (formerly Caliper Life Sciences) (Maryland, 
USA) to be evaluated in radioligand binding assays in which binding to the dopaminergic 
receptor subtypes D1, D2 and D3 and the serotonergic receptor subtypes 5-HT1A, 5-HT2A and 
5-HT2C was measured. Details of the assays have been reported by Salie, S.; Hsu, N.; 
Semenya, D.; Jardine, A.; Jacobs, M. Novel Non-Neuroleptic Phenothiazines Inhibit 
Mycobacterium Tuberculosis Replication. J. Antimicrob. Chemother. 2014, 69 (6), 1551–
1558.
19
 The radioligand binding assay conditions were in accordance with industry standards 
as reported by Perkin Elmer (formerly Caliper Life Sciences) (www.perkinelmer.com). Well-
established 3H-labelled reference ligands were utilized as reported in chapter 4 (Figure 4.9). 
The dopaminergic and serotonergic receptors subtypes were prepared as shown below: 
 
 
 D1 receptor   (HEK-293 cells expressing human recombinant D1 subtype receptor)  
 D2 receptor   (CHO cells expressing human recombinant D2 subtype receptor)  
 D3 receptor   (SF9 cells expressing rat recombinant D3 subtype receptor)  
 5-HT1A  receptor   (bovine hippocampal membrane) 
 5-HT2A  receptor   (rat cortical membrane)  
 5-HT2C receptor   (pig choroid plexus membrane) 
The reaction conditions for the radioligand binding of the dopaminergic and serotonergic 
receptors subtypes are outlined below: 






 D1 receptor   (50mM Tris–HCl (pH 7.4), 5mM KCl & 5mM MgCl2 at 25 °C; 1mM EDTA and 1.5 mM 
CaCl2 also added) 
 D2 receptor   (50mM Tris–HCl (pH 7.4), 5mM KCl & 5mM MgCl2 at 25 °C; 1mM EDTA and 120mM 
NaCl also added) 
 D3 receptor   (50mM Tris–HCl (pH 7.4), 5mM KCl & 5mM MgCl2 at 25 °C; 5mM EDTA, 120mM 
NaCl and 1.5mM CaCl2 also added) 
 5-HT1A  receptor   (50mM Tris–HCl (pH 7.4) at 25 °C) 
 5-HT2A receptor    (50mM Tris–HCl (pH 7.6) at 37 °C) 
 5-HT2C receptor    (50mM Tris–HCl (pH 7.7) , 4mM CaCl2 and 0.1% ascorbic acid at 37 °C) 
 
The reactions were terminated by rapid vacuum filtration onto glass fibre filters. 
Radioactivity trapped onto the filters was measured and compared with control values to 
evaluate interactions of the modified phenothiazines with the respective receptors. Assays 
were performed in duplicate. The average bound radioactivity of the reference compound in 
the presence of the modified phenothiazines was then expressed as a percentage. 
Interpretation of results was as follows: -20% to + 20% (inactive) standard baseline; 20% to 
49% (marginal activity); > 50% (active).  
 
7.6 In vitro ADMET assays                                                                                                 
7.6.1 Kinetic Solubility 
The kinetic solubility assay was carried out using a miniaturised shake flask method (UCT 
Division of Clinical Pharmacology). Details of the method have been reported by van der 
Westhuyzen et al.
16
 Briefly, calibration standards (10-220 µM in DMSO) were prepared from 
10 mM stock solutions of the test compounds (DS0031, DS0032, DS0034 and DS0034). Test 
compound stock solution were also used to spike (1:50) duplicate aqueous samples of FaSSIF  
 






(bio-relevant buffer that simulates the small intestine juices in fasted state, pH 6.5), with a 
final DMSO concentration of 2%. The solutions were shaken for 2 hours at 25 °C, filtered 
and analysed using HPLC-DAD (Agilent 1200 Rapid Resolution HPLC with a diode array 
detector).  
7.6.2 Microsomal metabolic stability 
The metabolic stability of selected (DS0031, DS0032, DS0034 and DS0034) compounds was 
performed using a single time point microsomal stability assay (UCT Division of Clinical 
Pharmacology).
16,20
 In brief, the test compounds were incubated individually in mouse liver 
microsomes (0.4 mg/mL) at 37 °C for 30 min (single time point), in the presence and absence 
of the cofactor NADPH (1mM). Reactions were quenched by adding 300 µL of ice cold 
acetonitrile containing internal standard (carbamazepine, 0.0236 µg/mL). Test compounds in 
the supernatant were analysed by means of LC-MS/MS (Agilent Rapid Resolution HPLC AB 
SCIEX 4000 QTRAP MS) for the disappearance of parent compound. 
7.7 In vivo toxicity 
The toxicity potential of test compounds (DS0034 and DS0035) was evaluated at a dose of 
100mg/kg as the maximum starting dose and outcomes were measured against the known in 
clinically approved phenothiazine drug, thioridazine, or against no treatment (UCT IIDMM). 
Briefly, initial studies were conducted to evaluate the maximal tolerated dose of thioridazine 
in mice. 6-8-week-old adult female C57Bl/6 mice (n=10/group) were challenged with 
100mg/kg, 40mg/kg, 20mg/kg and 10mg/kg by oral gavage, the animals were monitored for 
survival and changes in body weight were measured.  To evaluate toxicity of single dose 
(100mg/kg) administration, test compounds were administered by oral gavage in a volume in  
 
 






200 µL.  The animals were monitored for survival and changes in body weight were 
measured over 14 days. To evaluate toxicity in animals which received therapy on a daily 
basis, mice (n=10-15/group) were challenged with either thioridazine (10mg/kg or 20mg/kg) 
or test compounds (100mg/kg) administered in 200 µL water by oral gavage on a daily basis.  
Changes in body weights were measured and recorded on a daily basis.  The experiment was 
terminated after 14 days when all animals were humanely sacrificed and organs (heart, lung, 
brain, kidney, liver and spleen) removed and weighed.   
 
7.8 Evaluation against U-251 glioblastoma cell line using an MTT assay 
The anticancer effects were determined using an 3-(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide (MTT) assay as previously described by Mosmann T with slight 
modifications (University of the Western Cape, Department of Medical Bioscience).
21
 The 
human malignant glioma cell line U-251 (glioblastoma multiforme, World Health 
Organization grade IV) was generously donated by the Prince Laboratory, Faculty of Health 
Sciences, UCT. Cells were cultured in monolayer using Dulbeco Modified Eagles Medium 
(DMEM, Lonza Group Ltd., Verviers, Belgium) with phenol red supplemented with 10% 
foetal bovine serum (FBS, Gibco, Life Technologies Corporation, Paisley, UK) and 1% 100 
U/mL penicillin and 100 μg/mL (Lonza Group Ltd. Verviers, Belgium). All cells were grown 
at 37°C in a humidified atmosphere consisting of 5% CO2 and 95% air. Media was replaced 
every two to three days and cells were sub-cultured by splitting with trypsin (Lonza Group 
Ltd., Verviers, Belgium). Briefly, U251 cells were plated in 96-well cell culture plates at a 
cell density of 5000 cells per well and incubated overnight for 24 hours. The medium was 
thereafter replaced with fresh medium containing increasing concentrations of the various 
phenothiazine derivatives and a vehicle control of untreated cells was included to compare  
 
 






with the treated cells. All treatment including the vehicle control lasted for 48 hours and was 
done in triplicate. After the 48 hours incubation, 10 μl of the MTT (Sigma-Aldrich Co 
Germany) solution (5 mg/ml) was added to each well and the cells were incubated for an 
additional 4 hours at 37°C. The medium was removed and 100 μL of dimethyl sulfoxide 
(DMSO) was added to each well to solubilize the MTT formazan. The cell culture plates 
were then placed on a shaker for 10 minutes and the absorbance was read at 570 nm using a 
BMG Labtech Omega® POLARStar multimodal plate reader. The percentage cell viability 
was calculated using the formula below:  
                 
                         
                           
       
The half maximal inhibitory concentration (IC50) was determined via a survival curve using 
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